>HW416143.1 JP 2013544752-A/82: Nucleic acids having anti-metabolic syndrome effects
TGCAGATGATCCC
>HW416142.1 JP 2013544752-A/81: Nucleic acids having anti-metabolic syndrome effects
TGATACCACCAGA
>HW399765.1 WO 2013191199-A/20: Method for alteration of antibody H chain
GCTAGCCTCGAGA
>XM_007161733.1 Phaseolus vulgaris hypothetical protein (PHAVU_001G0988001g) mRNA, partial cds
GATAATACCTTGA
>XM_007153815.1 Phaseolus vulgaris hypothetical protein (PHAVU_003G0723000g) mRNA, partial cds
ATGGCCCACAAGT
>HJ724954.1 Sequence 14 from patent US 8658607
NNNNNGTGTGTGT
>HJ724952.1 Sequence 12 from patent US 8658607
GGGGGGTGTGTGT
>HJ723805.1 Sequence 9 from patent US 8658364
TCTCTCTCAACAA
>HJ722957.1 Sequence 34 from patent US 8658155
CTCATTTACATAC
>HJ722944.1 Sequence 21 from patent US 8658155
GGAAGTGGGTCAC
>HJ722890.1 Sequence 8 from patent US 8658153
TCGTCGCCTCGGC
>HJ722864.1 Sequence 6 from patent US 8658017
GTCGTACGGCTAA
>HJ721396.1 Sequence 7 from patent US 8652812
GGTGGTGGTGGTG
>HJ721395.1 Sequence 6 from patent US 8652812
CACCACCACCACC
>HJ717285.1 Sequence 337 from patent US 8648185
TTCCGCGTACGTT
>HJ717281.1 Sequence 331 from patent US 8648185
TTCCGCGTACGTT
>HJ717248.1 Sequence 296 from patent US 8648185
TTCCGCGTACGTT
>HJ717247.1 Sequence 294 from patent US 8648185
TTCCGCGTACGTT
>HJ717039.1 Sequence 84 from patent US 8648185
TTCCGCGTACGTT
>HJ715843.1 Sequence 9 from patent US 8648051
TGGTGGTGGTGGT
>HJ715311.1 Sequence 76 from patent US 8647856
DTAAACATGTAGG
>HJ714200.1 Sequence 974 from patent US 8645115
AGGAAACAGAACC
>HJ714163.1 Sequence 934 from patent US 8645115
TCACACAGGAAAG
>HJ714161.1 Sequence 932 from patent US 8645115
AGGAGGATTACAA
>HJ714076.1 Sequence 844 from patent US 8645115
AGGAATTTAAATG
>HJ710685.1 Sequence 61 from patent US 8642751
TTTGTTCGTCTTA
>HJ710684.1 Sequence 60 from patent US 8642751
TTTGTTCGTCTTA
>HJ710683.1 Sequence 59 from patent US 8642751
TTTGTTCGTCTTA
>HJ710682.1 Sequence 58 from patent US 8642751
TTTGTTCGTCTTA
>HJ710681.1 Sequence 57 from patent US 8642751
TTTGCTCGTCTTA
>HJ710680.1 Sequence 56 from patent US 8642751
TTTGCTCGTCTTA
>HJ710679.1 Sequence 55 from patent US 8642751
TTTGCTCGTCTTA
>HJ710678.1 Sequence 54 from patent US 8642751
TTTGCTCGTCTTA
>HJ703269.1 Sequence 45 from patent US 8642045
TTTTTTTTTTTTT
>HW381594.1 JP 2013226096-A/12: A method for determining skin type in a subject and a method for providing cosmetic preparations to the subject
CCTGCCCGCTCGC
>HW381593.1 JP 2013226096-A/11: A method for determining skin type in a subject and a method for providing cosmetic preparations to the subject
CCTGCCTGCTCGC
>HW389478.1 JP 2013539357-A/24: ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES (RSV) AND METHODS OF USE
GGCCNNNNNGGCC
>HW387898.1 WO 2013176136-A/28: Composition for detecting Mycoplasma and Acholeplasma
GGTAATACATAGG
>HW387897.1 WO 2013176136-A/27: Composition for detecting Mycoplasma and Acholeplasma
CGGTAATACATAG
>HW387874.1 WO 2013176136-A/4: Composition for detecting Mycoplasma and Acholeplasma
GGTAATACATAGG
>HW387335.1 WO 2013175656-A/5: Novel nucleic acid derivative, and conjugated molecule of nucleic acid derivative and amine compound
CCNGTGGATAACA
>HW387334.1 WO 2013175656-A/4: Novel nucleic acid derivative, and conjugated molecule of nucleic acid derivative and amine compound
CCNGTGGATAACA
>HW387333.1 WO 2013175656-A/3: Novel nucleic acid derivative, and conjugated molecule of nucleic acid derivative and amine compound
CCNGTGGATAACA
>HW387332.1 WO 2013175656-A/2: Novel nucleic acid derivative, and conjugated molecule of nucleic acid derivative and amine compound
CCNGTGGATAACA
>HW387331.1 WO 2013175656-A/1: Novel nucleic acid derivative, and conjugated molecule of nucleic acid derivative and amine compound
CCNGTGGATAACA
>HW370852.1 JP 2012213404-A/2230: Detection of RNA
ATTCTCTCAGACT
>HW370835.1 JP 2012213404-A/2213: Detection of RNA
GCCAAGGAGCACG
>HW370831.1 JP 2012213404-A/2209: Detection of RNA
GGCCAAGGAGCAC
>HW370827.1 JP 2012213404-A/2205: Detection of RNA
TGGCCAAGGAGCA
>HW370824.1 JP 2012213404-A/2202: Detection of RNA
GTCTGCTTCTGGA
>HW370658.1 JP 2012213404-A/2036: Detection of RNA
CACTGCTTCGTGG
>HW370657.1 JP 2012213404-A/2035: Detection of RNA
CACTGCTTCGTGG
>HW370641.1 JP 2012213404-A/2019: Detection of RNA
CACTGCTTCGTGG
>HW370635.1 JP 2012213404-A/2013: Detection of RNA
CACTGCTTCGTGG
>HW370256.1 JP 2012213404-A/1634: Detection of RNA
ATTCTCTCAGACT
>HW370191.1 JP 2012213404-A/1569: Detection of RNA
CAACGCTTCCTCC
>HW369647.1 JP 2012213404-A/1025: Detection of RNA
CAACGCTTCGTGG
>HW369639.1 JP 2012213404-A/1017: Detection of RNA
CACTGCTTCGTGG
>HW369633.1 JP 2012213404-A/1011: Detection of RNA
CACTGCTTCGTGG
>HW369546.1 JP 2012213404-A/924: Detection of RNA
CACTGCTTCGTGG
>HW369540.1 JP 2012213404-A/918: Detection of RNA
CACTGCTTCGTGG
>HW369534.1 JP 2012213404-A/912: Detection of RNA
CACTGCTTCGTGG
>HW369522.1 JP 2012213404-A/900: Detection of RNA
CAACGCTTCGTGG
>HW369414.1 JP 2012213404-A/792: Detection of RNA
CACTGCTTCGTGG
>HW369406.1 JP 2012213404-A/784: Detection of RNA
CACTGCTTCGTGG
>HW369400.1 JP 2012213404-A/778: Detection of RNA
CACTGCTTCGTGG
>HW369394.1 JP 2012213404-A/772: Detection of RNA
CACTGCTTCGTGG
>HW369388.1 JP 2012213404-A/766: Detection of RNA
CACTGCTTCGTGG
>HW369382.1 JP 2012213404-A/760: Detection of RNA
CACTGCTTCGTGG
>HW369376.1 JP 2012213404-A/754: Detection of RNA
CACTGCTTCGTGG
>HW369324.1 JP 2012213404-A/702: Detection of RNA
CACTGCTTCGTGG
>HW369290.1 JP 2012213404-A/668: Detection of RNA
CACTGCTTCGTGG
>HW369213.1 JP 2012213404-A/591: Detection of RNA
CACTGCTTCGTGG
>HW369174.1 JP 2012213404-A/552: Detection of RNA
GGGCCAGAGGGCT
>HW368782.1 JP 2012213404-A/160: Detection of RNA
ACGAGCGTCTTTG
>HW367203.1 JP 2012193192-A/14: Method for modulating responsiveness to steroids
ACAGTTCGTCCAT
>HW376196.1 JP 2012235793-A/112: PROTEASE INHIBITION
GGCCNNNNNGGCC
>HW364649.1 JP 2012165751-A/56: Detection of Nucleic Acids from Multiple Types of Human Papillomaviruses
GTAGAAACCTCGC
>HW373218.1 JP 2012213406-A/4: NUCLEOTIDE AND PROTEIN SEQUENCES OF NOGO GENES AND METHODS BASED THEREON
GCCGCCRCCATGG
>HW381259.1 JP 2012525124-A/201: Hepcidin binding nucleic acids
GCAGGYAATCTGC
>HW381256.1 JP 2012525124-A/198: Hepcidin binding nucleic acids
GGCGTGTTAGTGC
>HW381255.1 JP 2012525124-A/197: Hepcidin binding nucleic acids
AGCGTGATAGTGC
>HW381254.1 JP 2012525124-A/196: Hepcidin binding nucleic acids
GGCGTGAGAGTGC
>HW381253.1 JP 2012525124-A/195: Hepcidin binding nucleic acids
GGAGTGTTAGTTC
>HW381252.1 JP 2012525124-A/194: Hepcidin binding nucleic acids
GGCGTGATAGTGC
>HW381246.1 JP 2012525124-A/188: Hepcidin binding nucleic acids
GCAGGCAATCTGC
>HW381245.1 JP 2012525124-A/187: Hepcidin binding nucleic acids
GCAGGTAATCTGC
>HW381240.1 JP 2012525124-A/182: Hepcidin binding nucleic acids
GCAGATAATCTGC
>HW381238.1 JP 2012525124-A/180: Hepcidin binding nucleic acids
RGMGTGWKAGTKC
>HW381227.1 JP 2012525124-A/169: Hepcidin binding nucleic acids
GCGCCCTTCCTCC
>HW381158.1 JP 2012525124-A/100: Hepcidin binding nucleic acids
TCCAGGTTCTGGA
>JC467204.1 Sequence 292 from Patent EP2363416
CATGGTGGCGGCG
>JC465616.1 Sequence 24 from Patent EP2206782
CATCTGCTACTCG
>JC451376.1 Sequence 93 from Patent EP2585596
GCCAGTCACAAAT
>JC426540.1 Sequence 7 from Patent EP2311992
CGTGGTACCCCTT
>JC426538.1 Sequence 5 from Patent EP2311992
CGTGGTGACCCTT
>JC372250.1 Sequence 5820 from Patent EP2470660
ACACATTTTTTAA
>JC372108.1 Sequence 5678 from Patent EP2470660
TATCGGTGATAAC
>JC372098.1 Sequence 5668 from Patent EP2470660
AAAATAAAAATTG
>JC372096.1 Sequence 5666 from Patent EP2470660
AAGAGGTGAGCAA
>JC372095.1 Sequence 5665 from Patent EP2470660
TTAAAAAACTATT
>JC372083.1 Sequence 5653 from Patent EP2470660
AAAAGGATTTAGT
>JC372079.1 Sequence 5649 from Patent EP2470660
AATAAATAAAGGA
>JC372017.1 Sequence 5587 from Patent EP2470660
TAATATCAAACTC
>JC371565.1 Sequence 5135 from Patent EP2470660
ATTAAAAAAAAAG
>JC371356.1 Sequence 4926 from Patent EP2470660
TTTAAAAATAGAT
>JC371317.1 Sequence 4887 from Patent EP2470660
ATAACTCCTCCTT
>JC371075.1 Sequence 4645 from Patent EP2470660
ATAAACACTTCCT
>JC370999.1 Sequence 4569 from Patent EP2470660
AAAAAACATCCCC
>JC370985.1 Sequence 4555 from Patent EP2470660
ATAATCACATATC
>JC370977.1 Sequence 4547 from Patent EP2470660
AAGTCAGTTAATA
>JC442372.1 Sequence 11 from Patent EP2683242
CAGAGCAAGGACG
>JC258355.1 Sequence 53 from Patent EP2361979
CAACTGCCCGCAA
>JC258356.1 Sequence 54 from Patent EP2361979
CATCCCTCCGCAA
>JC258413.1 Sequence 111 from Patent EP2361979
CATCCCTCCGCAA
>JC258405.1 Sequence 103 from Patent EP2361979
CAACTGCCCGCAA
>JC291635.1 Sequence 7 from Patent EP2302074
CGTGGTACCCCTT
>JC291633.1 Sequence 5 from Patent EP2302074
CGTGGTGACCCTT
>JC285729.1 Sequence 394 from Patent EP2402437
ATGGAACCCTGAA
>JC285236.1 Sequence 11 from Patent WO2013022738
TCGCGAGCTTCCT
>JC304851.1 Sequence 63 from Patent WO2012104729
TACACCCNNNCAT
>JC304841.1 Sequence 53 from Patent WO2012104729
GACACCCAAACAT
>JC304840.1 Sequence 52 from Patent WO2012104729
CACACCCAAACAT
>JC304839.1 Sequence 51 from Patent WO2012104729
AACACCCAAACAT
>JC304792.1 Sequence 4 from Patent WO2012104729
TACACCCAAACAT
>JC311821.1 Sequence 16 from Patent EP2453903
AGCAGCGTTCTTG
>JC310678.1 Sequence 394 from Patent EP2402438
ATGGAACCCTGAA
>JC296653.1 Sequence 171 from Patent EP2427553
AAACTGAGCTCCA
>JC333937.1 Sequence 166 from Patent EP2504430
TACACCCNNNCAT
>JC333901.1 Sequence 130 from Patent EP2504430
YTATCATTGATAG
>JC296575.1 Sequence 93 from Patent EP2427553
TGGAGCTCAGTTT
>JC370896.1 Sequence 4466 from Patent EP2470660
ATTTATTCTATCC
>JC370648.1 Sequence 4218 from Patent EP2470660
ATTGGTTAGATAT
>JC370603.1 Sequence 4173 from Patent EP2470660
GTATGGTGATTAA
>JC370549.1 Sequence 4119 from Patent EP2470660
AGTAAAGGATCTG
>JC370417.1 Sequence 3987 from Patent EP2470660
CGGATTTTTTAAA
>JC370350.1 Sequence 3920 from Patent EP2470660
TTAAATAACCTTC
>JC370255.1 Sequence 3825 from Patent EP2470660
AAGGTAGAATATT
>JC370140.1 Sequence 3710 from Patent EP2470660
TTTTTTTATTTTT
>JC370026.1 Sequence 3596 from Patent EP2470660
AGCTCGTTCCGCT
>JC370016.1 Sequence 3586 from Patent EP2470660
TTTGGTGATATAT
>JC369954.1 Sequence 3524 from Patent EP2470660
TTTTTAATTACGG
>JC369875.1 Sequence 3445 from Patent EP2470660
TTTCTTTTTTTTC
>JC369835.1 Sequence 3405 from Patent EP2470660
ATGATTTTTGAAA
>JC369731.1 Sequence 3301 from Patent EP2470660
TTTAATTTTAAGT
>JC369545.1 Sequence 3115 from Patent EP2470660
TTAATAAAAAATA
>JC369045.1 Sequence 2615 from Patent EP2470660
GGATTTTTAATCC
>JC369015.1 Sequence 2585 from Patent EP2470660
CTCCTTAAAGGAG
>JC368986.1 Sequence 2556 from Patent EP2470660
GTTAAAATTTAAC
>JC368960.1 Sequence 2530 from Patent EP2470660
GATTAAAATAATC
>JC368945.1 Sequence 2515 from Patent EP2470660
GAGATTTAATCTC
>JC368864.1 Sequence 2434 from Patent EP2470660
GTATTTTAGATAC
>JC368845.1 Sequence 2415 from Patent EP2470660
TGCATTTAATGCA
>JC368844.1 Sequence 2414 from Patent EP2470660
TGCATTTAATGCA
>JC368401.1 Sequence 1971 from Patent EP2470660
TTAGTTTAACTAA
>JC368362.1 Sequence 1932 from Patent EP2470660
GCTACATTGTAGC
>JC368339.1 Sequence 1909 from Patent EP2470660
CAGAACTCTTCTG
>JC368335.1 Sequence 1905 from Patent EP2470660
TTATTATAAATAA
>JC368159.1 Sequence 1729 from Patent EP2470660
GTAAGCAACTTAC
>JC368149.1 Sequence 1719 from Patent EP2470660
GATGATTTTCATC
>JC277659.1 Sequence 300 from Patent WO2011088076
GYRCCGTACCCGG
>JC277654.1 Sequence 295 from Patent WO2011088076
TGGTGCGGATGGG
>JC277650.1 Sequence 291 from Patent WO2011088076
GCCGGRGYAARYA
>JC277641.1 Sequence 282 from Patent WO2011088076
ACGAARACGGTRA
>JC277627.1 Sequence 268 from Patent WO2011088076
CACTGRAAGGTGG
>JC277619.1 Sequence 260 from Patent WO2011088076
RCAGYAAGCAGGA
>JC277608.1 Sequence 249 from Patent WO2011088076
GCGCCRTAYGGCT
>JC277604.1 Sequence 245 from Patent WO2011088076
GCGCCRTAYGGCT
>JC277565.1 Sequence 206 from Patent WO2011088076
GAARTCGCAAGAY
>JC277530.1 Sequence 171 from Patent WO2011088076
GGRCGTCTTTTTT
>JC277529.1 Sequence 170 from Patent WO2011088076
AAGAGACGTCCTC
>JC277523.1 Sequence 164 from Patent WO2011088076
YYGAAGGAACGCR
>JC277519.1 Sequence 160 from Patent WO2011088076
GGGTTRRATGCCC
>JC277515.1 Sequence 156 from Patent WO2011088076
GGTRATGTCTCCT
>JC277494.1 Sequence 135 from Patent WO2011088076
GCCGGGCRAYGCA
>JC277487.1 Sequence 128 from Patent WO2011088076
GGCCGCTTTTTTT
>JC277486.1 Sequence 127 from Patent WO2011088076
RRRAAARGCGGCY
>JC277485.1 Sequence 126 from Patent WO2011088076
YTGCCCGCYTTCG
>JC277481.1 Sequence 122 from Patent WO2011088076
CTCAAATCYTGTY
>JC277474.1 Sequence 115 from Patent WO2011088076
CAAGGTTTTGCYY
>JC277470.1 Sequence 111 from Patent WO2011088076
YCACRTCCTGYGR
>JC277466.1 Sequence 107 from Patent WO2011088076
TGCCCTRGTRRCY
>JC277452.1 Sequence 93 from Patent WO2011088076
RRRCTTCGATCGA
>JC277440.1 Sequence 81 from Patent WO2011088076
GCGCCRTAYGGCT
>JC277437.1 Sequence 78 from Patent WO2011088076
CAAGGTTTTGCYY
>JC277432.1 Sequence 73 from Patent WO2011088076
YCACRTCCTGYGR
>JC277429.1 Sequence 70 from Patent WO2011088076
GGCCGCTTTTTTT
>JC277411.1 Sequence 52 from Patent WO2011088076
YYGAAGGAACGCR
>JC277408.1 Sequence 49 from Patent WO2011088076
TGGTGCGGATGGG
>JC277407.1 Sequence 48 from Patent WO2011088076
GGGTTRRATGCCC
>JC277403.1 Sequence 44 from Patent WO2011088076
GGTRATGTCTCCT
>JC277398.1 Sequence 39 from Patent WO2011088076
GYRCCGTACCCGG
>JC265326.1 Sequence 14 from Patent EP2458009
GGCCNNNNNGGCC
>JC283506.1 Sequence 34 from Patent WO2012092284
CTCATTTACATAC
>JC283493.1 Sequence 21 from Patent WO2012092284
GGAAGTGGGTCAC
>JC353995.1 Sequence 42 from Patent EP2501810
GGTGAGTACTAGT
>JC245724.1 Sequence 85 from Patent EP2325209
GCCGCCRCCATGG
>JC243307.1 Sequence 7 from Patent EP2333118
CGTGGTACCCCTT
>JC243305.1 Sequence 5 from Patent EP2333118
CGTGGTGACCCTT
>JC242028.1 Sequence 7 from Patent EP2322649
CGTGGTACCCCTT
>JC242026.1 Sequence 5 from Patent EP2322649
CGTGGTGACCCTT
>JC231603.1 Sequence 2 from Patent WO2012149470
CGTCTAAATCATG
>JC203669.1 Sequence 92 from Patent WO2012039137
GCAGCAAGGAATT
>JC203668.1 Sequence 91 from Patent WO2012039137
TTGAAGCAGCCAG
>JC203667.1 Sequence 90 from Patent WO2012039137
AAGTTTTGCTGTC
>JC203666.1 Sequence 89 from Patent WO2012039137
TTGCCTGAGAGTC
>JC203665.1 Sequence 88 from Patent WO2012039137
CCAGAAGTGACGA
>JC203664.1 Sequence 87 from Patent WO2012039137
AGTCTCCATTGAG
>JC203663.1 Sequence 86 from Patent WO2012039137
AGATGGGGAACCA
>JC203662.1 Sequence 85 from Patent WO2012039137
AGAGGAAGTCTCC
>JC203661.1 Sequence 84 from Patent WO2012039137
ACTTGTCTGGGAG
>JC203660.1 Sequence 83 from Patent WO2012039137
CGTGTTGTGATAT
>JC203659.1 Sequence 82 from Patent WO2012039137
TGCAGATGATCCC
>JC203658.1 Sequence 81 from Patent WO2012039137
TGATACCACCAGA
>JC198805.1 Sequence 36 from Patent WO2011123396
WATCAANNNNTTR
>JC191239.1 Sequence 88 from Patent WO2013022782
CCACTGGCATCCC
>JC190995.1 Sequence 437 from Patent WO2012025251
GGGGGGCGCGACC
>JC190678.1 Sequence 120 from Patent WO2012025251
GGGGGGCGCGACC
>JC190677.1 Sequence 119 from Patent WO2012025251
GGGGGRCGCGAYC
>JC184275.1 Sequence 26 from Patent WO2012097849
TTATTCTTATAGG
>HJ702489.1 Sequence 202 from patent US 8629117
GGATTTCTTTGGC
>HJ702465.1 Sequence 178 from patent US 8629117
CCCTGGCTCGGGG
>HJ702399.1 Sequence 112 from patent US 8629117
CGGCAGTGCCCCG
>HJ702396.1 Sequence 109 from patent US 8629117
CCCGAGGAGCGGG
>HJ702389.1 Sequence 102 from patent US 8629117
CGGCGGCGGCTCG
>HJ702378.1 Sequence 91 from patent US 8629117
CGATGCGCTTCCG
>HJ699427.1 Sequence 3 from patent US 8618279
ACTTGTTGACATT
>HJ699125.1 Sequence 337 from patent US 8618277
TTCCGCGTACGTT
>HJ699121.1 Sequence 331 from patent US 8618277
TTCCGCGTACGTT
>HJ699088.1 Sequence 296 from patent US 8618277
TTCCGCGTACGTT
>HJ699087.1 Sequence 294 from patent US 8618277
TTCCGCGTACGTT
>HJ698879.1 Sequence 84 from patent US 8618277
TTCCGCGTACGTT
>HJ697986.1 Sequence 401 from patent US 8617876
CCAAAGTTGGGGT
>HJ697983.1 Sequence 398 from patent US 8617876
TGGGGTTTTTCCC
>HJ697982.1 Sequence 397 from patent US 8617876
GAATGGGAAAAAC
>HJ697977.1 Sequence 392 from patent US 8617876
TCCTGGGAATGGG
>HJ697966.1 Sequence 381 from patent US 8617876
GGGTCAGGGATCA
>HJ697958.1 Sequence 373 from patent US 8617876
ATTAACGGTGGTG
>HJ697944.1 Sequence 359 from patent US 8617876
CTGATGTCATCCT
>HJ697936.1 Sequence 351 from patent US 8617876
GCTGTTAATTAAA
>HJ697933.1 Sequence 348 from patent US 8617876
ATTTAATTAACAG
>HJ697930.1 Sequence 345 from patent US 8617876
TGTTAATTAAATG
>HJ697926.1 Sequence 341 from patent US 8617876
ACATTTAATTAAC
>HJ697917.1 Sequence 332 from patent US 8617876
AGGCTCCATGCTC
>HJ697915.1 Sequence 330 from patent US 8617876
GAATGGGAAGGTC
>HJ697912.1 Sequence 327 from patent US 8617876
AGGAATGAATGGG
>HJ697910.1 Sequence 325 from patent US 8617876
ATGGAGGAATGAA
>HJ697907.1 Sequence 322 from patent US 8617876
AGGAAGGAATGGA
>HJ697906.1 Sequence 321 from patent US 8617876
CAGGAAGGAATGG
>HJ697900.1 Sequence 315 from patent US 8617876
AGCACAGAATGGG
>HJ697897.1 Sequence 312 from patent US 8617876
TAGGGATAAGTGT
>HJ697887.1 Sequence 302 from patent US 8617876
TGAAAGATGAGTT
>HJ697883.1 Sequence 298 from patent US 8617876
GGAGGAGGGGCAC
>HJ697880.1 Sequence 295 from patent US 8617876
TCCCCAAGGCCAG
>HJ697876.1 Sequence 290 from patent US 8617876
CACTCACCTGGGA
>HJ697872.1 Sequence 286 from patent US 8617876
AATAATTAATGAG
>HJ697870.1 Sequence 284 from patent US 8617876
CTCATTAATTATT
>HJ697869.1 Sequence 283 from patent US 8617876
AAATAATTAATGA
>HJ697866.1 Sequence 280 from patent US 8617876
AGAAATAATTAAT
>HJ697855.1 Sequence 269 from patent US 8617876
TGTGCAGAATGAA
>HJ697851.1 Sequence 264 from patent US 8617876
TGGCTGGGGGAAG
>HJ697843.1 Sequence 256 from patent US 8617876
GGCCCAAGGTTAG
>HJ697841.1 Sequence 254 from patent US 8617876
AGGGGGCTGCCCC
>HJ697840.1 Sequence 253 from patent US 8617876
GGGGCTGCCCCCG
>HJ697836.1 Sequence 248 from patent US 8617876
TGGAATTTGCGCC
>HJ697812.1 Sequence 224 from patent US 8617876
TCTGGGGGGGTCA
>HJ697791.1 Sequence 203 from patent US 8617876
TCAGCATCTGGGA
>HJ697789.1 Sequence 201 from patent US 8617876
ATCTGGGAGATTG
>HJ697780.1 Sequence 192 from patent US 8617876
GGGGATTAATATG
>HJ697778.1 Sequence 189 from patent US 8617876
GGGCCTAATTGGC
>HJ697773.1 Sequence 184 from patent US 8617876
GGGCCAAGGTGAC
>HJ697769.1 Sequence 180 from patent US 8617876
ATTAACGCTGGTC
>HJ697767.1 Sequence 178 from patent US 8617876
ATGAGGTCAAGGT
>HJ697763.1 Sequence 174 from patent US 8617876
GGCATTGAATGGA
>HJ697753.1 Sequence 164 from patent US 8617876
CTCTTAAGCCTCA
>HJ697746.1 Sequence 157 from patent US 8617876
GGGGGGGGGGTCT
>HJ697738.1 Sequence 149 from patent US 8617876
TGAAGGGGGGGGG
>HJ697735.1 Sequence 146 from patent US 8617876
AAACCATCTGATC
>HJ697733.1 Sequence 144 from patent US 8617876
GACAGATCAGATG
>HJ697725.1 Sequence 136 from patent US 8617876
CCCAACAGGCGTC
>HJ697722.1 Sequence 133 from patent US 8617876
GCACTGTTTCCTC
>HJ697712.1 Sequence 123 from patent US 8617876
GCCATATGCAAAT
>HJ697710.1 Sequence 121 from patent US 8617876
GCCTTGAACTGAA
>HJ697699.1 Sequence 110 from patent US 8617876
ACATTTATTAATG
>HJ697690.1 Sequence 101 from patent US 8617876
GTGTCTAATTGCT
>JC105987.1 Sequence 27 from Patent WO2013177427
CTACATTGGATGG
>JC173532.1 Sequence 968 from Patent WO2013143699
ATTTCCTTTTATG
>JC173274.1 Sequence 710 from Patent WO2013143699
CCTCCCCTCGATG
>JC102788.1 Sequence 9 from Patent WO2013179061
GGCGTGGTGGCAC
>JC102638.1 Sequence 20 from Patent WO2013148272
ATCGCAGCGGCCC
>JC102637.1 Sequence 19 from Patent WO2013148272
ATCGCAGAAGGCC
>JC102634.1 Sequence 16 from Patent WO2013148272
ATCGCAGCGGCCC
>JC102633.1 Sequence 15 from Patent WO2013148272
ATCGCAGAAGGCC
>JC101387.1 Sequence 5 from Patent WO2013179067
GCCCAAGCTGGCA
>JC100929.1 Sequence 32 from Patent WO2013181256
ATTGGASAATTGC
>JC100917.1 Sequence 20 from Patent WO2013181256
ATTWTTTACCAAC
>JC100916.1 Sequence 19 from Patent WO2013181256
GAAGTCCTSGGGT
>JC100903.1 Sequence 6 from Patent WO2013181256
GGGTGTAAGTSAG
>HW340370.1 JP 2013198488-A/111: METHODS FOR SELECTING MEDICATIONS
CAACGTGCTGGTG
>HW340338.1 JP 2013198488-A/79: METHODS FOR SELECTING MEDICATIONS
TGGAGATCATGAT
>HW340303.1 JP 2013198488-A/44: METHODS FOR SELECTING MEDICATIONS
AGCTTATTACAGC
>HW350582.1 JP 2013534826-A/38: Lowering Saturated Fatty Acid Content of Plant Seeds
ACAACCAAAAATG
>HW350581.1 JP 2013534826-A/37: Lowering Saturated Fatty Acid Content of Plant Seeds
GGATCCAACAATG
>HW349806.1 JP 2013534806-A/24: Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions
GACGTGGTGCAAA
>HW349791.1 JP 2013534806-A/9: Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions
GACGTGGTGCAGA
>HW349790.1 JP 2013534806-A/8: Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions
GACGTGGTGCAAA
>HW349789.1 JP 2013534806-A/7: Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions
GACATGGTCCAGA
>HW349451.1 WO 2013154128-A/490: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACACCTATGGAA
>HW349450.1 WO 2013154128-A/489: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACCTATGGAATC
>HW349449.1 WO 2013154128-A/488: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CATACTGGTACAC
>HW349448.1 WO 2013154128-A/487: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATACTGGTACACC
>HW349447.1 WO 2013154128-A/486: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCTTGATGCAGTG
>HW349446.1 WO 2013154128-A/485: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTTGATGCAGTGT
>HW349445.1 WO 2013154128-A/484: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGATGCAGTGTGA
>HW349444.1 WO 2013154128-A/483: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GATGCAGTGTGAG
>HW349443.1 WO 2013154128-A/482: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATGCAGTGTGAGT
>HW349442.1 WO 2013154128-A/481: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAACTGTACAGGT
>HW349441.1 WO 2013154128-A/480: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TACAGGTTGCTTC
>HW349440.1 WO 2013154128-A/479: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAAAGCCTTGAGC
>HW349439.1 WO 2013154128-A/478: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGCTAGCATGTTG
>HW349438.1 WO 2013154128-A/477: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CATGATGTGTACC
>HW349437.1 WO 2013154128-A/476: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGATGTGTACCAG
>HW349436.1 WO 2013154128-A/475: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATGTGTACCAGCC
>HW349435.1 WO 2013154128-A/474: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCATAGAGGTGGT
>HW349434.1 WO 2013154128-A/473: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CATAGAGGTGGTA
>HW349433.1 WO 2013154128-A/472: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGTGTGGCAAAG
>HW349432.1 WO 2013154128-A/471: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGAAGATGGAGCA
>HW349431.1 WO 2013154128-A/470: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGTGGATCCAGAT
>HW349430.1 WO 2013154128-A/469: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATCCAGATGAGGA
>HW349429.1 WO 2013154128-A/468: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACAGAGGTGCTGA
>HW349428.1 WO 2013154128-A/467: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTGATGTAGTCT
>HW349427.1 WO 2013154128-A/466: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCAGTCCAGATGT
>HW349426.1 WO 2013154128-A/465: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGCCACCAGTAAT
>HW349425.1 WO 2013154128-A/464: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCCACCAGTAATA
>HW349424.1 WO 2013154128-A/463: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATCCATATGGAGG
>HW349423.1 WO 2013154128-A/462: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CATATGGAGGTGT
>HW349422.1 WO 2013154128-A/461: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCAGCACTTCTAT
>HW349421.1 WO 2013154128-A/460: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGCATCTGCATGT
>HW349420.1 WO 2013154128-A/459: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAACAGGAAGTCC
>HW349419.1 WO 2013154128-A/458: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAAGAGGACCAAG
>HW349418.1 WO 2013154128-A/457: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAGTGCCAAGAGA
>HW349417.1 WO 2013154128-A/456: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCCAAGAGATAG
>HW349416.1 WO 2013154128-A/455: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAGAGGATGATCA
>HW349415.1 WO 2013154128-A/454: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTGCTGGTAAACC
>HW349414.1 WO 2013154128-A/453: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGTAGTAGACCA
>HW349413.1 WO 2013154128-A/452: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GACCACCAAGACA
>HW349412.1 WO 2013154128-A/451: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACACAAGTATGC
>HW349411.1 WO 2013154128-A/450: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACACAAGTATGCC
>HW349410.1 WO 2013154128-A/449: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCAGAGTTGCAG
>HW349409.1 WO 2013154128-A/448: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCAGTCACTGTAG
>HW349408.1 WO 2013154128-A/447: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGAAGGACACCTT
>HW349407.1 WO 2013154128-A/446: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGGACACCTTGC
>HW349406.1 WO 2013154128-A/445: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTATCTGCTCAG
>HW349405.1 WO 2013154128-A/444: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTGCAGCATGTA
>HW349404.1 WO 2013154128-A/443: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCAGCATGTAGA
>HW349403.1 WO 2013154128-A/442: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAGCATGTAGAG
>HW349402.1 WO 2013154128-A/441: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCATGTAGAGCC
>HW349401.1 WO 2013154128-A/440: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGAAGGACACCTT
>HW349400.1 WO 2013154128-A/439: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGGACACCTTGC
>HW349399.1 WO 2013154128-A/438: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTATCTGCTCAG
>HW349398.1 WO 2013154128-A/437: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTGCAGCATGTA
>HW349397.1 WO 2013154128-A/436: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCAGCATGTAGA
>HW349396.1 WO 2013154128-A/435: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAGCATGTAGAG
>HW349395.1 WO 2013154128-A/434: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCATGTAGAGCC
>HW349394.1 WO 2013154128-A/433: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGAAGGACACCTT
>HW349393.1 WO 2013154128-A/432: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGGACACCTTGC
>HW349392.1 WO 2013154128-A/431: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTATCTGCTCAG
>HW349391.1 WO 2013154128-A/430: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTGCAGCATGTA
>HW349390.1 WO 2013154128-A/429: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCAGCATGTAGA
>HW349389.1 WO 2013154128-A/428: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAGCATGTAGAG
>HW349388.1 WO 2013154128-A/427: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCATGTAGAGCC
>HW349387.1 WO 2013154128-A/426: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGAAGGACACCTT
>HW349386.1 WO 2013154128-A/425: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGGACACCTTGC
>HW349385.1 WO 2013154128-A/424: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTATCTGCTCAG
>HW349384.1 WO 2013154128-A/423: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTGCAGCATGTA
>HW349383.1 WO 2013154128-A/422: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCAGCATGTAGA
>HW349382.1 WO 2013154128-A/421: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAGCATGTAGAG
>HW349381.1 WO 2013154128-A/420: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCATGTAGAGCC
>HW349380.1 WO 2013154128-A/419: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGAAGGACACCTT
>HW349379.1 WO 2013154128-A/418: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGGACACCTTGC
>HW349378.1 WO 2013154128-A/417: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTATCTGCTCAG
>HW349377.1 WO 2013154128-A/416: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTGCAGCATGTA
>HW349376.1 WO 2013154128-A/415: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCAGCATGTAGA
>HW349375.1 WO 2013154128-A/414: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAGCATGTAGAG
>HW349374.1 WO 2013154128-A/413: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCATGTAGAGCC
>HW349373.1 WO 2013154128-A/412: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTATGGCTGAGCT
>HW349372.1 WO 2013154128-A/411: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAGGAGTTCAGAA
>HW349371.1 WO 2013154128-A/410: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTGGAACCACAGG
>HW349370.1 WO 2013154128-A/409: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGTTGCTGGTTTC
>HW349369.1 WO 2013154128-A/408: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATACATCCTCACC
>HW349368.1 WO 2013154128-A/407: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TACATCCTCACCA
>HW349367.1 WO 2013154128-A/406: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGTTGGTTTCTGG
>HW349366.1 WO 2013154128-A/405: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTTGGTTTCTGGC
>HW349365.1 WO 2013154128-A/404: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCCTCTGAACCTT
>HW349364.1 WO 2013154128-A/403: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGATGTCCTTGTG
>HW349363.1 WO 2013154128-A/402: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGAGCTCCTTCCT
>HW349362.1 WO 2013154128-A/401: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTGGAGTTGAAC
>HW349361.1 WO 2013154128-A/400: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGAACAGGTCTGC
>HW349360.1 WO 2013154128-A/399: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AACAGGTCTGCAG
>HW349359.1 WO 2013154128-A/398: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGATGCCTTGGTT
>HW349358.1 WO 2013154128-A/397: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTGAAGTATGGAG
>HW349357.1 WO 2013154128-A/396: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGAAAGAGACCA
>HW349356.1 WO 2013154128-A/395: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTTCTGGATTGCA
>HW349355.1 WO 2013154128-A/394: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCTGGATTGCAAC
>HW349354.1 WO 2013154128-A/393: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGGATTGCAACA
>HW349353.1 WO 2013154128-A/392: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GATTTGTAGCAGG
>HW349352.1 WO 2013154128-A/391: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TAGCAGGTACAGG
>HW349351.1 WO 2013154128-A/390: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTCCTGCTGATCA
>HW349350.1 WO 2013154128-A/389: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCTGATCAGCTG
>HW349349.1 WO 2013154128-A/388: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACCTCAAGCACT
>HW349348.1 WO 2013154128-A/387: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACCTCAAGCACTG
>HW349347.1 WO 2013154128-A/386: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCACTGTGTCTGA
>HW349346.1 WO 2013154128-A/385: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACTGTGTCTGAA
>HW349345.1 WO 2013154128-A/384: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTGGCAACAGCAA
>HW349344.1 WO 2013154128-A/383: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGTCAACTGCAGT
>HW349343.1 WO 2013154128-A/382: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GACAGTCTCTGGT
>HW349342.1 WO 2013154128-A/381: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGTAGCAGCACA
>HW349341.1 WO 2013154128-A/380: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACAAGGCTGTCTC
>HW349340.1 WO 2013154128-A/379: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCTCCTGGTCAAC
>HW349339.1 WO 2013154128-A/378: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCATGAGTAGGAG
>HW349338.1 WO 2013154128-A/377: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCACTTGGTCCAA
>HW349337.1 WO 2013154128-A/376: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACTTGGTCCAAC
>HW349336.1 WO 2013154128-A/375: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTCAGAGTTGATC
>HW349335.1 WO 2013154128-A/374: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGAGTTGATCAG
>HW349334.1 WO 2013154128-A/373: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCAACAGGATCA
>HW349333.1 WO 2013154128-A/372: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGATCAAGTTCAG
>HW349332.1 WO 2013154128-A/371: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GATCAAGTTCAGC
>HW349331.1 WO 2013154128-A/370: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGTGTAGCCAGT
>HW349330.1 WO 2013154128-A/369: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGTGTAGCCAGTG
>HW349329.1 WO 2013154128-A/368: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AACACATCAGGCC
>HW349328.1 WO 2013154128-A/367: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGGCCTCAGAGAA
>HW349327.1 WO 2013154128-A/366: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAGTGCTGTACTT
>HW349326.1 WO 2013154128-A/365: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCTAGGAGTGGCA
>HW349325.1 WO 2013154128-A/364: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTCTTGTGGCCTT
>HW349324.1 WO 2013154128-A/363: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCTTGTGGCCTTC
>HW349323.1 WO 2013154128-A/362: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCACACACCTTTC
>HW349322.1 WO 2013154128-A/361: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACACCTTTCCAG
>HW349321.1 WO 2013154128-A/360: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACACCTTTCCAGC
>HW349320.1 WO 2013154128-A/359: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGGTATGTCAGCC
>HW349319.1 WO 2013154128-A/358: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTCAAGCTCTGA
>HW349318.1 WO 2013154128-A/357: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGACAGCTTGTGC
>HW349317.1 WO 2013154128-A/356: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGTCCACAACCT
>HW349316.1 WO 2013154128-A/355: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTAGACACTCTGG
>HW349315.1 WO 2013154128-A/354: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCCTCCACATACA
>HW349314.1 WO 2013154128-A/353: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGCTATGCTCCT
>HW349313.1 WO 2013154128-A/352: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCTATGCTCCTG
>HW349312.1 WO 2013154128-A/351: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TATCACAGCAGGT
>HW349311.1 WO 2013154128-A/350: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCACAGCAGGTTA
>HW349310.1 WO 2013154128-A/349: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGCAGGTTACAA
>HW349309.1 WO 2013154128-A/348: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCAGGTTACAAC
>HW349308.1 WO 2013154128-A/347: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAGGTTACAACA
>HW349307.1 WO 2013154128-A/346: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTAAACTGTCCA
>HW349306.1 WO 2013154128-A/345: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACCTCTTACTGA
>HW349305.1 WO 2013154128-A/344: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGTGTTCTACACC
>HW349304.1 WO 2013154128-A/343: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTGTTCTACACCA
>HW349303.1 WO 2013154128-A/342: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATTGCTGTAGCAG
>HW349302.1 WO 2013154128-A/341: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAAGCAAAGTCAG
>HW349301.1 WO 2013154128-A/340: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACAAGCAAGGCTA
>HW349300.1 WO 2013154128-A/339: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAAGCAAGGCTAG
>HW349299.1 WO 2013154128-A/338: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGCAAGGCTAGG
>HW349298.1 WO 2013154128-A/337: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CATCTTGTGATCC
>HW349297.1 WO 2013154128-A/336: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GACCAAAAAGGAC
>HW349296.1 WO 2013154128-A/335: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TAGGAAACTCAGC
>HW349295.1 WO 2013154128-A/334: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AACTCAGCTTGGT
>HW349294.1 WO 2013154128-A/333: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCAGCTTGGTTAG
>HW349293.1 WO 2013154128-A/332: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGCTTGGTTAGT
>HW349292.1 WO 2013154128-A/331: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCTTGGTTAGTG
>HW349291.1 WO 2013154128-A/330: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTTGGTTAGTGT
>HW349290.1 WO 2013154128-A/329: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGGTTAGTGTGTC
>HW349289.1 WO 2013154128-A/328: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTTAGTGTGTCA
>HW349288.1 WO 2013154128-A/327: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTTAGTGTGTCAG
>HW349287.1 WO 2013154128-A/326: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTAGTGTGTCAGG
>HW349286.1 WO 2013154128-A/325: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTCAGGCACTTTC
>HW349285.1 WO 2013154128-A/324: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCACTTTCTGAGA
>HW349284.1 WO 2013154128-A/323: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTCAGCAACTCTA
>HW349283.1 WO 2013154128-A/322: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAACTCTACAGG
>HW349282.1 WO 2013154128-A/321: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCAAGTTCAGAC
>HW349281.1 WO 2013154128-A/320: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GACAATACAGCTG
>HW349280.1 WO 2013154128-A/319: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAAAGCTGTGGCA
>HW349279.1 WO 2013154128-A/318: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAAGCTGTGGCAA
>HW349278.1 WO 2013154128-A/317: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTTCCACACATGA
>HW349277.1 WO 2013154128-A/316: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCACACATGATC
>HW349276.1 WO 2013154128-A/315: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TAGCCTAAACCAC
>HW349275.1 WO 2013154128-A/314: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTAAACCACTCC
>HW349274.1 WO 2013154128-A/313: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTACCAACCAAG
>HW349273.1 WO 2013154128-A/312: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTACCAACCAAGT
>HW349272.1 WO 2013154128-A/311: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TACCAACCAAGTC
>HW349271.1 WO 2013154128-A/310: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TATCAAACCAGGC
>HW349270.1 WO 2013154128-A/309: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATCAAACCAGGCC
>HW349269.1 WO 2013154128-A/308: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGGCCAGCTGATT
>HW349268.1 WO 2013154128-A/307: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAACTGGATAGTC
>HW349267.1 WO 2013154128-A/306: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACTGGATAGTCAG
>HW349266.1 WO 2013154128-A/305: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGGATAGTCAGC
>HW349265.1 WO 2013154128-A/304: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGATAGTCAGCAC
>HW349264.1 WO 2013154128-A/303: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GATAGTCAGCACC
>HW349263.1 WO 2013154128-A/302: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCATCTCATGTTC
>HW349262.1 WO 2013154128-A/301: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTCATGTTCCATC
>HW349261.1 WO 2013154128-A/300: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGTTCCATCATGG
>HW349260.1 WO 2013154128-A/299: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTCTCATTCCAAG
>HW349258.1 WO 2013154128-A/297: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGGTCAGCTCAAC
>HW349257.1 WO 2013154128-A/296: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTCAGCTCAACT
>HW349256.1 WO 2013154128-A/295: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTAATCTTGTGGC
>HW349255.1 WO 2013154128-A/294: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCAGCTGCATAT
>HW349254.1 WO 2013154128-A/293: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAGCTGCATATG
>HW349253.1 WO 2013154128-A/292: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCTGCATATGTC
>HW349252.1 WO 2013154128-A/291: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCTAGAGTGAAG
>HW349251.1 WO 2013154128-A/290: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTAGAGTGAAGT
>HW349250.1 WO 2013154128-A/289: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTAACTCTGTCAG
>HW349249.1 WO 2013154128-A/288: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTCTGTCAGAGGA
>HW349248.1 WO 2013154128-A/287: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTCAGCTTCAAT
>HW349247.1 WO 2013154128-A/286: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAATAGCTTCTGC
>HW349246.1 WO 2013154128-A/285: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGAGCAAGTTCA
>HW349245.1 WO 2013154128-A/284: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCACAAACAATGG
>HW349244.1 WO 2013154128-A/283: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAGCTAGGATGTG
>HW349243.1 WO 2013154128-A/282: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCTAGGATGTGA
>HW349242.1 WO 2013154128-A/281: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTAGGATGTGAA
>HW349241.1 WO 2013154128-A/280: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TAGGATGTGAAGG
>HW349240.1 WO 2013154128-A/279: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTACAACCTTCA
>HW349239.1 WO 2013154128-A/278: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACAAATTGCTGC
>HW349238.1 WO 2013154128-A/277: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTATCCTGATGT
>HW349237.1 WO 2013154128-A/276: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTATCCTGATGTG
>HW349236.1 WO 2013154128-A/275: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TATCCTGATGTGC
>HW349235.1 WO 2013154128-A/274: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAACAAGCAACTG
>HW349234.1 WO 2013154128-A/273: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAACTGAACTAG
>HW349233.1 WO 2013154128-A/272: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAAAGGTGCATG
>HW349232.1 WO 2013154128-A/271: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTGCATGATTTG
>HW349231.1 WO 2013154128-A/270: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTGCATGATTTGC
>HW349230.1 WO 2013154128-A/269: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATCCAACAGTAGC
>HW349229.1 WO 2013154128-A/268: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCAACAGTAGCC
>HW349228.1 WO 2013154128-A/267: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCAACAGTAGCCT
>HW349227.1 WO 2013154128-A/266: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTATCAGAGGCCA
>HW349226.1 WO 2013154128-A/265: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTTAACCACAAC
>HW349225.1 WO 2013154128-A/264: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTAGTCCATAGT
>HW349224.1 WO 2013154128-A/263: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCATAGTGAAGG
>HW349223.1 WO 2013154128-A/262: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAAGAGCACAGAT
>HW349222.1 WO 2013154128-A/261: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCCTCTATACCAC
>HW349221.1 WO 2013154128-A/260: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTCTATACCACC
>HW349220.1 WO 2013154128-A/259: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACTTGGCAGACCA
>HW349219.1 WO 2013154128-A/258: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTTGGCAGACCAT
>HW349218.1 WO 2013154128-A/257: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTGGCAGACCATC
>HW349217.1 WO 2013154128-A/256: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATTGCAAGTGAGG
>HW349216.1 WO 2013154128-A/255: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCAAGTGAGGTT
>HW349215.1 WO 2013154128-A/254: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCAAGTGAGGTTA
>HW349214.1 WO 2013154128-A/253: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAAGTGAGGTTAG
>HW349213.1 WO 2013154128-A/252: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGGAGACCTTCC
>HW349212.1 WO 2013154128-A/251: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTGTTTAGTTGC
>HW349211.1 WO 2013154128-A/250: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TAGTTGCAGCATC
>HW349210.1 WO 2013154128-A/249: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGAGAGTCCAAA
>HW349209.1 WO 2013154128-A/248: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGAGAGTCCAAAG
>HW349208.1 WO 2013154128-A/247: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GACAGTTCTGAAC
>HW349207.1 WO 2013154128-A/246: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCTGTCAGGTGAA
>HW349206.1 WO 2013154128-A/245: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGTCAGGTGAAGT
>HW349205.1 WO 2013154128-A/244: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGGTGAAGTCCTA
>HW349204.1 WO 2013154128-A/243: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTGAAGTCCTAA
>HW349203.1 WO 2013154128-A/242: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTCCTAAAGCTTG
>HW349202.1 WO 2013154128-A/241: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCTAAAGCTTGC
>HW349201.1 WO 2013154128-A/240: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTAAAGCTTGCA
>HW349200.1 WO 2013154128-A/239: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGCTTGCATTCC
>HW349199.1 WO 2013154128-A/238: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTGCATTCCACCA
>HW349198.1 WO 2013154128-A/237: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TACTAGAGCAGAC
>HW349197.1 WO 2013154128-A/236: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAGCAGACAGATA
>HW349196.1 WO 2013154128-A/235: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGACAGATAGCA
>HW349195.1 WO 2013154128-A/234: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGACAGATAGCAC
>HW349194.1 WO 2013154128-A/233: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGATAGCACCTTC
>HW349193.1 WO 2013154128-A/232: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATAGCACCTTCAG
>HW349192.1 WO 2013154128-A/231: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACTCTGCTTGTGG
>HW349191.1 WO 2013154128-A/230: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTCCACAGTAGT
>HW349190.1 WO 2013154128-A/229: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGTATAGGTCCTC
>HW349189.1 WO 2013154128-A/228: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTATAGGTCCTCA
>HW349188.1 WO 2013154128-A/227: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACTAGCCAGTAT
>HW349187.1 WO 2013154128-A/226: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACTAGCCAGTATG
>HW349153.1 WO 2013154128-A/192: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCATGTTTCAGCA
>HW349154.1 WO 2013154128-A/193: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCATGTTTCAGC
>HW349186.1 WO 2013154128-A/225: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGCCAGTATGATG
>HW349185.1 WO 2013154128-A/224: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGTATGATGAGC
>HW349184.1 WO 2013154128-A/223: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTTGGTTGCCATA
>HW349183.1 WO 2013154128-A/222: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTTGCCATAAGCT
>HW349182.1 WO 2013154128-A/221: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTTGAAGGCAGTC
>HW349181.1 WO 2013154128-A/220: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTGTTGAGCAAGG
>HW349180.1 WO 2013154128-A/219: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGAGCAAGGCAAC
>HW349179.1 WO 2013154128-A/218: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGCCATTTTAGC
>HW349178.1 WO 2013154128-A/217: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGTGGAGAGTTGT
>HW349177.1 WO 2013154128-A/216: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACTGGTGAACCA
>HW349176.1 WO 2013154128-A/215: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACTGGTGAACCAA
>HW349175.1 WO 2013154128-A/214: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGGTGAACCAAGC
>HW349174.1 WO 2013154128-A/213: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTGAACCAAGCAT
>HW349173.1 WO 2013154128-A/212: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AATGCCTCCAGAC
>HW349172.1 WO 2013154128-A/211: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ATGCCTCCAGACT
>HW349171.1 WO 2013154128-A/210: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCCTCCAGACTTA
>HW349170.1 WO 2013154128-A/209: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCTCCAGACTTAA
>HW349169.1 WO 2013154128-A/208: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGAAAGGTTATGC
>HW349168.1 WO 2013154128-A/207: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGTTATGCAAGGT
>HW349167.1 WO 2013154128-A/206: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTTATGCAAGGTC
>HW349166.1 WO 2013154128-A/205: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTATGCAAGGTCC
>HW349165.1 WO 2013154128-A/204: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAGCTGTTTCTAC
>HW349164.1 WO 2013154128-A/203: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAATAGCAGACAC
>HW349163.1 WO 2013154128-A/202: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGACACCATCTGA
>HW349162.1 WO 2013154128-A/201: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGTCTGGAAGCTT
>HW349161.1 WO 2013154128-A/200: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AAGCTGATGGACC
>HW349160.1 WO 2013154128-A/199: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GATGGACCATAAC
>HW349159.1 WO 2013154128-A/198: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGACCATAACTGC
>HW349158.1 WO 2013154128-A/197: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
ACCATAACTGCAG
>HW349157.1 WO 2013154128-A/196: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TAACTGCAGCCTT
>HW349156.1 WO 2013154128-A/195: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AACTGCAGCCTTA
>HW349155.1 WO 2013154128-A/194: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGCAAGTTCTGCA
>HW349152.1 WO 2013154128-A/191: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTGATGGTTCAGC
>HW349151.1 WO 2013154128-A/190: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GATGGTTCAGCCA
>HW349150.1 WO 2013154128-A/189: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTGGACATTAGTG
>HW349149.1 WO 2013154128-A/188: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGGACATTAGTGG
>HW349148.1 WO 2013154128-A/187: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGAGCAGCATCAA
>HW349147.1 WO 2013154128-A/186: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CTAATGTCTCAGG
>HW349146.1 WO 2013154128-A/185: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTGCATACTGTCC
>HW349145.1 WO 2013154128-A/184: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCATACTGTCCAT
>HW349144.1 WO 2013154128-A/183: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGCTACTTGTTC
>HW349143.1 WO 2013154128-A/182: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCTTGAGTGAAGG
>HW349142.1 WO 2013154128-A/181: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTGAGTGAAGGAC
>HW349141.1 WO 2013154128-A/180: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCAGGATTGCCTT
>HW349140.1 WO 2013154128-A/179: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CAGGATTGCCTTT
>HW349139.1 WO 2013154128-A/178: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GGATTGCCTTTAC
>HW349138.1 WO 2013154128-A/177: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GATTGCCTTTACC
>HW349137.1 WO 2013154128-A/176: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGCCTTTACCACT
>HW349136.1 WO 2013154128-A/175: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TTACCACTCAGAG
>HW349135.1 WO 2013154128-A/174: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TACCACTCAGAGA
>HW349134.1 WO 2013154128-A/173: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TAGTGGCACCAGA
>HW349133.1 WO 2013154128-A/172: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CACCAGAATGGAT
>HW349132.1 WO 2013154128-A/171: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGAGTCCAGGTAA
>HW349131.1 WO 2013154128-A/170: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GAGTCCAGGTAAG
>HW349130.1 WO 2013154128-A/169: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
AGTCCAGGTAAGA
>HW349129.1 WO 2013154128-A/168: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCAGGTAAGACT
>HW349128.1 WO 2013154128-A/167: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCCAGTGACTAAC
>HW349127.1 WO 2013154128-A/166: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
CCAGTGACTAACA
>HW349126.1 WO 2013154128-A/165: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTGACTAACAGCC
>HW349125.1 WO 2013154128-A/164: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTCTGGTTCCATG
>HW349124.1 WO 2013154128-A/163: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCCATGTCCAACT
>HW349123.1 WO 2013154128-A/162: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGTCCAACTCCAT
>HW349122.1 WO 2013154128-A/161: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GTCCAACTCCATC
>HW349121.1 WO 2013154128-A/160: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
GCTTGAGTAGCCA
>HW349120.1 WO 2013154128-A/159: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TGAGTAGCCATTG
>HW349119.1 WO 2013154128-A/158: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCCTCAGACCTTC
>HW349118.1 WO 2013154128-A/157: Method for screening of medicine composite for novel arteriosclerosis treatment and arteriosclerosis therapeutic agent
TCAGACCTTCCTC
>HW348040.1 WO 2013150902-A/32: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW348038.1 WO 2013150902-A/30: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW348036.1 WO 2013150902-A/28: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW348034.1 WO 2013150902-A/26: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW348029.1 WO 2013150902-A/21: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW348027.1 WO 2013150902-A/19: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW348025.1 WO 2013150902-A/17: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW348023.1 WO 2013150902-A/15: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW348014.1 WO 2013150902-A/6: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
CGCAATNTAACGC
>HW348013.1 WO 2013150902-A/5: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTGNGTTTTT
>HW348012.1 WO 2013150902-A/4: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTCNCTTTTT
>HW348011.1 WO 2013150902-A/3: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTANATTTTT
>HW348010.1 WO 2013150902-A/2: A process for the production of a 5'-phosphorylated oligodeoxynucleotide comprising cleavage of an oligodeoxynucleotide including a non-native base
TTTTTTNTTTTTT
>HW363617.1 JP 2013535495-A/19: INJECTABLE PHARMACEUTICAL COMPOSITION FOR PREVENTING, STABILISING AND/OR INHIBITING PATHOLOGICAL NEOVASCULARIZATION-RELATED CONDITIONS
TCGCCATGCTGCT
>HW355338.1 JP 2013535198-A/19: A YEAST ARTIFICIAL CHROMOSOME CARRYING THE MAMMALIAN GLYCOSYLATION PATHWAY
GGCCGACTCGGCC
>HW355337.1 JP 2013535198-A/18: A YEAST ARTIFICIAL CHROMOSOME CARRYING THE MAMMALIAN GLYCOSYLATION PATHWAY
GGCCCCTGAGGCC
>HW355336.1 JP 2013535198-A/17: A YEAST ARTIFICIAL CHROMOSOME CARRYING THE MAMMALIAN GLYCOSYLATION PATHWAY
GGCCACGCTGGCC
>HW355335.1 JP 2013535198-A/16: A YEAST ARTIFICIAL CHROMOSOME CARRYING THE MAMMALIAN GLYCOSYLATION PATHWAY
GGCCGCTATGGCC
>HW355334.1 JP 2013535198-A/15: A YEAST ARTIFICIAL CHROMOSOME CARRYING THE MAMMALIAN GLYCOSYLATION PATHWAY
GGCCTGACGGGCC
>HW355333.1 JP 2013535198-A/14: A YEAST ARTIFICIAL CHROMOSOME CARRYING THE MAMMALIAN GLYCOSYLATION PATHWAY
GGCCCGTACGGCC
>HW355332.1 JP 2013535198-A/13: A YEAST ARTIFICIAL CHROMOSOME CARRYING THE MAMMALIAN GLYCOSYLATION PATHWAY
GGCCATGCAGGCC
>HW355229.1 JP 2013534132-A/3: Process
GTCTGTGGAAGCG
>HW355186.1 JP 2013534130-A/4184: ANTIBODY LIBRARIES
NNTTTTGATATCT
>HW355185.1 JP 2013534130-A/4183: ANTIBODY LIBRARIES
GCTTTTGATATCT
>JC078732.1 Sequence 2199 from Patent EP2663334
CTTCGACCACTGG
>JC078724.1 Sequence 2191 from Patent EP2663334
CTTTGACTACTGG
>JC078707.1 Sequence 2174 from Patent EP2663334
TTTTAATATCTGG
>JC078698.1 Sequence 2165 from Patent EP2663334
TTTTGATATTTGG
>JC078684.1 Sequence 2151 from Patent EP2663334
CTTTGACTACTGG
>JC078673.1 Sequence 2140 from Patent EP2663334
CCCCTACTTGGCC
>JC078669.1 Sequence 2136 from Patent EP2663334
TAACTCCTTCTCA
>JC078640.1 Sequence 2107 from Patent EP2663334
GGATAGTGAACTA
>JC078633.1 Sequence 2100 from Patent EP2663334
GTGGTCCTAGGTG
>JC078627.1 Sequence 2094 from Patent EP2663334
TGGGTCCAGTTAC
>JC078626.1 Sequence 2093 from Patent EP2663334
ATTACAGCGCTTC
>JC078576.1 Sequence 2043 from Patent EP2663334
GCGGAATAGAGTA
>JC088798.1 Sequence 85 from Patent WO2013156786
GTAGTGCTGTTCG
>JC099262.1 Sequence 20 from Patent WO2013178674
TCATTGCAACTTG
>JC086658.1 Sequence 10125 from Patent EP2663334
CTTTGGCTACTGG
>JC086617.1 Sequence 10084 from Patent EP2663334
TTTGAATATCTGG
>JC086613.1 Sequence 10080 from Patent EP2663334
ATTAGATACTATC
>JC086611.1 Sequence 10078 from Patent EP2663334
TTTGGAGTGGTTA
>JC086597.1 Sequence 10064 from Patent EP2663334
CTACAGAGACTAC
>JC086592.1 Sequence 10059 from Patent EP2663334
ATTGCTATGGGGA
>JC086581.1 Sequence 10048 from Patent EP2663334
TTTTTGGAGTGGT
>JC086574.1 Sequence 10041 from Patent EP2663334
TGGCCGGGAGAGG
>JC086529.1 Sequence 9996 from Patent EP2663334
CCGCTCGAGGGCG
>JC086484.1 Sequence 9951 from Patent EP2663334
TGTGCAAAAGATA
>JC076579.1 Sequence 45 from Patent EP2663334
ATTAGATACTATC
>JC052935.1 Sequence 32 from Patent EP2576832
CCGACGACCGACG
>JC084160.1 Sequence 7627 from Patent EP2663334
CTTTGACTACTGG
>JC084147.1 Sequence 7614 from Patent EP2663334
CTTTGACTACTGG
>JC084132.1 Sequence 7599 from Patent EP2663334
CTTTGACTACTGG
>JC084131.1 Sequence 7598 from Patent EP2663334
CTTTGACTACTGG
>JC084122.1 Sequence 7589 from Patent EP2663334
CATGGACGTCTGG
>JC084119.1 Sequence 7586 from Patent EP2663334
CTTTGACTCCTGG
>JC084067.1 Sequence 7534 from Patent EP2663334
CTTTGACTACTGG
>JC084006.1 Sequence 7473 from Patent EP2663334
CTTTGACTCTTGG
>JC083995.1 Sequence 7462 from Patent EP2663334
TTTTGATGTGTGG
>JC083993.1 Sequence 7460 from Patent EP2663334
CTTTGACTACTGG
>JC083989.1 Sequence 7456 from Patent EP2663334
CTTTGACTCCTGG
>JC083984.1 Sequence 7451 from Patent EP2663334
GTGGGGGGATCAA
>JC083983.1 Sequence 7450 from Patent EP2663334
CCTATAAAGGTTG
>JC083981.1 Sequence 7448 from Patent EP2663334
GATTTTTCGCAGA
>JC083975.1 Sequence 7442 from Patent EP2663334
CCCCGTCCCCCGC
>JC083974.1 Sequence 7441 from Patent EP2663334
TCTTCCCTACAAG
>JC083965.1 Sequence 7432 from Patent EP2663334
GATTTTTCGCAGC
>JC083943.1 Sequence 7410 from Patent EP2663334
GACACGGGGGAGG
>JC083937.1 Sequence 7404 from Patent EP2663334
CGGGTCCCTCAGG
>JC083928.1 Sequence 7395 from Patent EP2663334
TTCGGCTGTCCAC
>JC083889.1 Sequence 7356 from Patent EP2663334
GAGTATAGCAGCT
>JC083878.1 Sequence 7345 from Patent EP2663334
TAGCAGCAGCTGG
>JC083868.1 Sequence 7335 from Patent EP2663334
AGTGGGAGCTACT
>JC083862.1 Sequence 7329 from Patent EP2663334
GGGGTGATACGCT
>JC083854.1 Sequence 7321 from Patent EP2663334
CATATTGTAGAGG
>JC083852.1 Sequence 7319 from Patent EP2663334
GTATAGTTTTGTT
>JC083848.1 Sequence 7315 from Patent EP2663334
TAGTCTTTATTAC
>JC083846.1 Sequence 7313 from Patent EP2663334
TGAGTACGGTGAC
>JC083842.1 Sequence 7309 from Patent EP2663334
TGAATACGGCGAC
>JC083839.1 Sequence 7306 from Patent EP2663334
TAGCAGTGGCTGG
>JC083797.1 Sequence 7264 from Patent EP2663334
TATGGCCCGAGCC
>JC083778.1 Sequence 7245 from Patent EP2663334
AGAGATGCCTACA
>JC083776.1 Sequence 7243 from Patent EP2663334
GGGGGGTATGGTT
>JC083774.1 Sequence 7241 from Patent EP2663334
GGGAGGGCTATGC
>JC083772.1 Sequence 7239 from Patent EP2663334
GGGAGGGCTATGC
>JC083766.1 Sequence 7233 from Patent EP2663334
GTGGTCCTAGGTG
>JC083745.1 Sequence 7212 from Patent EP2663334
TGGGTGATGTTGT
>JC083742.1 Sequence 7209 from Patent EP2663334
GATCCCGACCAAC
>JC083739.1 Sequence 7206 from Patent EP2663334
GATCCCGACCAAC
>JC083737.1 Sequence 7204 from Patent EP2663334
GATCCCGACCAAC
>JC083733.1 Sequence 7200 from Patent EP2663334
GATCCCGACCAAC
>JC083732.1 Sequence 7199 from Patent EP2663334
GATCCCGACCAAC
>JC083722.1 Sequence 7189 from Patent EP2663334
GTTGTTGGCCCAT
>JC083720.1 Sequence 7187 from Patent EP2663334
CACCCCTCGTATC
>JC083707.1 Sequence 7174 from Patent EP2663334
AGGGGTCCCGCTA
>JC083703.1 Sequence 7170 from Patent EP2663334
AATCAACGTTCCT
>JC083689.1 Sequence 7156 from Patent EP2663334
GAGACTCTCCTAA
>JC083576.1 Sequence 7043 from Patent EP2663334
TTGTATCCCGTTC
>JC083521.1 Sequence 6988 from Patent EP2663334
CGTGGATGGGGGA
>JC083406.1 Sequence 6873 from Patent EP2663334
TGTGTAAAACATA
>JC083404.1 Sequence 6871 from Patent EP2663334
TGTGTAAAACATA
>JC083401.1 Sequence 6868 from Patent EP2663334
TGTGTAAAAGATA
>JC060408.1 Sequence 84 from Patent EP2650368
GCCGCCACCATGG
>JC060395.1 Sequence 71 from Patent EP2650368
GGGTTTTTTTGGG
>JC060384.1 Sequence 60 from Patent EP2650368
GGTTTTTTTTTGG
>JC037398.1 Sequence 6 from Patent EP2674751
GTCGTACGGCTAA
>JC037163.1 Sequence 10 from Patent EP2674483
AGGTCANAGGTCA
>JC033996.1 Sequence 4 from Patent EP2598636
ATGGCGGATGGTT
>JC029163.1 Sequence 5 from Patent WO2013185042
AAATCAATAAATG
>JC026013.1 Sequence 52 from Patent EP2661171
ACGGCCCACACGC
>JC025809.1 Sequence 261 from Patent EP2661487
GCCGGTMMCGSYC
>JC025785.1 Sequence 237 from Patent EP2661487
AAWNRTAAAYARG
>JC025762.1 Sequence 214 from Patent EP2661487
TTCTTKTYYTTTT
>JB995178.1 Sequence 9 from Patent WO2013096906
GTCGTACGGCTAA
>JC025734.1 Sequence 186 from Patent EP2661487
GRTGYAYGGRTGY
>JC025671.1 Sequence 123 from Patent EP2661487
RMACCCANNCAYY
>JC025667.1 Sequence 119 from Patent EP2661487
GAANNTTCNNGAA
>JC011089.1 Sequence 9 from Patent WO2013096897
GTCGTACGGCTAA
>JC011030.1 Sequence 6 from Patent EP2647711
CACAGGAAGGGGA
>JC020758.1 Sequence 6 from Patent EP2677309
GTCGTACGGCTAA
>JC020009.1 Sequence 6 from Patent EP2677308
GTCGTACGGCTAA
>JC019314.1 Sequence 3 from Patent WO2013091612
WNRMSCAAAMSMW
>JC019310.1 Sequence 6 from Patent EP2653861
GTCGTACGGCTAA
>JC019089.1 Sequence 79 from Patent EP2653549
AAAATCGGCGCCG
>JC019088.1 Sequence 78 from Patent EP2653549
GAAATCGGCGCCG
>JC018967.1 Sequence 3 from Patent EP2655601
CCCCGACGCGTCT
>JC018956.1 Sequence 1 from Patent EP2644701
AGGAGCCACCATG
>JC018237.1 Sequence 66 from Patent EP2673637
TGCCTGAAAAGCC
>JC016264.1 Sequence 6 from Patent EP2639579
GTCGTACGGCTAA
>JC015817.1 Sequence 6 from Patent EP2639578
GTCGTACGGCTAA
>JC013574.1 Sequence 16 from Patent EP2673380
GGCCNNNNNGGCC
>JB973260.1 Sequence 114 from Patent EP2683387
GAGTGAAACATTG
>JB973257.1 Sequence 111 from Patent EP2683387
TGGAARATATAAT
>JB973256.1 Sequence 110 from Patent EP2683387
TTCCTAAACTGTT
>JB973255.1 Sequence 109 from Patent EP2683387
TGACTGTRGATTT
>JB973254.1 Sequence 108 from Patent EP2683387
CCCTTKACTATAA
>JB973253.1 Sequence 107 from Patent EP2683387
TTGTARCCCTCTG
>JB973252.1 Sequence 106 from Patent EP2683387
GCCATCRCATTGT
>JB973251.1 Sequence 105 from Patent EP2683387
CTGAACGWCTTGC
>JB973247.1 Sequence 101 from Patent EP2683387
CCTTTGGGCGGAT
>JB973246.1 Sequence 100 from Patent EP2683387
CCCTCTGYGTGCT
>JB973242.1 Sequence 96 from Patent EP2683387
CCCCACSAAGTGT
>JB973241.1 Sequence 95 from Patent EP2683387
GGACCCCMCGAAG
>JB973240.1 Sequence 94 from Patent EP2683387
TGAAAARGACCCC
>JB973238.1 Sequence 92 from Patent EP2683387
TTGCTGGGTGAAA
>JB973237.1 Sequence 91 from Patent EP2683387
GACTGAARAGCTA
>JB973235.1 Sequence 89 from Patent EP2683387
TGGATTWCATCAA
>JB973234.1 Sequence 88 from Patent EP2683387
GCATACCCTAATC
>JB973229.1 Sequence 83 from Patent EP2683387
CTGGATTTACATC
>JB973225.1 Sequence 79 from Patent EP2683387
CCAGGTTTATGAC
>JB973224.1 Sequence 78 from Patent EP2683387
CCGTTATGCGCAC
>JB973223.1 Sequence 77 from Patent EP2683387
GCTTGYTGGTGAA
>JB973221.1 Sequence 75 from Patent EP2683387
GCTCCGTTATGGC
>JB973219.1 Sequence 73 from Patent EP2683387
CCCGCAGSCCTGG
>JB973210.1 Sequence 64 from Patent EP2683387
GCCCTGGGCGTCG
>JB973208.1 Sequence 62 from Patent EP2683387
CTTGATTTATTTG
>JB973206.1 Sequence 60 from Patent EP2683387
GCCCTGGMGTGAT
>JB973205.1 Sequence 59 from Patent EP2683387
CGTGATTAGTGAT
>JB973204.1 Sequence 58 from Patent EP2683387
GGCGACCCGCAGC
>JB973200.1 Sequence 54 from Patent EP2683387
CAGACTTTGCTTT
>JB973197.1 Sequence 51 from Patent EP2683387
GTCAGCCCGCGCG
>JB973195.1 Sequence 49 from Patent EP2683387
GAGGATTTGGAAA
>JB973173.1 Sequence 27 from Patent EP2683387
GAGTGAAAACATT
>JB973168.1 Sequence 22 from Patent EP2683387
CTTTGGGCGGATC
>JB981669.1 Sequence 20 from Patent EP2682467
TCGCCATGCTGCT
>JB979999.1 Sequence 20 from Patent WO2014006110
TCGCCATGCTGCT
>JB974457.1 Sequence 15 from Patent EP2678043
GAGGAGGGCCGGG
>JB972912.1 Sequence 15 from Patent EP2683729
GNNNNCNNNCNGA
>JB972902.1 Sequence 5 from Patent EP2683729
ANANNCNNNCNNC
>JB972718.1 Sequence 7 from Patent EP2622103
TGACGACTGCATT
>JB973217.1 Sequence 71 from Patent EP2683387
ATTATGGGACAGG
>JB981686.1 Sequence 7 from Patent EP2682478
TCGGGCCATTAGC
>JB981684.1 Sequence 5 from Patent EP2682478
AGCCCGGTAATCG
>JB981623.1 Sequence 7 from Patent WO2014006561
TCGGGCCATTAGC
>JB981621.1 Sequence 5 from Patent WO2014006561
AGCCCGGTAATCG
>JB978151.1 Sequence 2 from Patent EP2681327
AGGTCANAGGTCA
>HW334693.1 JP 2013531981-A/2105: Native Ligation
GGATTTCTTTGGC
>HW334671.1 JP 2013531981-A/2083: Native Ligation
CGGCAGTGCCCCG
>HW334668.1 JP 2013531981-A/2080: Native Ligation
CCCGACGAGCCGG
>HW334587.1 JP 2013531981-A/1999: Native Ligation
GAGCCACTGCGCC
>HW334299.1 JP 2013531981-A/1711: Native Ligation
CGTTGTACTCTCG
>HW334277.1 JP 2013531981-A/1689: Native Ligation
GCGGCCATCTGCG
>HW334276.1 JP 2013531981-A/1688: Native Ligation
GGCCATCTGCGCC
>HW334271.1 JP 2013531981-A/1683: Native Ligation
CGGCTTCCTCCCC
>HW334263.1 JP 2013531981-A/1675: Native Ligation
AGGCACCGGGCAG
>HW334262.1 JP 2013531981-A/1674: Native Ligation
GCACCGGGCAGTC
>HW334181.1 JP 2013531981-A/1593: Native Ligation
GCTATATGCAGGG
>HW334173.1 JP 2013531981-A/1585: Native Ligation
CCGAAAAATTGGG
>HW334163.1 JP 2013531981-A/1575: Native Ligation
CTGCTGTTGGCAG
>HW334150.1 JP 2013531981-A/1562: Native Ligation
CCCTCCTAAGCGG
>HW334149.1 JP 2013531981-A/1561: Native Ligation
CTCCCTCCTAAGC
>HW334148.1 JP 2013531981-A/1560: Native Ligation
GCAGGCGTCACCC
>HW334144.1 JP 2013531981-A/1556: Native Ligation
CGGTTCACTCGGC
>HW334143.1 JP 2013531981-A/1555: Native Ligation
CCGGTGAGGAGGG
>HW334142.1 JP 2013531981-A/1554: Native Ligation
GCCGGTGAGGAGG
>HW334137.1 JP 2013531981-A/1549: Native Ligation
CGCACTTGTAGCG
>HW326268.1 JP 2013532952-A/4313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW326266.1 JP 2013532952-A/4311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW326264.1 JP 2013532952-A/4309: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW325748.1 JP 2013532952-A/3793: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325746.1 JP 2013532952-A/3791: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325744.1 JP 2013532952-A/3789: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325742.1 JP 2013532952-A/3787: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325740.1 JP 2013532952-A/3785: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325738.1 JP 2013532952-A/3783: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>HW325736.1 JP 2013532952-A/3781: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325734.1 JP 2013532952-A/3779: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325732.1 JP 2013532952-A/3777: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325730.1 JP 2013532952-A/3775: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325728.1 JP 2013532952-A/3773: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325726.1 JP 2013532952-A/3771: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325724.1 JP 2013532952-A/3769: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325722.1 JP 2013532952-A/3767: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325720.1 JP 2013532952-A/3765: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGATTCAAGTCA
>HW325718.1 JP 2013532952-A/3763: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAAAACCAA
>HW325716.1 JP 2013532952-A/3761: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAGCAAAGAA
>HW325714.1 JP 2013532952-A/3759: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGCAACA
>HW325712.1 JP 2013532952-A/3757: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>HW325710.1 JP 2013532952-A/3755: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATCTATGACAA
>HW325708.1 JP 2013532952-A/3753: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCAAAGATAA
>HW325706.1 JP 2013532952-A/3751: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCTACCAGAAA
>HW325704.1 JP 2013532952-A/3749: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCTACCAGAA
>HW325702.1 JP 2013532952-A/3747: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAAGATAATGA
>HW325700.1 JP 2013532952-A/3745: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAACTCTACCAGA
>HW325698.1 JP 2013532952-A/3743: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATATAGCAAA
>HW325696.1 JP 2013532952-A/3741: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW325694.1 JP 2013532952-A/3739: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATCTATGACAAA
>HW325692.1 JP 2013532952-A/3737: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGCAGAGTACA
>HW325690.1 JP 2013532952-A/3735: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTCAAGCAGA
>HW325688.1 JP 2013532952-A/3733: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATGACAAGTTCA
>HW325686.1 JP 2013532952-A/3731: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAACGAAATCTAA
>HW325684.1 JP 2013532952-A/3729: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>HW325682.1 JP 2013532952-A/3727: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAAAGATGGAGA
>HW325680.1 JP 2013532952-A/3725: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>HW325678.1 JP 2013532952-A/3723: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATATGTTCTTA
>HW325676.1 JP 2013532952-A/3721: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>HW325674.1 JP 2013532952-A/3719: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCAACACATCAA
>HW325672.1 JP 2013532952-A/3717: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCAGAGTACAA
>HW325670.1 JP 2013532952-A/3715: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTACACACAA
>HW325668.1 JP 2013532952-A/3713: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>HW325666.1 JP 2013532952-A/3711: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>HW325664.1 JP 2013532952-A/3709: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>HW325662.1 JP 2013532952-A/3707: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACACACAGCATAA
>HW325660.1 JP 2013532952-A/3705: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>HW325658.1 JP 2013532952-A/3703: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTCAAGCAA
>HW325654.1 JP 2013532952-A/3699: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>HW325652.1 JP 2013532952-A/3697: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>HW325648.1 JP 2013532952-A/3693: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>HW325646.1 JP 2013532952-A/3691: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>HW325644.1 JP 2013532952-A/3689: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>HW325642.1 JP 2013532952-A/3687: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>HW325638.1 JP 2013532952-A/3683: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>HW325636.1 JP 2013532952-A/3681: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>HW325632.1 JP 2013532952-A/3677: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>HW325628.1 JP 2013532952-A/3673: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>HW325626.1 JP 2013532952-A/3671: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>HW325624.1 JP 2013532952-A/3669: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>HW325622.1 JP 2013532952-A/3667: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>HW325620.1 JP 2013532952-A/3665: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>HW325618.1 JP 2013532952-A/3663: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>HW325616.1 JP 2013532952-A/3661: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>HW325614.1 JP 2013532952-A/3659: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>HW325612.1 JP 2013532952-A/3657: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>HW325610.1 JP 2013532952-A/3655: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>HW325608.1 JP 2013532952-A/3653: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>HW325606.1 JP 2013532952-A/3651: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>HW325604.1 JP 2013532952-A/3649: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>HW325602.1 JP 2013532952-A/3647: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>HW325600.1 JP 2013532952-A/3645: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>HW325598.1 JP 2013532952-A/3643: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>HW325596.1 JP 2013532952-A/3641: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>HW325594.1 JP 2013532952-A/3639: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325592.1 JP 2013532952-A/3637: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325590.1 JP 2013532952-A/3635: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325588.1 JP 2013532952-A/3633: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325586.1 JP 2013532952-A/3631: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325584.1 JP 2013532952-A/3629: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325582.1 JP 2013532952-A/3627: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325580.1 JP 2013532952-A/3625: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325578.1 JP 2013532952-A/3623: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325576.1 JP 2013532952-A/3621: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325574.1 JP 2013532952-A/3619: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325572.1 JP 2013532952-A/3617: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325570.1 JP 2013532952-A/3615: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325568.1 JP 2013532952-A/3613: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325558.1 JP 2013532952-A/3603: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>HW325556.1 JP 2013532952-A/3601: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>HW325554.1 JP 2013532952-A/3599: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>HW325552.1 JP 2013532952-A/3597: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>HW325550.1 JP 2013532952-A/3595: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>HW325548.1 JP 2013532952-A/3593: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW325546.1 JP 2013532952-A/3591: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>HW325544.1 JP 2013532952-A/3589: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>HW325542.1 JP 2013532952-A/3587: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>HW325540.1 JP 2013532952-A/3585: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>HW325538.1 JP 2013532952-A/3583: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>HW325536.1 JP 2013532952-A/3581: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>HW325534.1 JP 2013532952-A/3579: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>HW325532.1 JP 2013532952-A/3577: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>HW325530.1 JP 2013532952-A/3575: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>HW325528.1 JP 2013532952-A/3573: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>HW325524.1 JP 2013532952-A/3569: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>HW325520.1 JP 2013532952-A/3565: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>HW325516.1 JP 2013532952-A/3561: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>HW325512.1 JP 2013532952-A/3557: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>HW325508.1 JP 2013532952-A/3553: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>HW325504.1 JP 2013532952-A/3549: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>HW325500.1 JP 2013532952-A/3545: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>HW325496.1 JP 2013532952-A/3541: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>HW325492.1 JP 2013532952-A/3537: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>HW325490.1 JP 2013532952-A/3535: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>HW325488.1 JP 2013532952-A/3533: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>HW325486.1 JP 2013532952-A/3531: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>HW325484.1 JP 2013532952-A/3529: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>HW325482.1 JP 2013532952-A/3527: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>HW325480.1 JP 2013532952-A/3525: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>HW325478.1 JP 2013532952-A/3523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>HW325476.1 JP 2013532952-A/3521: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>HW325474.1 JP 2013532952-A/3519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>HW325472.1 JP 2013532952-A/3517: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>HW325470.1 JP 2013532952-A/3515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>HW325468.1 JP 2013532952-A/3513: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>HW325466.1 JP 2013532952-A/3511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>HW325464.1 JP 2013532952-A/3509: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>HW325462.1 JP 2013532952-A/3507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325460.1 JP 2013532952-A/3505: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325458.1 JP 2013532952-A/3503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325456.1 JP 2013532952-A/3501: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325454.1 JP 2013532952-A/3499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325452.1 JP 2013532952-A/3497: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325450.1 JP 2013532952-A/3495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325448.1 JP 2013532952-A/3493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325446.1 JP 2013532952-A/3491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325444.1 JP 2013532952-A/3489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325442.1 JP 2013532952-A/3487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325440.1 JP 2013532952-A/3485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325438.1 JP 2013532952-A/3483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325436.1 JP 2013532952-A/3481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325434.1 JP 2013532952-A/3479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325432.1 JP 2013532952-A/3477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325430.1 JP 2013532952-A/3475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325428.1 JP 2013532952-A/3473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325426.1 JP 2013532952-A/3471: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325424.1 JP 2013532952-A/3469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325398.1 JP 2013532952-A/3443: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325396.1 JP 2013532952-A/3441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325394.1 JP 2013532952-A/3439: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325392.1 JP 2013532952-A/3437: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325390.1 JP 2013532952-A/3435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325388.1 JP 2013532952-A/3433: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325386.1 JP 2013532952-A/3431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325384.1 JP 2013532952-A/3429: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325382.1 JP 2013532952-A/3427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325380.1 JP 2013532952-A/3425: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325378.1 JP 2013532952-A/3423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325376.1 JP 2013532952-A/3421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325374.1 JP 2013532952-A/3419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325372.1 JP 2013532952-A/3417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325370.1 JP 2013532952-A/3415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325368.1 JP 2013532952-A/3413: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325366.1 JP 2013532952-A/3411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325364.1 JP 2013532952-A/3409: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325362.1 JP 2013532952-A/3407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325360.1 JP 2013532952-A/3405: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325358.1 JP 2013532952-A/3403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325356.1 JP 2013532952-A/3401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325324.1 JP 2013532952-A/3369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325322.1 JP 2013532952-A/3367: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325320.1 JP 2013532952-A/3365: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325318.1 JP 2013532952-A/3363: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325316.1 JP 2013532952-A/3361: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325314.1 JP 2013532952-A/3359: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325312.1 JP 2013532952-A/3357: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325310.1 JP 2013532952-A/3355: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325308.1 JP 2013532952-A/3353: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325306.1 JP 2013532952-A/3351: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325304.1 JP 2013532952-A/3349: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325302.1 JP 2013532952-A/3347: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325300.1 JP 2013532952-A/3345: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325298.1 JP 2013532952-A/3343: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW333057.1 JP 2013531981-A/469: Native Ligation
TTTTAGTGCACAT
>HW325296.1 JP 2013532952-A/3341: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW325294.1 JP 2013532952-A/3339: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW325292.1 JP 2013532952-A/3337: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>HW325290.1 JP 2013532952-A/3335: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW325286.1 JP 2013532952-A/3331: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>HW325284.1 JP 2013532952-A/3329: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>HW325280.1 JP 2013532952-A/3325: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>HW325278.1 JP 2013532952-A/3323: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>HW325276.1 JP 2013532952-A/3321: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>HW325272.1 JP 2013532952-A/3317: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>HW325268.1 JP 2013532952-A/3313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>HW325266.1 JP 2013532952-A/3311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>HW325262.1 JP 2013532952-A/3307: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>HW325258.1 JP 2013532952-A/3303: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>HW325256.1 JP 2013532952-A/3301: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>HW325254.1 JP 2013532952-A/3299: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>HW325252.1 JP 2013532952-A/3297: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>HW325250.1 JP 2013532952-A/3295: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>HW325248.1 JP 2013532952-A/3293: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>HW325246.1 JP 2013532952-A/3291: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>HW325242.1 JP 2013532952-A/3287: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>HW325238.1 JP 2013532952-A/3283: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>HW325234.1 JP 2013532952-A/3279: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>HW325232.1 JP 2013532952-A/3277: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGCTGACCTGG
>HW325230.1 JP 2013532952-A/3275: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATCAAGTTTGAG
>HW325228.1 JP 2013532952-A/3273: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGCAAGATCGGC
>HW325226.1 JP 2013532952-A/3271: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACACGTTTGGC
>HW325224.1 JP 2013532952-A/3269: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTAAATTCTGTGG
>HW325222.1 JP 2013532952-A/3267: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAAATTCTGTG
>HW325220.1 JP 2013532952-A/3265: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGACTTCGGC
>HW325218.1 JP 2013532952-A/3263: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTGCGAAGCTG
>HW325216.1 JP 2013532952-A/3261: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCGAAGCTGACC
>HW325214.1 JP 2013532952-A/3259: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACGGAGACATGG
>HW325212.1 JP 2013532952-A/3257: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGTTCCAAGAC
>HW325210.1 JP 2013532952-A/3255: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACCAGTGCACG
>HW325208.1 JP 2013532952-A/3253: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACAACGCC
>HW325206.1 JP 2013532952-A/3251: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCGAAGCTGAC
>HW325204.1 JP 2013532952-A/3249: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAAGCTGACCTG
>HW325202.1 JP 2013532952-A/3247: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCCAAGACCT
>HW325200.1 JP 2013532952-A/3245: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTATCAAGTTTG
>HW325198.1 JP 2013532952-A/3243: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACTGGAAGAC
>HW325196.1 JP 2013532952-A/3241: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCGAAGCTGA
>HW325194.1 JP 2013532952-A/3239: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCCTTGCGAAGC
>HW325192.1 JP 2013532952-A/3237: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGGTCATGAAG
>HW325190.1 JP 2013532952-A/3235: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGACACGTTTGG
>HW325188.1 JP 2013532952-A/3233: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTAAATTCTG
>HW325186.1 JP 2013532952-A/3231: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCAGGCCTTGC
>HW325184.1 JP 2013532952-A/3229: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAGAGAAGCAG
>HW325182.1 JP 2013532952-A/3227: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGTATGTACC
>HW325180.1 JP 2013532952-A/3225: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGAACTGCAG
>HW325178.1 JP 2013532952-A/3223: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGTTTGAGCT
>HW325176.1 JP 2013532952-A/3221: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTCAGGCCTTG
>HW325174.1 JP 2013532952-A/3219: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACTTCGGCTCC
>HW325172.1 JP 2013532952-A/3217: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACTTCGGCTC
>HW325170.1 JP 2013532952-A/3215: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGATGTACGG
>HW325168.1 JP 2013532952-A/3213: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAAGCTGACCT
>HW325166.1 JP 2013532952-A/3211: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAGGCCTTGCGA
>HW325164.1 JP 2013532952-A/3209: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGGAGACATGGC
>HW325162.1 JP 2013532952-A/3207: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACGTTTGGCC
>HW325160.1 JP 2013532952-A/3205: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCGAGGTCATGA
>HW325158.1 JP 2013532952-A/3203: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGACAACGCCT
>HW325156.1 JP 2013532952-A/3201: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGATGTACGGAG
>HW325154.1 JP 2013532952-A/3199: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAAGACACGTT
>HW325152.1 JP 2013532952-A/3197: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAAATTCTGTGGA
>HW325150.1 JP 2013532952-A/3195: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCATGAAGA
>HW325148.1 JP 2013532952-A/3193: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAACGCCTC
>HW325146.1 JP 2013532952-A/3191: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGAGACATGGCA
>HW325144.1 JP 2013532952-A/3189: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGTGGAGTATG
>HW325142.1 JP 2013532952-A/3187: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGCTAAATTCT
>HW325140.1 JP 2013532952-A/3185: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGGCCTTGCGAA
>HW325138.1 JP 2013532952-A/3183: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGCAAGATCGG
>HW325136.1 JP 2013532952-A/3181: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCGACTGGAAG
>HW325134.1 JP 2013532952-A/3179: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGCCTTGCGAAG
>HW325132.1 JP 2013532952-A/3177: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGACACGTTTG
>HW325130.1 JP 2013532952-A/3175: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGTCAGGCCTT
>HW325128.1 JP 2013532952-A/3173: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCATGAAGAAG
>HW325126.1 JP 2013532952-A/3171: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCTGACCTGGA
>HW325124.1 JP 2013532952-A/3169: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGAAGTGTAA
>HW325122.1 JP 2013532952-A/3167: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGTTCCTTAA
>HW325120.1 JP 2013532952-A/3165: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAAAGGTTA
>HW325118.1 JP 2013532952-A/3163: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATACCGAGCTA
>HW325116.1 JP 2013532952-A/3161: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTTGAGAGTGT
>HW325114.1 JP 2013532952-A/3159: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATACCGAGCTAAA
>HW325112.1 JP 2013532952-A/3157: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCCTTTATTA
>HW325110.1 JP 2013532952-A/3155: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGGACAGCTT
>HW325108.1 JP 2013532952-A/3153: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATACGAGTAATA
>HW325106.1 JP 2013532952-A/3151: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATCTAAGTTAA
>HW325104.1 JP 2013532952-A/3149: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGCTCAGATA
>HW325102.1 JP 2013532952-A/3147: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTGATCAGTTT
>HW325100.1 JP 2013532952-A/3145: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGTAGAATGTAA
>HW325098.1 JP 2013532952-A/3143: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTAAATTCTGT
>HW325096.1 JP 2013532952-A/3141: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATCAAGTTTGA
>HW325094.1 JP 2013532952-A/3139: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGACACGTTT
>HW325092.1 JP 2013532952-A/3137: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTACCAGTGCAC
>HW325090.1 JP 2013532952-A/3135: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACATCTTT
>HW325088.1 JP 2013532952-A/3133: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCAGTAGCACA
>HW325086.1 JP 2013532952-A/3131: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTCTGTGGAG
>HW325084.1 JP 2013532952-A/3129: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGTATGT
>HW325082.1 JP 2013532952-A/3127: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTTGAGCTT
>HW325080.1 JP 2013532952-A/3125: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCCTATCAAGTT
>HW325078.1 JP 2013532952-A/3123: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACGGAGACAT
>HW325076.1 JP 2013532952-A/3121: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCTGTGGAGT
>HW325074.1 JP 2013532952-A/3119: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTATCAAGTTT
>HW325072.1 JP 2013532952-A/3117: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCGAGGAGTG
>HW325070.1 JP 2013532952-A/3115: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTTGCGAAGCT
>HW325068.1 JP 2013532952-A/3113: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTACGGAGACA
>HW325066.1 JP 2013532952-A/3111: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGACTGGAAGA
>HW325064.1 JP 2013532952-A/3109: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTGGAGCGCC
>HW325062.1 JP 2013532952-A/3107: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTACAACTGTC
>HW325060.1 JP 2013532952-A/3105: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTACAACTGTCC
>HW325058.1 JP 2013532952-A/3103: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGCCATTACAAC
>HW325056.1 JP 2013532952-A/3101: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCATTACAACTGT
>HW325054.1 JP 2013532952-A/3099: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGGTCCAGACC
>HW325052.1 JP 2013532952-A/3097: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTGGAGCGC
>HW325050.1 JP 2013532952-A/3095: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACCTGTGCCTG
>HW325048.1 JP 2013532952-A/3093: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTGCCTGGTCC
>HW325046.1 JP 2013532952-A/3091: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTGGAAGACACG
>HW325044.1 JP 2013532952-A/3089: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCCATTACAACT
>HW325042.1 JP 2013532952-A/3087: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTGAGCTTTCT
>HW325040.1 JP 2013532952-A/3085: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGCGCCTGTT
>HW325038.1 JP 2013532952-A/3083: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGAGCGCCTG
>HW325036.1 JP 2013532952-A/3081: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTTTCTGGCT
>HW325034.1 JP 2013532952-A/3079: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATTACAACTG
>HW325032.1 JP 2013532952-A/3077: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAGCGCCTGTTC
>HW325030.1 JP 2013532952-A/3075: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACTGGAAGACA
>HW325028.1 JP 2013532952-A/3073: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGGAGCGCCT
>HW325026.1 JP 2013532952-A/3071: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGGAAGATGTA
>HW325024.1 JP 2013532952-A/3069: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW325022.1 JP 2013532952-A/3067: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW325020.1 JP 2013532952-A/3065: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW325018.1 JP 2013532952-A/3063: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW324986.1 JP 2013532952-A/3031: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW324984.1 JP 2013532952-A/3029: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW324982.1 JP 2013532952-A/3027: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW324980.1 JP 2013532952-A/3025: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW324978.1 JP 2013532952-A/3023: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW324974.1 JP 2013532952-A/3019: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>HW324970.1 JP 2013532952-A/3015: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>HW324966.1 JP 2013532952-A/3011: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>HW324962.1 JP 2013532952-A/3007: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>HW324960.1 JP 2013532952-A/3005: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>HW324958.1 JP 2013532952-A/3003: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>HW324956.1 JP 2013532952-A/3001: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>HW324954.1 JP 2013532952-A/2999: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>HW324952.1 JP 2013532952-A/2997: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>HW324950.1 JP 2013532952-A/2995: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>HW324946.1 JP 2013532952-A/2991: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>HW324944.1 JP 2013532952-A/2989: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>HW324942.1 JP 2013532952-A/2987: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>HW324940.1 JP 2013532952-A/2985: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>HW324938.1 JP 2013532952-A/2983: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>HW324934.1 JP 2013532952-A/2979: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>HW324932.1 JP 2013532952-A/2977: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>HW324928.1 JP 2013532952-A/2973: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>HW324926.1 JP 2013532952-A/2971: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>HW324924.1 JP 2013532952-A/2969: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>HW324922.1 JP 2013532952-A/2967: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>HW324918.1 JP 2013532952-A/2963: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW324916.1 JP 2013532952-A/2961: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>HW324912.1 JP 2013532952-A/2957: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>HW324910.1 JP 2013532952-A/2955: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>HW324908.1 JP 2013532952-A/2953: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>HW324906.1 JP 2013532952-A/2951: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>HW324904.1 JP 2013532952-A/2949: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>HW324902.1 JP 2013532952-A/2947: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>HW324900.1 JP 2013532952-A/2945: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>HW324890.1 JP 2013532952-A/2935: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>HW324888.1 JP 2013532952-A/2933: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>HW324886.1 JP 2013532952-A/2931: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>HW324884.1 JP 2013532952-A/2929: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>HW324882.1 JP 2013532952-A/2927: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>HW324880.1 JP 2013532952-A/2925: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>HW324878.1 JP 2013532952-A/2923: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>HW324876.1 JP 2013532952-A/2921: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>HW324874.1 JP 2013532952-A/2919: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>HW324872.1 JP 2013532952-A/2917: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>HW324870.1 JP 2013532952-A/2915: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>HW324868.1 JP 2013532952-A/2913: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>HW324866.1 JP 2013532952-A/2911: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>HW324864.1 JP 2013532952-A/2909: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>HW324862.1 JP 2013532952-A/2907: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>HW324860.1 JP 2013532952-A/2905: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>HW324858.1 JP 2013532952-A/2903: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>HW324856.1 JP 2013532952-A/2901: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>HW324852.1 JP 2013532952-A/2897: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>HW324848.1 JP 2013532952-A/2893: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>HW324844.1 JP 2013532952-A/2889: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>HW324840.1 JP 2013532952-A/2885: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>HW324836.1 JP 2013532952-A/2881: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>HW324832.1 JP 2013532952-A/2877: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>HW324828.1 JP 2013532952-A/2873: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>HW324826.1 JP 2013532952-A/2871: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCCAGCAAC
>HW324824.1 JP 2013532952-A/2869: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTCGAACGACT
>HW324822.1 JP 2013532952-A/2867: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGCAATTAATA
>HW324820.1 JP 2013532952-A/2865: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCCAGCAATTAA
>HW324818.1 JP 2013532952-A/2863: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGTCTGGAAA
>HW324816.1 JP 2013532952-A/2861: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGTGTATCTAT
>HW324814.1 JP 2013532952-A/2859: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCCGTGAAT
>HW324812.1 JP 2013532952-A/2857: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGTGATTGATA
>HW324810.1 JP 2013532952-A/2855: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGAGTGCTG
>HW324808.1 JP 2013532952-A/2853: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTTATGGACT
>HW324806.1 JP 2013532952-A/2851: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGGTCACTGATT
>HW324804.1 JP 2013532952-A/2849: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACGAAAGCCA
>HW324802.1 JP 2013532952-A/2847: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCATGAGAATTG
>HW324800.1 JP 2013532952-A/2845: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTCAATTGCTTA
>HW324798.1 JP 2013532952-A/2843: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCCACAGCCA
>HW324796.1 JP 2013532952-A/2841: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGCATTCCGAT
>HW324794.1 JP 2013532952-A/2839: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGCTGAAACC
>HW324792.1 JP 2013532952-A/2837: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAACAGGCTGATT
>HW324790.1 JP 2013532952-A/2835: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTACCATGAGAA
>HW324788.1 JP 2013532952-A/2833: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCCGTGAA
>HW324786.1 JP 2013532952-A/2831: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAGTCAGGAACT
>HW324784.1 JP 2013532952-A/2829: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCAATGATGA
>HW324782.1 JP 2013532952-A/2827: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTGTGGTTTAT
>HW324780.1 JP 2013532952-A/2825: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACTCTGATGA
>HW324778.1 JP 2013532952-A/2823: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATTAATAAA
>HW324776.1 JP 2013532952-A/2821: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAATTGCTTAT
>HW324774.1 JP 2013532952-A/2819: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATCACTGTA
>HW324772.1 JP 2013532952-A/2817: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATTCTATAGAA
>HW324770.1 JP 2013532952-A/2815: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAACTAATGTGT
>HW324768.1 JP 2013532952-A/2813: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCCGATGTGATT
>HW324766.1 JP 2013532952-A/2811: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATAAGCGGAAAG
>HW324764.1 JP 2013532952-A/2809: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCTGGATG
>HW324762.1 JP 2013532952-A/2807: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGAATGGTGC
>HW324760.1 JP 2013532952-A/2805: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACCTCACACATG
>HW324758.1 JP 2013532952-A/2803: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGCAACCGAA
>HW324756.1 JP 2013532952-A/2801: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATGAATAGAAA
>HW324754.1 JP 2013532952-A/2799: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAATAACTAAT
>HW324752.1 JP 2013532952-A/2797: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTTGAATGTGTA
>HW324750.1 JP 2013532952-A/2795: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGGTTGAATGT
>HW324748.1 JP 2013532952-A/2793: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCATGAATTT
>HW324746.1 JP 2013532952-A/2791: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAGTGCTGAA
>HW324744.1 JP 2013532952-A/2789: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGAAACGAGTCA
>HW324742.1 JP 2013532952-A/2787: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGCATACAAG
>HW324740.1 JP 2013532952-A/2785: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAGATAGTGCAT
>HW324738.1 JP 2013532952-A/2783: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATGAGCATT
>HW324736.1 JP 2013532952-A/2781: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTTCGCAGAC
>HW324734.1 JP 2013532952-A/2779: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCAACGAAAG
>HW324732.1 JP 2013532952-A/2777: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTTGTGGCTTC
>HW324730.1 JP 2013532952-A/2775: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTGGAAATAA
>HW324728.1 JP 2013532952-A/2773: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCGTGAATTC
>HW324726.1 JP 2013532952-A/2771: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGACGAGGACAT
>HW324724.1 JP 2013532952-A/2769: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGACACATATGA
>HW324722.1 JP 2013532952-A/2767: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTGATGAGTCT
>HW324720.1 JP 2013532952-A/2765: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCATTTAGTCAA
>HW324718.1 JP 2013532952-A/2763: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTCAGGAACTT
>HW324716.1 JP 2013532952-A/2761: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATTCCGATGT
>HW324714.1 JP 2013532952-A/2759: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATTTAGTCAAA
>HW324712.1 JP 2013532952-A/2757: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGTCCAGATT
>HW324710.1 JP 2013532952-A/2755: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGATGGCCGA
>HW324708.1 JP 2013532952-A/2753: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATGGTGCATAC
>HW324706.1 JP 2013532952-A/2751: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACCAAGGAAA
>HW324704.1 JP 2013532952-A/2749: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCATTCTATA
>HW332977.1 JP 2013531981-A/389: Native Ligation
AAAACATCTTGTT
>HW332969.1 JP 2013531981-A/381: Native Ligation
CATTGTTCAATAT
>HW332967.1 JP 2013531981-A/379: Native Ligation
ATTGTTCAATATC
>HW332963.1 JP 2013531981-A/375: Native Ligation
TCTGAAAATGTTT
>HW332875.1 JP 2013531981-A/287: Native Ligation
ACTTTTAACTTGA
>HW332870.1 JP 2013531981-A/282: Native Ligation
TTGTCATAGATTT
>HW324702.1 JP 2013532952-A/2747: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCAGTTAAACA
>HW324700.1 JP 2013532952-A/2745: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATAAGCGGAAA
>HW324698.1 JP 2013532952-A/2743: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTCCAGATTAT
>HW324696.1 JP 2013532952-A/2741: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATGAAACGAGT
>HW324694.1 JP 2013532952-A/2739: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTGAATGTGT
>HW324692.1 JP 2013532952-A/2737: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGTCCAGATTA
>HW324690.1 JP 2013532952-A/2735: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGAAAGCGA
>HW324688.1 JP 2013532952-A/2733: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCCAGCAATT
>HW324686.1 JP 2013532952-A/2731: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTATAGAAGAA
>HW324684.1 JP 2013532952-A/2729: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTGTATCTATT
>HW324682.1 JP 2013532952-A/2727: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATAGTGCATCT
>HW324680.1 JP 2013532952-A/2725: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATTGATAGTCA
>HW324678.1 JP 2013532952-A/2723: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAGGAGTTGAA
>HW324676.1 JP 2013532952-A/2721: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGATGAGAGCAA
>HW324674.1 JP 2013532952-A/2719: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCAACGAAA
>HW324672.1 JP 2013532952-A/2717: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCTCATGAATAG
>HW324670.1 JP 2013532952-A/2715: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCTCATGAAT
>HW324668.1 JP 2013532952-A/2713: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGCCTTCTGATT
>HW324666.1 JP 2013532952-A/2711: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATTTCGTATT
>HW324664.1 JP 2013532952-A/2709: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGATGATAT
>HW324662.1 JP 2013532952-A/2707: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAGCCATGACCA
>HW324660.1 JP 2013532952-A/2705: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCGTATTTCT
>HW324658.1 JP 2013532952-A/2703: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTTCGTATTT
>HW324656.1 JP 2013532952-A/2701: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGGAAAGCCAAT
>HW324654.1 JP 2013532952-A/2699: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCATGACCAC
>HW324652.1 JP 2013532952-A/2697: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATGACCACAT
>HW324650.1 JP 2013532952-A/2695: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCACATGGATGA
>HW324648.1 JP 2013532952-A/2693: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAAGCCAA
>HW324646.1 JP 2013532952-A/2691: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCGGAAAGCCA
>HW324644.1 JP 2013532952-A/2689: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTCACCATTC
>HW324642.1 JP 2013532952-A/2687: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACAGCCATGAA
>HW324640.1 JP 2013532952-A/2685: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGAGGTCAAA
>HW324638.1 JP 2013532952-A/2683: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTCTCACCATT
>HW324636.1 JP 2013532952-A/2681: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGACTGAGGTCA
>HW324634.1 JP 2013532952-A/2679: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATGAATCT
>HW324632.1 JP 2013532952-A/2677: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCTGGATGA
>HW324630.1 JP 2013532952-A/2675: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGAGGTCAAT
>HW324628.1 JP 2013532952-A/2673: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGGTCAATTAA
>HW324626.1 JP 2013532952-A/2671: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGAGGTCAATT
>HW324624.1 JP 2013532952-A/2669: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCAATTAAA
>HW324622.1 JP 2013532952-A/2667: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGAGGTCAATTA
>HW324620.1 JP 2013532952-A/2665: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCATGAATTAGA
>HW324618.1 JP 2013532952-A/2663: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACACAGCATATA
>HW324616.1 JP 2013532952-A/2661: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATCTATGACAAA
>HW324614.1 JP 2013532952-A/2659: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGCAGAGTACA
>HW324612.1 JP 2013532952-A/2657: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTCAAGCAGA
>HW324610.1 JP 2013532952-A/2655: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATGACAAGTTCA
>HW324608.1 JP 2013532952-A/2653: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAACGAAATCTAA
>HW324606.1 JP 2013532952-A/2651: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>HW324604.1 JP 2013532952-A/2649: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAAAGATGGAGA
>HW324602.1 JP 2013532952-A/2647: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>HW324600.1 JP 2013532952-A/2645: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATATGTTCTTA
>HW324598.1 JP 2013532952-A/2643: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>HW324596.1 JP 2013532952-A/2641: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCAACACATCAA
>HW324594.1 JP 2013532952-A/2639: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCAGAGTACAA
>HW324592.1 JP 2013532952-A/2637: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTACACACAA
>HW324590.1 JP 2013532952-A/2635: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>HW324588.1 JP 2013532952-A/2633: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>HW324586.1 JP 2013532952-A/2631: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>HW324584.1 JP 2013532952-A/2629: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACACACAGCATAA
>HW324582.1 JP 2013532952-A/2627: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>HW324580.1 JP 2013532952-A/2625: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTCAAGCAA
>HW324576.1 JP 2013532952-A/2621: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>HW324574.1 JP 2013532952-A/2619: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>HW324570.1 JP 2013532952-A/2615: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>HW324568.1 JP 2013532952-A/2613: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>HW324566.1 JP 2013532952-A/2611: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>HW324564.1 JP 2013532952-A/2609: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>HW324560.1 JP 2013532952-A/2605: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>HW324558.1 JP 2013532952-A/2603: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>HW324554.1 JP 2013532952-A/2599: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>HW324550.1 JP 2013532952-A/2595: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>HW324548.1 JP 2013532952-A/2593: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>HW324546.1 JP 2013532952-A/2591: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>HW324544.1 JP 2013532952-A/2589: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>HW324542.1 JP 2013532952-A/2587: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>HW324540.1 JP 2013532952-A/2585: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>HW324538.1 JP 2013532952-A/2583: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>HW324536.1 JP 2013532952-A/2581: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>HW324534.1 JP 2013532952-A/2579: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>HW324532.1 JP 2013532952-A/2577: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>HW324530.1 JP 2013532952-A/2575: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>HW324528.1 JP 2013532952-A/2573: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>HW324526.1 JP 2013532952-A/2571: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>HW324524.1 JP 2013532952-A/2569: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>HW324522.1 JP 2013532952-A/2567: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>HW324520.1 JP 2013532952-A/2565: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>HW324518.1 JP 2013532952-A/2563: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>HW324516.1 JP 2013532952-A/2561: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>HW324514.1 JP 2013532952-A/2559: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>HW324512.1 JP 2013532952-A/2557: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>HW324510.1 JP 2013532952-A/2555: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>HW324508.1 JP 2013532952-A/2553: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>HW324506.1 JP 2013532952-A/2551: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW324504.1 JP 2013532952-A/2549: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>HW324502.1 JP 2013532952-A/2547: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>HW324500.1 JP 2013532952-A/2545: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>HW324498.1 JP 2013532952-A/2543: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>HW324496.1 JP 2013532952-A/2541: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>HW324494.1 JP 2013532952-A/2539: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>HW324492.1 JP 2013532952-A/2537: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>HW324490.1 JP 2013532952-A/2535: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>HW324488.1 JP 2013532952-A/2533: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>HW324486.1 JP 2013532952-A/2531: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>HW324482.1 JP 2013532952-A/2527: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>HW324478.1 JP 2013532952-A/2523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>HW324474.1 JP 2013532952-A/2519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>HW324470.1 JP 2013532952-A/2515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>HW324466.1 JP 2013532952-A/2511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>HW324462.1 JP 2013532952-A/2507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>HW324458.1 JP 2013532952-A/2503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>HW324454.1 JP 2013532952-A/2499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>HW324450.1 JP 2013532952-A/2495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>HW324448.1 JP 2013532952-A/2493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>HW324446.1 JP 2013532952-A/2491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>HW324444.1 JP 2013532952-A/2489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>HW324442.1 JP 2013532952-A/2487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>HW324440.1 JP 2013532952-A/2485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>HW324438.1 JP 2013532952-A/2483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>HW324436.1 JP 2013532952-A/2481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>HW324434.1 JP 2013532952-A/2479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>HW324432.1 JP 2013532952-A/2477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>HW324430.1 JP 2013532952-A/2475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>HW324428.1 JP 2013532952-A/2473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>HW324426.1 JP 2013532952-A/2471: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>HW324424.1 JP 2013532952-A/2469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>HW324422.1 JP 2013532952-A/2467: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>HW324420.1 JP 2013532952-A/2465: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW324418.1 JP 2013532952-A/2463: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW324416.1 JP 2013532952-A/2461: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>HW324414.1 JP 2013532952-A/2459: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW324410.1 JP 2013532952-A/2455: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>HW324408.1 JP 2013532952-A/2453: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>HW324404.1 JP 2013532952-A/2449: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>HW324402.1 JP 2013532952-A/2447: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>HW324400.1 JP 2013532952-A/2445: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>HW324396.1 JP 2013532952-A/2441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>HW324392.1 JP 2013532952-A/2437: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>HW324390.1 JP 2013532952-A/2435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>HW324386.1 JP 2013532952-A/2431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>HW324382.1 JP 2013532952-A/2427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>HW324380.1 JP 2013532952-A/2425: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>HW324378.1 JP 2013532952-A/2423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>HW324376.1 JP 2013532952-A/2421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>HW324374.1 JP 2013532952-A/2419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>HW324372.1 JP 2013532952-A/2417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>HW324370.1 JP 2013532952-A/2415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>HW324366.1 JP 2013532952-A/2411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>HW324362.1 JP 2013532952-A/2407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>HW324359.1 JP 2013532952-A/2404: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>HW324358.1 JP 2013532952-A/2403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGCTGACCTGG
>HW324357.1 JP 2013532952-A/2402: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATCAAGTTTGAG
>HW324356.1 JP 2013532952-A/2401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGCAAGATCGGC
>HW324355.1 JP 2013532952-A/2400: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACACGTTTGGC
>HW324354.1 JP 2013532952-A/2399: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTAAATTCTGTGG
>HW324353.1 JP 2013532952-A/2398: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAAATTCTGTG
>HW324352.1 JP 2013532952-A/2397: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGACTTCGGC
>HW324351.1 JP 2013532952-A/2396: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTGCGAAGCTG
>HW324350.1 JP 2013532952-A/2395: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCGAAGCTGACC
>HW324349.1 JP 2013532952-A/2394: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACGGAGACATGG
>HW324348.1 JP 2013532952-A/2393: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGTTCCAAGAC
>HW324347.1 JP 2013532952-A/2392: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACCAGTGCACG
>HW324346.1 JP 2013532952-A/2391: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACAACGCC
>HW324345.1 JP 2013532952-A/2390: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCGAAGCTGAC
>HW324344.1 JP 2013532952-A/2389: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAAGCTGACCTG
>HW324343.1 JP 2013532952-A/2388: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCCAAGACCT
>HW324342.1 JP 2013532952-A/2387: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTATCAAGTTTG
>HW324341.1 JP 2013532952-A/2386: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACTGGAAGAC
>HW324340.1 JP 2013532952-A/2385: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCGAAGCTGA
>HW324339.1 JP 2013532952-A/2384: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCCTTGCGAAGC
>HW324338.1 JP 2013532952-A/2383: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGGTCATGAAG
>HW324337.1 JP 2013532952-A/2382: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGACACGTTTGG
>HW324336.1 JP 2013532952-A/2381: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTAAATTCTG
>HW324335.1 JP 2013532952-A/2380: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCAGGCCTTGC
>HW324334.1 JP 2013532952-A/2379: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAGAGAAGCAG
>HW324333.1 JP 2013532952-A/2378: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGTATGTACC
>HW324332.1 JP 2013532952-A/2377: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGAACTGCAG
>HW324331.1 JP 2013532952-A/2376: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGTTTGAGCT
>HW324330.1 JP 2013532952-A/2375: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTCAGGCCTTG
>HW324329.1 JP 2013532952-A/2374: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACTTCGGCTCC
>HW324328.1 JP 2013532952-A/2373: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACTTCGGCTC
>HW324327.1 JP 2013532952-A/2372: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGATGTACGG
>HW324326.1 JP 2013532952-A/2371: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAAGCTGACCT
>HW324325.1 JP 2013532952-A/2370: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAGGCCTTGCGA
>HW324324.1 JP 2013532952-A/2369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGGAGACATGGC
>HW324323.1 JP 2013532952-A/2368: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACGTTTGGCC
>HW324322.1 JP 2013532952-A/2367: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCGAGGTCATGA
>HW324321.1 JP 2013532952-A/2366: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGACAACGCCT
>HW324320.1 JP 2013532952-A/2365: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGATGTACGGAG
>HW324319.1 JP 2013532952-A/2364: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAAGACACGTT
>HW324318.1 JP 2013532952-A/2363: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAAATTCTGTGGA
>HW324317.1 JP 2013532952-A/2362: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCATGAAGA
>HW324316.1 JP 2013532952-A/2361: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAACGCCTC
>HW324315.1 JP 2013532952-A/2360: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGAGACATGGCA
>HW324314.1 JP 2013532952-A/2359: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGTGGAGTATG
>HW324313.1 JP 2013532952-A/2358: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGAGCTAAATTCT
>HW324312.1 JP 2013532952-A/2357: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGGCCTTGCGAA
>HW324311.1 JP 2013532952-A/2356: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGCAAGATCGG
>HW324310.1 JP 2013532952-A/2355: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCGACTGGAAG
>HW324309.1 JP 2013532952-A/2354: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGCCTTGCGAAG
>HW324308.1 JP 2013532952-A/2353: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGACACGTTTG
>HW324307.1 JP 2013532952-A/2352: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGTCAGGCCTT
>HW324306.1 JP 2013532952-A/2351: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTCATGAAGAAG
>HW324305.1 JP 2013532952-A/2350: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCTGACCTGGA
>HW324304.1 JP 2013532952-A/2349: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGAAGTGTAA
>HW324303.1 JP 2013532952-A/2348: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGTTCCTTAA
>HW324302.1 JP 2013532952-A/2347: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAAAGGTTA
>HW324301.1 JP 2013532952-A/2346: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATACCGAGCTA
>HW324300.1 JP 2013532952-A/2345: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTTGAGAGTGT
>HW324299.1 JP 2013532952-A/2344: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATACCGAGCTAAA
>HW324298.1 JP 2013532952-A/2343: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCCTTTATTA
>HW324297.1 JP 2013532952-A/2342: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGGACAGCTT
>HW324296.1 JP 2013532952-A/2341: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATACGAGTAATA
>HW324295.1 JP 2013532952-A/2340: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATCTAAGTTAA
>HW324294.1 JP 2013532952-A/2339: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGCTCAGATA
>HW324293.1 JP 2013532952-A/2338: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTGATCAGTTT
>HW324292.1 JP 2013532952-A/2337: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGGTAGAATGTAA
>HW324291.1 JP 2013532952-A/2336: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCTAAATTCTGT
>HW324290.1 JP 2013532952-A/2335: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATCAAGTTTGA
>HW324289.1 JP 2013532952-A/2334: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAGACACGTTT
>HW324288.1 JP 2013532952-A/2333: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTACCAGTGCAC
>HW324287.1 JP 2013532952-A/2332: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATGACATCTTT
>HW324286.1 JP 2013532952-A/2331: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCAGTAGCACA
>HW324285.1 JP 2013532952-A/2330: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTCTGTGGAG
>HW324284.1 JP 2013532952-A/2329: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGTATGT
>HW324283.1 JP 2013532952-A/2328: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAAGTTTGAGCTT
>HW324282.1 JP 2013532952-A/2327: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCCTATCAAGTT
>HW324281.1 JP 2013532952-A/2326: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACGGAGACAT
>HW324280.1 JP 2013532952-A/2325: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCTGTGGAGT
>HW324279.1 JP 2013532952-A/2324: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTATCAAGTTT
>HW324278.1 JP 2013532952-A/2323: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCGAGGAGTG
>HW324277.1 JP 2013532952-A/2322: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCTTGCGAAGCT
>HW324276.1 JP 2013532952-A/2321: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTACGGAGACA
>HW324275.1 JP 2013532952-A/2320: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCGACTGGAAGA
>HW324274.1 JP 2013532952-A/2319: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGTGGAGCGCC
>HW324273.1 JP 2013532952-A/2318: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTACAACTGTC
>HW324272.1 JP 2013532952-A/2317: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTACAACTGTCC
>HW324271.1 JP 2013532952-A/2316: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGCCATTACAAC
>HW324270.1 JP 2013532952-A/2315: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCATTACAACTGT
>HW324269.1 JP 2013532952-A/2314: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTGGTCCAGACC
>HW324268.1 JP 2013532952-A/2313: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTGGAGCGC
>HW324267.1 JP 2013532952-A/2312: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGACCTGTGCCTG
>HW324266.1 JP 2013532952-A/2311: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTGCCTGGTCC
>HW324265.1 JP 2013532952-A/2310: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTGGAAGACACG
>HW324264.1 JP 2013532952-A/2309: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCCATTACAACT
>HW324263.1 JP 2013532952-A/2308: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTGAGCTTTCT
>HW324262.1 JP 2013532952-A/2307: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGAGCGCCTGTT
>HW324261.1 JP 2013532952-A/2306: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGAGCGCCTG
>HW324260.1 JP 2013532952-A/2305: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGCTTTCTGGCT
>HW324259.1 JP 2013532952-A/2304: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATTACAACTG
>HW324258.1 JP 2013532952-A/2303: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAGCGCCTGTTC
>HW324257.1 JP 2013532952-A/2302: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACTGGAAGACA
>HW324255.1 JP 2013532952-A/2300: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGGAGCGCCT
>HW324253.1 JP 2013532952-A/2298: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGGAAGATGTA
>HW324249.1 JP 2013532952-A/2294: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>HW324245.1 JP 2013532952-A/2290: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>HW324241.1 JP 2013532952-A/2286: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>HW324237.1 JP 2013532952-A/2282: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>HW324235.1 JP 2013532952-A/2280: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>HW324233.1 JP 2013532952-A/2278: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>HW324231.1 JP 2013532952-A/2276: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>HW324229.1 JP 2013532952-A/2274: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>HW324227.1 JP 2013532952-A/2272: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>HW324225.1 JP 2013532952-A/2270: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>HW324221.1 JP 2013532952-A/2266: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>HW324219.1 JP 2013532952-A/2264: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>HW324217.1 JP 2013532952-A/2262: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>HW324215.1 JP 2013532952-A/2260: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>HW324213.1 JP 2013532952-A/2258: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>HW324209.1 JP 2013532952-A/2254: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>HW324207.1 JP 2013532952-A/2252: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>HW324203.1 JP 2013532952-A/2248: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>HW324201.1 JP 2013532952-A/2246: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>HW324199.1 JP 2013532952-A/2244: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>HW324197.1 JP 2013532952-A/2242: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>HW324193.1 JP 2013532952-A/2238: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW324191.1 JP 2013532952-A/2236: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>HW324187.1 JP 2013532952-A/2232: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>HW324185.1 JP 2013532952-A/2230: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>HW324183.1 JP 2013532952-A/2228: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>HW324181.1 JP 2013532952-A/2226: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>HW324179.1 JP 2013532952-A/2224: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>HW324177.1 JP 2013532952-A/2222: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>HW324175.1 JP 2013532952-A/2220: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>HW324173.1 JP 2013532952-A/2218: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>HW324171.1 JP 2013532952-A/2216: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>HW324169.1 JP 2013532952-A/2214: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>HW324167.1 JP 2013532952-A/2212: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>HW324165.1 JP 2013532952-A/2210: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>HW324163.1 JP 2013532952-A/2208: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>HW324161.1 JP 2013532952-A/2206: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>HW324159.1 JP 2013532952-A/2204: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>HW324157.1 JP 2013532952-A/2202: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>HW324155.1 JP 2013532952-A/2200: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>HW324153.1 JP 2013532952-A/2198: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>HW324151.1 JP 2013532952-A/2196: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>HW324149.1 JP 2013532952-A/2194: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>HW324147.1 JP 2013532952-A/2192: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>HW324145.1 JP 2013532952-A/2190: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>HW324143.1 JP 2013532952-A/2188: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>HW324141.1 JP 2013532952-A/2186: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>HW324139.1 JP 2013532952-A/2184: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>HW324135.1 JP 2013532952-A/2180: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>HW324131.1 JP 2013532952-A/2176: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>HW324127.1 JP 2013532952-A/2172: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>HW324123.1 JP 2013532952-A/2168: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>HW324119.1 JP 2013532952-A/2164: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>HW324115.1 JP 2013532952-A/2160: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>HW324111.1 JP 2013532952-A/2156: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>HW324109.1 JP 2013532952-A/2154: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCCAGCAAC
>HW324107.1 JP 2013532952-A/2152: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTCGAACGACT
>HW324105.1 JP 2013532952-A/2150: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGCAATTAATA
>HW324103.1 JP 2013532952-A/2148: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCCAGCAATTAA
>HW324101.1 JP 2013532952-A/2146: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGTCTGGAAA
>HW324099.1 JP 2013532952-A/2144: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGTGTATCTAT
>HW324097.1 JP 2013532952-A/2142: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCCGTGAAT
>HW324095.1 JP 2013532952-A/2140: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGTGATTGATA
>HW324093.1 JP 2013532952-A/2138: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGAGTGCTG
>HW324091.1 JP 2013532952-A/2136: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTTATGGACT
>HW324089.1 JP 2013532952-A/2134: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGGTCACTGATT
>HW324087.1 JP 2013532952-A/2132: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACGAAAGCCA
>HW324085.1 JP 2013532952-A/2130: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCATGAGAATTG
>HW324083.1 JP 2013532952-A/2128: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTCAATTGCTTA
>HW324081.1 JP 2013532952-A/2126: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTCCACAGCCA
>HW324079.1 JP 2013532952-A/2124: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGCATTCCGAT
>HW324077.1 JP 2013532952-A/2122: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTGCTGAAACC
>HW324075.1 JP 2013532952-A/2120: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAACAGGCTGATT
>HW324073.1 JP 2013532952-A/2118: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTACCATGAGAA
>HW324071.1 JP 2013532952-A/2116: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCCGTGAA
>HW324069.1 JP 2013532952-A/2114: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAGTCAGGAACT
>HW324067.1 JP 2013532952-A/2112: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCAATGATGA
>HW324065.1 JP 2013532952-A/2110: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTGTGGTTTAT
>HW324063.1 JP 2013532952-A/2108: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACTCTGATGA
>HW324061.1 JP 2013532952-A/2106: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATTAATAAA
>HW324059.1 JP 2013532952-A/2104: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAATTGCTTAT
>HW324057.1 JP 2013532952-A/2102: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATCACTGTA
>HW324055.1 JP 2013532952-A/2100: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATTCTATAGAA
>HW324053.1 JP 2013532952-A/2098: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAACTAATGTGT
>HW324051.1 JP 2013532952-A/2096: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCCGATGTGATT
>HW324049.1 JP 2013532952-A/2094: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATAAGCGGAAAG
>HW324047.1 JP 2013532952-A/2092: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCAGCTGGATG
>HW324045.1 JP 2013532952-A/2090: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTGAATGGTGC
>HW324043.1 JP 2013532952-A/2088: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACCTCACACATG
>HW324041.1 JP 2013532952-A/2086: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCAGCAACCGAA
>HW324039.1 JP 2013532952-A/2084: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATGAATAGAAA
>HW324037.1 JP 2013532952-A/2082: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGAAATAACTAAT
>HW324035.1 JP 2013532952-A/2080: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGTTGAATGTGTA
>HW324033.1 JP 2013532952-A/2078: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGGTTGAATGT
>HW324031.1 JP 2013532952-A/2076: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCATGAATTT
>HW324029.1 JP 2013532952-A/2074: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAGTGCTGAA
>HW324027.1 JP 2013532952-A/2072: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGAAACGAGTCA
>HW324025.1 JP 2013532952-A/2070: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGCATACAAG
>HW324023.1 JP 2013532952-A/2068: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTAGATAGTGCAT
>HW324021.1 JP 2013532952-A/2066: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAATGAGCATT
>HW324019.1 JP 2013532952-A/2064: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTTTCGCAGAC
>HW324017.1 JP 2013532952-A/2062: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCAACGAAAG
>HW324015.1 JP 2013532952-A/2060: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTTTGTGGCTTC
>HW324013.1 JP 2013532952-A/2058: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTGGAAATAA
>HW324011.1 JP 2013532952-A/2056: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCCGTGAATTC
>HW324009.1 JP 2013532952-A/2054: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGACGAGGACAT
>HW324007.1 JP 2013532952-A/2052: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGACACATATGA
>HW324005.1 JP 2013532952-A/2050: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTGATGAGTCT
>HW324003.1 JP 2013532952-A/2048: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCATTTAGTCAA
>HW324001.1 JP 2013532952-A/2046: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGTCAGGAACTT
>HW323999.1 JP 2013532952-A/2044: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATTCCGATGT
>HW323997.1 JP 2013532952-A/2042: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATTTAGTCAAA
>HW323995.1 JP 2013532952-A/2040: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGTCCAGATT
>HW323993.1 JP 2013532952-A/2038: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGATGGCCGA
>HW323991.1 JP 2013532952-A/2036: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATGGTGCATAC
>HW323989.1 JP 2013532952-A/2034: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCGACCAAGGAAA
>HW323987.1 JP 2013532952-A/2032: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTCATTCTATA
>HW323985.1 JP 2013532952-A/2030: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACCAGTTAAACA
>HW323983.1 JP 2013532952-A/2028: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATAAGCGGAAA
>HW323981.1 JP 2013532952-A/2026: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTCCAGATTAT
>HW323979.1 JP 2013532952-A/2024: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTATGAAACGAGT
>HW323977.1 JP 2013532952-A/2022: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTTGAATGTGT
>HW323975.1 JP 2013532952-A/2020: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGTCCAGATTA
>HW323973.1 JP 2013532952-A/2018: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGAAAGCGA
>HW323971.1 JP 2013532952-A/2016: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCCAGCAATT
>HW323969.1 JP 2013532952-A/2014: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTATAGAAGAA
>HW323967.1 JP 2013532952-A/2012: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGTGTATCTATT
>HW323965.1 JP 2013532952-A/2010: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATAGTGCATCT
>HW323963.1 JP 2013532952-A/2008: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATTGATAGTCA
>HW323961.1 JP 2013532952-A/2006: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGAGGAGTTGAA
>HW323959.1 JP 2013532952-A/2004: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGATGAGAGCAA
>HW323957.1 JP 2013532952-A/2002: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCAACGAAA
>HW323955.1 JP 2013532952-A/2000: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCTCATGAATAG
>HW323953.1 JP 2013532952-A/1998: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCTCATGAAT
>HW323951.1 JP 2013532952-A/1996: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGCCTTCTGATT
>HW323949.1 JP 2013532952-A/1994: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATTTCGTATT
>HW323947.1 JP 2013532952-A/1992: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGGATGATAT
>HW323945.1 JP 2013532952-A/1990: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAGCCATGACCA
>HW323943.1 JP 2013532952-A/1988: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCGTATTTCT
>HW323941.1 JP 2013532952-A/1986: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATTTCGTATTT
>HW323939.1 JP 2013532952-A/1984: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCGGAAAGCCAAT
>HW323937.1 JP 2013532952-A/1982: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCCATGACCAC
>HW323935.1 JP 2013532952-A/1980: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCCATGACCACAT
>HW323933.1 JP 2013532952-A/1978: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCACATGGATGA
>HW323931.1 JP 2013532952-A/1976: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAAGCCAA
>HW323929.1 JP 2013532952-A/1974: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGCGGAAAGCCA
>HW323927.1 JP 2013532952-A/1972: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCTCACCATTC
>HW323925.1 JP 2013532952-A/1970: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACAGCCATGAA
>HW323923.1 JP 2013532952-A/1968: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTGAGGTCAAA
>HW323921.1 JP 2013532952-A/1966: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTCTCACCATT
>HW323919.1 JP 2013532952-A/1964: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGACTGAGGTCA
>HW323917.1 JP 2013532952-A/1962: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATGAATCT
>HW323915.1 JP 2013532952-A/1960: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCAGCTGGATGA
>HW323913.1 JP 2013532952-A/1958: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGAGGTCAAT
>HW323911.1 JP 2013532952-A/1956: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGGTCAATTAA
>HW323909.1 JP 2013532952-A/1954: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTGAGGTCAATT
>HW323907.1 JP 2013532952-A/1952: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGGTCAATTAAA
>HW323905.1 JP 2013532952-A/1950: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGAGGTCAATTA
>HW323903.1 JP 2013532952-A/1948: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCATGAATTAGA
>HW323507.1 JP 2013532952-A/1552: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTCTAGTTGA
>HW323505.1 JP 2013532952-A/1550: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCACCTTTCTAGA
>HW323503.1 JP 2013532952-A/1548: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAAAAGTTAA
>HW323501.1 JP 2013532952-A/1546: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGACCAAAAGTA
>HW323497.1 JP 2013532952-A/1542: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGACCAAAAGA
>HW323495.1 JP 2013532952-A/1540: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGACCAAAAA
>HW323491.1 JP 2013532952-A/1536: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGTGACCAAAA
>HW323489.1 JP 2013532952-A/1534: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAGAGTGTGACA
>HW323487.1 JP 2013532952-A/1532: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGCTTTCTGA
>HW323483.1 JP 2013532952-A/1528: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCACCTTTCTAA
>HW323479.1 JP 2013532952-A/1524: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTTGAGAGTGTA
>HW323477.1 JP 2013532952-A/1522: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGTTTATTTGTA
>HW323473.1 JP 2013532952-A/1518: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGCCAGATTA
>HW323469.1 JP 2013532952-A/1514: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCCTGTAACA
>HW323467.1 JP 2013532952-A/1512: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTCGATTAGAA
>HW323465.1 JP 2013532952-A/1510: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTGATTCGAAA
>HW323463.1 JP 2013532952-A/1508: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTCTGATTCGA
>HW323461.1 JP 2013532952-A/1506: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGAGAAGGAAAA
>HW323459.1 JP 2013532952-A/1504: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTGAGAAGGAA
>HW323457.1 JP 2013532952-A/1502: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGTGTAATTA
>HW323453.1 JP 2013532952-A/1498: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATAGCATCTTAA
>HW323449.1 JP 2013532952-A/1494: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAGAATGTTAA
>HW323445.1 JP 2013532952-A/1490: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTAACTCATA
>HW323136.1 JP 2013532952-A/1181: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAATAAATCTTA
>HW323134.1 JP 2013532952-A/1179: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGAATAAATCTA
>HW323132.1 JP 2013532952-A/1177: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTGAATAAATCA
>HW323130.1 JP 2013532952-A/1175: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGAGTTCATCTA
>HW323128.1 JP 2013532952-A/1173: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TAGAGGCAGGCAA
>HW323126.1 JP 2013532952-A/1171: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGAGGCAGGCAAA
>HW323124.1 JP 2013532952-A/1169: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACACCACTGTAA
>HW323122.1 JP 2013532952-A/1167: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCATTTTAA
>HW323120.1 JP 2013532952-A/1165: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTTACAGGAAA
>HW323118.1 JP 2013532952-A/1163: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGGCAAACTTA
>HW323116.1 JP 2013532952-A/1161: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGGAACAGCA
>HW323114.1 JP 2013532952-A/1159: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTTCTCAGTTCA
>HW323112.1 JP 2013532952-A/1157: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGTCACTATA
>HW323110.1 JP 2013532952-A/1155: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGAGAAAGAAA
>HW323108.1 JP 2013532952-A/1153: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAAATAGAA
>HW323106.1 JP 2013532952-A/1151: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTCGTTGTTTCA
>HW323104.1 JP 2013532952-A/1149: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTGATTCTGGA
>HW323102.1 JP 2013532952-A/1147: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTGCAGTGAA
>HW323100.1 JP 2013532952-A/1145: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGAAATTTCA
>HW323098.1 JP 2013532952-A/1143: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGAAAGAGAACAA
>HW323096.1 JP 2013532952-A/1141: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGCAGTGATTTGA
>HW323094.1 JP 2013532952-A/1139: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATGAAAGAGAAA
>HW323092.1 JP 2013532952-A/1137: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAGTTGTA
>HW323090.1 JP 2013532952-A/1135: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTCACTTTGCA
>HW323088.1 JP 2013532952-A/1133: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCACTTTGCATA
>HW323086.1 JP 2013532952-A/1131: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTGCATTTAGTA
>HW323084.1 JP 2013532952-A/1129: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTTGCATTTAGA
>HW323082.1 JP 2013532952-A/1127: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAGAGAACATA
>HW323080.1 JP 2013532952-A/1125: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCTTTCTCAGTTA
>HW323078.1 JP 2013532952-A/1123: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTCTTTCTCAGTA
>HW323076.1 JP 2013532952-A/1121: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTAGTCAAAAA
>HW323074.1 JP 2013532952-A/1119: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTTTGCATTTAA
>HW323072.1 JP 2013532952-A/1117: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCATTTAGTCA
>HW323070.1 JP 2013532952-A/1115: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCTCAGTTTAA
>HW323066.1 JP 2013532952-A/1111: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTTTGCCTA
>HW323062.1 JP 2013532952-A/1107: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATTTGCTTTTGA
>HW323058.1 JP 2013532952-A/1103: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCCATGAAA
>HW323054.1 JP 2013532952-A/1099: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCGTATTTA
>HW323050.1 JP 2013532952-A/1095: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGATTTGCTTTA
>HW323046.1 JP 2013532952-A/1091: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGCTTTTGCA
>HW323042.1 JP 2013532952-A/1087: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATGAATCTGATA
>HW323040.1 JP 2013532952-A/1085: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTGCTCTGCAA
>HW323038.1 JP 2013532952-A/1083: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGGCCTGTTAA
>HW323036.1 JP 2013532952-A/1081: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAAACACACTGCA
>HW323034.1 JP 2013532952-A/1079: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACACACTGCAAA
>HW323032.1 JP 2013532952-A/1077: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTTGAATAAAA
>HW323030.1 JP 2013532952-A/1075: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGGAAAATAAA
>HW323028.1 JP 2013532952-A/1073: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATGCAGCTAAA
>HW323026.1 JP 2013532952-A/1071: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATCACGGTGAA
>HW323024.1 JP 2013532952-A/1069: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAGTCTGAGAA
>HW323022.1 JP 2013532952-A/1067: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGTTAGTGTA
>HW323020.1 JP 2013532952-A/1065: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGTTGTATGTAA
>HW323018.1 JP 2013532952-A/1063: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCTCGGTATA
>HW323016.1 JP 2013532952-A/1061: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGGTGACAATGAA
>HW323012.1 JP 2013532952-A/1057: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGTGTTGATTAA
>HW323010.1 JP 2013532952-A/1055: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTCTACATTTCA
>HW323008.1 JP 2013532952-A/1053: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTGCCTAAGGAA
>HW323006.1 JP 2013532952-A/1051: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGACAACGATGA
>HW323004.1 JP 2013532952-A/1049: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACAACAACAAA
>HW323002.1 JP 2013532952-A/1047: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCAAACGAGA
>HW323000.1 JP 2013532952-A/1045: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCATCAGTGTTAA
>HW322998.1 JP 2013532952-A/1043: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTCAGTTTAGA
>HW322996.1 JP 2013532952-A/1041: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTAAACCAGTGAA
>HW322994.1 JP 2013532952-A/1039: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGACGACAACGAA
>HW322992.1 JP 2013532952-A/1037: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATATGACCGAGAA
>HW322990.1 JP 2013532952-A/1035: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCAAACGAGCA
>HW322988.1 JP 2013532952-A/1033: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAGAAACTCATA
>HW322986.1 JP 2013532952-A/1031: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTATTGCTATGCA
>HW322984.1 JP 2013532952-A/1029: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAAACTCATGA
>HW322982.1 JP 2013532952-A/1027: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGCTTGTAACAA
>HW322980.1 JP 2013532952-A/1025: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAACAACAACA
>HW322976.1 JP 2013532952-A/1021: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATAAAACAGGTGA
>HW322972.1 JP 2013532952-A/1017: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCACTACAAAA
>HW322968.1 JP 2013532952-A/1013: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAATTTATTAGTA
>HW322964.1 JP 2013532952-A/1009: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTTGCACTACAAA
>HW322960.1 JP 2013532952-A/1005: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACTTTGCCA
>HW322956.1 JP 2013532952-A/1001: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGTGTTCTGTTA
>HW322952.1 JP 2013532952-A/997: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGGCTTAAGGAA
>HW322948.1 JP 2013532952-A/993: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCAGTGTTAAAA
>HW322944.1 JP 2013532952-A/989: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TATTTATTGTGTA
>HW322480.1 JP 2013532952-A/525: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAGATTCAAGTCA
>HW322478.1 JP 2013532952-A/523: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATGACAAAACCAA
>HW322476.1 JP 2013532952-A/521: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAGCAAAGAA
>HW322474.1 JP 2013532952-A/519: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTGTGGAGCAACA
>HW322472.1 JP 2013532952-A/517: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGATTCAAGTCAA
>HW322470.1 JP 2013532952-A/515: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATCTATGACAA
>HW322468.1 JP 2013532952-A/513: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCAAAGATAA
>HW322466.1 JP 2013532952-A/511: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCTACCAGAAA
>HW322464.1 JP 2013532952-A/509: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTCTACCAGAA
>HW322462.1 JP 2013532952-A/507: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAAAGATAATGA
>HW322460.1 JP 2013532952-A/505: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAACTCTACCAGA
>HW322458.1 JP 2013532952-A/503: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAATATAGCAAA
>HW322454.1 JP 2013532952-A/499: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCTATGACAAGA
>HW322452.1 JP 2013532952-A/497: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAAGTTCAAGCA
>HW322450.1 JP 2013532952-A/495: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAACACATCAGA
>HW322448.1 JP 2013532952-A/493: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAACGAAATCTA
>HW322446.1 JP 2013532952-A/491: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGACTTCCGCAA
>HW322444.1 JP 2013532952-A/489: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACGAAATCTATA
>HW322442.1 JP 2013532952-A/487: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACACACAGCATA
>HW322440.1 JP 2013532952-A/485: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGACAAGTTCAAA
>HW322438.1 JP 2013532952-A/483: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCAGAGTACACAA
>HW322436.1 JP 2013532952-A/481: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTATGACAAGTTA
>HW322434.1 JP 2013532952-A/479: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAAGTTCAAGA
>HW322432.1 JP 2013532952-A/477: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCAGAGTACACA
>HW322430.1 JP 2013532952-A/475: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCAAGCAGAGTAA
>HW322428.1 JP 2013532952-A/473: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGAGTACACACA
>HW322424.1 JP 2013532952-A/469: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTGCTTCAGCTA
>HW322422.1 JP 2013532952-A/467: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACAGCATATATAA
>HW322418.1 JP 2013532952-A/463: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTGCTTCAGCTCA
>HW322416.1 JP 2013532952-A/461: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATATATATGTTA
>HW322414.1 JP 2013532952-A/459: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAACAATTCA
>HW322412.1 JP 2013532952-A/457: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCATATATATGA
>HW322408.1 JP 2013532952-A/453: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGTACATTGACTA
>HW322406.1 JP 2013532952-A/451: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATATATATGTA
>HW322402.1 JP 2013532952-A/447: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACTATTGCTTCA
>HW322398.1 JP 2013532952-A/443: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTACATTGACTTA
>HW322396.1 JP 2013532952-A/441: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCATATATATA
>HW322394.1 JP 2013532952-A/439: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACAGCATATATA
>HW322390.1 JP 2013532952-A/435: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATCTGCAATAAA
>HW322386.1 JP 2013532952-A/431: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTGATTGACAA
>HW322382.1 JP 2013532952-A/427: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATTTGATTGAA
>HW322378.1 JP 2013532952-A/423: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCACATTTGATTA
>HW322376.1 JP 2013532952-A/421: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGAAGAAAGTTA
>HW322374.1 JP 2013532952-A/419: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAGTCTAATGAA
>HW322372.1 JP 2013532952-A/417: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCAGTATAAGTA
>HW322370.1 JP 2013532952-A/415: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGCAACACTTGA
>HW322368.1 JP 2013532952-A/413: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACTGATAGGAGA
>HW322366.1 JP 2013532952-A/411: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCAGATCACATA
>HW322362.1 JP 2013532952-A/407: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATCACATTTGATA
>HW322360.1 JP 2013532952-A/405: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATTTCATGTCTA
>HW322358.1 JP 2013532952-A/403: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTCTTTTAATGAA
>HW322356.1 JP 2013532952-A/401: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACCAGTATAAGA
>HW322354.1 JP 2013532952-A/399: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AATACCAGTCTTA
>HW322350.1 JP 2013532952-A/395: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCACCAACTTACA
>HW322348.1 JP 2013532952-A/393: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTCCAAACACA
>HW322344.1 JP 2013532952-A/389: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACTCCAAACACAA
>HW322342.1 JP 2013532952-A/387: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCTTCCTTCGAAA
>HW322340.1 JP 2013532952-A/385: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTTGACATCCAGA
>HW322338.1 JP 2013532952-A/383: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACCTCTCCTATA
>HW322334.1 JP 2013532952-A/379: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GATCACATTTGAA
>HW322332.1 JP 2013532952-A/377: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTATTATACA
>HW322328.1 JP 2013532952-A/373: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCACCAACTTAA
>HW322326.1 JP 2013532952-A/371: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCTCCTATTA
>HW322324.1 JP 2013532952-A/369: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GAAAACTGCTCAA
>HW322018.1 JP 2013532952-A/63: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CATTTGATTGACA
>HW322016.1 JP 2013532952-A/61: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAATACCAGTCTT
>HW322014.1 JP 2013532952-A/59: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACTGCCTCAATT
>HW322012.1 JP 2013532952-A/57: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CACATTTGATTGA
>HW322010.1 JP 2013532952-A/55: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACGCCAAGGAGGT
>HW322008.1 JP 2013532952-A/53: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTCCACTAGGAA
>HW322006.1 JP 2013532952-A/51: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGGTGATCAGAAA
>HW322004.1 JP 2013532952-A/49: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AAGTCCACTAGGA
>HW322002.1 JP 2013532952-A/47: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTCCACATATA
>HW322000.1 JP 2013532952-A/45: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CTCCTGCTAATGT
>HW321998.1 JP 2013532952-A/43: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GTGGTGATCAGAA
>HW321996.1 JP 2013532952-A/41: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CGCCAAGGAGGTT
>HW321994.1 JP 2013532952-A/39: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TTTCCATCTACAA
>HW321992.1 JP 2013532952-A/37: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TCCATCTACAACA
>HW321990.1 JP 2013532952-A/35: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ATTTCCATCTACA
>HW321988.1 JP 2013532952-A/33: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAAGGAGGTTTA
>HW321986.1 JP 2013532952-A/31: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACAGGAACCTGG
>HW321984.1 JP 2013532952-A/29: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GGCTCTCCTTCGA
>HW321982.1 JP 2013532952-A/27: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTCCACGGAGAA
>HW321980.1 JP 2013532952-A/25: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACCTGCAAGACTA
>HW321978.1 JP 2013532952-A/23: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GACTATCGACATG
>HW321976.1 JP 2013532952-A/21: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCATCGAGGCCAT
>HW321974.1 JP 2013532952-A/19: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGCGGAAGCGCAT
>HW321972.1 JP 2013532952-A/17: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CCAACATGATCGT
>HW321970.1 JP 2013532952-A/15: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAGCAAGGTCCTG
>HW321968.1 JP 2013532952-A/13: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
ACATGATCGTGCG
>HW321966.1 JP 2013532952-A/11: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AACATGATCGTGC
>HW321964.1 JP 2013532952-A/9: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TACAGCAAGGTCC
>HW321962.1 JP 2013532952-A/7: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
AGTGGATCCACGA
>HW321960.1 JP 2013532952-A/5: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
CAATTCCTGGCGA
>HW321958.1 JP 2013532952-A/3: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
TGATCGTGCGCTC
>HW321956.1 JP 2013532952-A/1: RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
GCTAATGGTGGAA
>HW319807.1 JP 2013176378-A/156: Detection of Nucleic Acids
CGCTGGACCGTGH
>HW319711.1 JP 2013176378-A/60: Detection of Nucleic Acids
CGGCGTGGCGAGC
>HW319704.1 JP 2013176378-A/53: Detection of Nucleic Acids
AACTATACAACCG
>HW319672.1 JP 2013176378-A/21: Detection of Nucleic Acids
CACTGCTTCGTGG
>HW319582.1 JP 2013179942-A/26: Collections of repeat proteins comprising repeat modules
TTCCGCGGATCCG
>HW318263.1 JP 2013184935-A/4: Asymmetric synthesis method and DNA-based hybrid catalyst used for the method
TATATATATATAT
>HJ692625.1 Sequence 9 from patent US 8592154
GTCGTACGGCTAA
>HJ692615.1 Sequence 9 from patent US 8592153
GTCGTACGGCTAA
>HJ692068.1 Sequence 6 from patent US 8575664
GTCGTACGGCTAA
>HJ691738.1 Sequence 38 from patent US 8575422
CGCTAGCCCCAAC
>HJ690804.1 Sequence 319 from patent US 8575325
GAAGGASAMGCTG
>HJ690803.1 Sequence 318 from patent US 8575325
TGCGACVTGGGGC
>HJ690507.1 Sequence 13 from patent US 8575325
TTTACCCGGTTCA
>HJ690503.1 Sequence 9 from patent US 8575325
GTTTACCCGGTTC
>HJ686799.1 Sequence 76 from patent US 8574886
GGGCCGGATCCGC
>HJ685895.1 Sequence 56 from patent US 8574841
GTAGAAACCTCGC
>HJ685812.1 Sequence 70 from patent US 8574839
TCCTTGCGTCCCA
>HJ685810.1 Sequence 68 from patent US 8574839
GCAGCTGACGGCA
>HJ685707.1 Sequence 38 from patent US 8574832
GGTGANNNNNNNN
>HJ685699.1 Sequence 29 from patent US 8574832
GGTGANNNNNNNN
>HJ685686.1 Sequence 16 from patent US 8574832
CATAGGNNNNNNN
>HJ685685.1 Sequence 15 from patent US 8574832
GTATCCNNNNNNN
>HJ685570.1 Sequence 84 from patent US 8574599
TGTCGTTGTCGTT
>HJ685015.1 Sequence 63 from patent US 8574564
CGGCGTCGTGCCG
>HJ685014.1 Sequence 62 from patent US 8574564
CGGCGCCGTGCCG
>HJ581005.1 Sequence 21 from patent US 8614103
GACCATACTTCAC
>HJ580050.1 Sequence 4 from patent US 8614060
CTCAGGTGATCCA
>HJ551817.1 Sequence 150 from patent US 8597665
AAAAAAAACGCCG
>HJ551793.1 Sequence 126 from patent US 8597665
TCGGAAANGTTCG
>HJ551775.1 Sequence 108 from patent US 8597665
TCGGAACCGTTCG
>HJ551774.1 Sequence 107 from patent US 8597665
TCGGTACCGTTCG
>HJ551773.1 Sequence 106 from patent US 8597665
TCGGTATCGGTCG
>HJ551768.1 Sequence 101 from patent US 8597665
TCGTTAACGTTCG
>HJ551766.1 Sequence 99 from patent US 8597665
TNGTGAACGTTCG
>HJ551764.1 Sequence 97 from patent US 8597665
TCGTGAACGTTCG
>HJ510608.1 Sequence 5 from patent US 8586717
TGGTGGTGGTGGT
>HJ509992.1 Sequence 1559 from patent US 8586554
TAGCCACCAACTG
>HJ509869.1 Sequence 1432 from patent US 8586554
TAGCCTCTGGATT
>HJ509601.1 Sequence 1163 from patent US 8586554
GCTAGCCTCTGGA
>HJ508809.1 Sequence 292 from patent US 8586554
GCACACAGCTGCC
>HJ508799.1 Sequence 280 from patent US 8586554
GGCATGAGCTTCA
>HJ508770.1 Sequence 245 from patent US 8586554
TGTTCCAGCCCAG
>HJ494979.1 Sequence 21 from patent US 8563528
GTCTGTGGAAGCG
>HJ494978.1 Sequence 20 from patent US 8563528
GTCTGTGGAAGCG
>HJ494975.1 Sequence 17 from patent US 8563528
ACGTGTTGTCTAC
>HJ494973.1 Sequence 15 from patent US 8563528
GTCTGTGGAAGCG
>HJ494970.1 Sequence 12 from patent US 8563528
ACGTGTTGTCTAC
>HJ494968.1 Sequence 10 from patent US 8563528
GTCTGTGGAAGCG
>HJ494965.1 Sequence 7 from patent US 8563528
ACGTGTTGTCTAC
>HJ494960.1 Sequence 2 from patent US 8563528
ACGTGTTGTCTAC
>HJ494517.1 Sequence 27 from patent US 8563286
DTAAACATGTAGG
>HJ508316.1 Sequence 449 from patent US 8586526
TGATACTGACTGT
>HJ508271.1 Sequence 377 from patent US 8586526
GCTCTTCAGCCTT
>HJ508151.1 Sequence 186 from patent US 8586526
GACCCTGCCTGCT
>HJ508091.1 Sequence 121 from patent US 8586526
TGATACTGACTGT
>HJ508084.1 Sequence 114 from patent US 8586526
CTTCATTACACCT
>HJ505990.1 Sequence 39 from patent US 8586303
TGAGGGCCNGGTA
>HJ505988.1 Sequence 37 from patent US 8586303
TGAGGGCCNGGTA
>HJ502629.1 Sequence 19 from patent US 8580947
TCGCCATGCTGCT
>HJ501918.1 Sequence 64 from patent US 8580756
GCAAGCATCCTGT
>HJ501917.1 Sequence 63 from patent US 8580756
GCAAGCATCCTGT
>HJ501916.1 Sequence 62 from patent US 8580756
GGCAAGCATCCTG
>HJ501915.1 Sequence 61 from patent US 8580756
GGCAAGCATCCTG
>HJ501907.1 Sequence 53 from patent US 8580756
GCAAGCATCCTGT
>HJ501906.1 Sequence 52 from patent US 8580756
GGCAAGCATCCTG
>HJ501901.1 Sequence 47 from patent US 8580756
GCAAGCATCCTGT
>HJ501900.1 Sequence 46 from patent US 8580756
GCAAGCATCCTGT
>HJ501899.1 Sequence 45 from patent US 8580756
GGCAAGCATGCTG
>HJ501898.1 Sequence 44 from patent US 8580756
GGCAAGCATCCTG
>HJ501886.1 Sequence 32 from patent US 8580756
GCATTGGTATTCA
>HJ501885.1 Sequence 31 from patent US 8580756
GCATTGGTATTCA
>HJ501884.1 Sequence 30 from patent US 8580756
GCATTGGTATTCA
>HJ501883.1 Sequence 29 from patent US 8580756
GCATTGGTATTCA
>HJ501882.1 Sequence 28 from patent US 8580756
GCATTGGTATTCA
>HJ501881.1 Sequence 27 from patent US 8580756
GCATTGGTATTCA
>HJ501880.1 Sequence 26 from patent US 8580756
GCATTGGTATTCA
>HJ501864.1 Sequence 10 from patent US 8580756
CATTGGTATTCAG
>HJ501863.1 Sequence 9 from patent US 8580756
GCATTGGTATTCA
>HJ501862.1 Sequence 8 from patent US 8580756
AGCATTGGTATTC
>HJ501861.1 Sequence 7 from patent US 8580756
CAGCATTGGTATT
>HJ500117.1 Sequence 1 from patent US 8580511
GCCGCCRCCATGG
>HJ499933.1 Sequence 84 from patent US 8580507
TAAAGGAAACTTA
>HJ498727.1 Sequence 198 from patent US 8580268
CGGCGCCGTGCCG
>HJ498684.1 Sequence 155 from patent US 8580268
NCGGCGGCCGCCG
>HW314285.1 JP 2013527765-A/54: COMPOSITIONS FOR LINKING ZINC FINGER MODULES
AAAGCGTGCTCCG
>HW314284.1 JP 2013527765-A/53: COMPOSITIONS FOR LINKING ZINC FINGER MODULES
AAAGCGGGCTCCG
>HW314283.1 JP 2013527765-A/52: COMPOSITIONS FOR LINKING ZINC FINGER MODULES
AAAGCGCGCTCCG
>HW314282.1 JP 2013527765-A/51: COMPOSITIONS FOR LINKING ZINC FINGER MODULES
AAAGCGAGCTCCG
>HW314276.1 JP 2013527765-A/45: COMPOSITIONS FOR LINKING ZINC FINGER MODULES
ACTCTGTTGGAAG
>HW314275.1 JP 2013527765-A/44: COMPOSITIONS FOR LINKING ZINC FINGER MODULES
ACTCTGGTGGAAG
>HW314274.1 JP 2013527765-A/43: COMPOSITIONS FOR LINKING ZINC FINGER MODULES
ACTCTGCTGGAAG
>HW314273.1 JP 2013527765-A/42: COMPOSITIONS FOR LINKING ZINC FINGER MODULES
ACTCTGATGGAAG
>HW312138.1 JP 2013529893-A/1: COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS
WATCAANNNNTTR
>HW312084.1 JP 2013527753-A/17: Vectors Conditionally Expressing Therapeutic Proteins, Host Comprising the Vectors, and Uses Thereof
AGGTCANAGGTCA
>HW311542.1 WO 2013118857-A/79: Antisense oligonucleotides against ACSL1
TCCTAACCCCTCA
>HW311484.1 WO 2013118857-A/21: Antisense oligonucleotides against ACSL1
TCCTAACCCCTTG
>HW311473.1 WO 2013118857-A/10: Antisense oligonucleotides against ACSL1
CTCCATGACACAG
>HW311472.1 WO 2013118857-A/9: Antisense oligonucleotides against ACSL1
AGCTCCATGACAC
>HW311471.1 WO 2013118857-A/8: Antisense oligonucleotides against ACSL1
GCTCCATGACACA
>HW309154.1 JP 2013150615-A/61: MARKERS FOR PRENATAL DIAGNOSIS AND MONITORING
AGCGAGAGATGCC
>HW308528.1 JP 2013159574-A/7: Deazapurine nucleoside derivatives, deazapurine nucleotide derivatives and polynucleotide derivatives
GCGTTANATTGCG
>HW308527.1 JP 2013159574-A/6: Deazapurine nucleoside derivatives, deazapurine nucleotide derivatives and polynucleotide derivatives
CGCAATNTAACGC
>HW308526.1 JP 2013159574-A/5: Deazapurine nucleoside derivatives, deazapurine nucleotide derivatives and polynucleotide derivatives
CGCAATNTAACGC
>HW308525.1 JP 2013159574-A/4: Deazapurine nucleoside derivatives, deazapurine nucleotide derivatives and polynucleotide derivatives
CGCAATNTAACGC
>HW308524.1 JP 2013159574-A/3: Deazapurine nucleoside derivatives, deazapurine nucleotide derivatives and polynucleotide derivatives
CGCAATNTAACGC
>HW308523.1 JP 2013159574-A/2: Deazapurine nucleoside derivatives, deazapurine nucleotide derivatives and polynucleotide derivatives
CGCAATNTAACGC
>HW308522.1 JP 2013159574-A/1: Deazapurine nucleoside derivatives, deazapurine nucleotide derivatives and polynucleotide derivatives
CGCAATNTAACGC
>HW308465.1 JP 2013158290-A/7: Probe for nucleic acid detection which combined silanization fluorescence agent, and method for detecting of nucleic acid by the probe
GAACTTTTTCCCG
>HW308464.1 JP 2013158290-A/6: Probe for nucleic acid detection which combined silanization fluorescence agent, and method for detecting of nucleic acid by the probe
GAACTATTTCCCG
>HW308463.1 JP 2013158290-A/5: Probe for nucleic acid detection which combined silanization fluorescence agent, and method for detecting of nucleic acid by the probe
GAACTGTTTCCCG
>HW308462.1 JP 2013158290-A/4: Probe for nucleic acid detection which combined silanization fluorescence agent, and method for detecting of nucleic acid by the probe
GAACTCTTTCCCG
>HW315668.1 JP 2013529083-A/281: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
TGATACTGACTGT
>HW315623.1 JP 2013529083-A/236: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
GCTCTTCAGCCTT
>HW315503.1 JP 2013529083-A/116: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
GACCCTGCCTGCT
>HW315443.1 JP 2013529083-A/56: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
TGATACTGACTGT
>HW315436.1 JP 2013529083-A/49: NOVEL DNA-BINDING PROTEINS AND USES THEREOF
CTTCATTACACCT
>HW151211.1 WO 2013054534-A/40: Medicaments for diseases associated with Amyloid beta and screening thereof
GCAGCAAGGAATT
>HW151210.1 WO 2013054534-A/39: Medicaments for diseases associated with Amyloid beta and screening thereof
TTGAAGCAGCCAG
>HW151209.1 WO 2013054534-A/38: Medicaments for diseases associated with Amyloid beta and screening thereof
AAGTTTTGCTGTC
>HW151208.1 WO 2013054534-A/37: Medicaments for diseases associated with Amyloid beta and screening thereof
TTGCCTGAGAGTC
>HW151207.1 WO 2013054534-A/36: Medicaments for diseases associated with Amyloid beta and screening thereof
CCAGAAGTGACGA
>HW151206.1 WO 2013054534-A/35: Medicaments for diseases associated with Amyloid beta and screening thereof
AGTCTCCATTGAG
>HW151205.1 WO 2013054534-A/34: Medicaments for diseases associated with Amyloid beta and screening thereof
AGATGGGGAACCA
>HW151204.1 WO 2013054534-A/33: Medicaments for diseases associated with Amyloid beta and screening thereof
AGAGGAAGTCTCC
>HW151203.1 WO 2013054534-A/32: Medicaments for diseases associated with Amyloid beta and screening thereof
ACTTGTCTGGGAG
>HW151202.1 WO 2013054534-A/31: Medicaments for diseases associated with Amyloid beta and screening thereof
CGTGTTGTGATAT
>HW151201.1 WO 2013054534-A/30: Medicaments for diseases associated with Amyloid beta and screening thereof
TGCAGATGATCCC
>HW151200.1 WO 2013054534-A/29: Medicaments for diseases associated with Amyloid beta and screening thereof
TGATACCACCAGA
>HW106496.1 JP 2012034701-A/181: PROTEASE SCREENING METHODS AND PROTEASES IDENTIFIED THEREBY
ATGGAACCCTGAA
>HW116055.1 JP 2012070761-A/5: Optimizing glycan processing in plants
AATACTTCCACCC
>HW081862.1 JP 2012533534-A/3: Peptide Vaccine Comprising Liposome-encapsulated Oligonucleotides and Peptides
AGCAGCGTTCTTG
>HW055842.1 JP 2012239430-A/2: A gene identification method and a expression analysis method on comprehensive fragmentation analysis
TTTTTTTTTTTTT
>HW046233.1 JP 2012523225-A/6: TRICYCLO-DNA ANTISENSE OLIGONUCLEOTIDES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE
TTAATTTAAGGAA
>HW044150.1 WO 2012157778-A/2: A gene identification method and a expression analysis method on comprehensive fragmentation analysis
TTTTTTTTTTTTT
>HV964666.1 JP 2012522001-A/1: COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS
TCGNNTCGNNTCG
>HV961169.1 WO 2012133947-A/14: FUNCTIONAL NUCLEIC ACID MOLECULE AND USE THEREOF
CATAGGGTTCATT
>HV963939.1 JP 2012521202-A/34: Method for determining the predisposition of a patient to changed biotransformation and to the development of undesired pharmaceutical effects in a treatment of the patient with Atorvastatin
CCCCAGGCCAATC
>HV949974.1 WO 2012121093-A/8: MULTI-DISEASE-RESISTANT MONOCOTS HAVING OPTIMIZED AGRICULTURAL CHARACTER
AGCTTGGCCAAAT
>HV945132.1 JP 2012515552-A/17: MYCOPLASMA GALLISEPTICUM FORMULATION
GTAAAACGACGGC
>HV780007.1 JP 2012514475-A/189: Recurrent Gene Fusions in Cancer
CTGTAACTGAAAA
>HV779995.1 JP 2012514475-A/177: Recurrent Gene Fusions in Cancer
CCAGAATCTCCAC
>HV779984.1 JP 2012514475-A/166: Recurrent Gene Fusions in Cancer
GGAGCGCGGCAGG
>HV779976.1 JP 2012514475-A/158: Recurrent Gene Fusions in Cancer
ACTCATCACAGCC
>HV779951.1 JP 2012514475-A/133: Recurrent Gene Fusions in Cancer
ACTGCCCTCCAGC
>HV779950.1 JP 2012514475-A/132: Recurrent Gene Fusions in Cancer
ACTGCACTCCAGC
>HV779929.1 JP 2012514475-A/111: Recurrent Gene Fusions in Cancer
GAGAGAAGACTCA
>HV779907.1 JP 2012514475-A/89: Recurrent Gene Fusions in Cancer
AAGCCCTTCAGCG
>HW297403.1 JP 2013523650-A/1422: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW297402.1 JP 2013523650-A/1421: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTGGAAGTCTA
>HW297398.1 JP 2013523650-A/1417: RNA INTERFERENCE IN OCULAR INDICATIONS
TATTGCTCTGCAA
>HW297396.1 JP 2013523650-A/1415: RNA INTERFERENCE IN OCULAR INDICATIONS
CGGTGACAATGAA
>HW297394.1 JP 2013523650-A/1413: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGTATATA
>HW297384.1 JP 2013523650-A/1403: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW297382.1 JP 2013523650-A/1401: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW297380.1 JP 2013523650-A/1399: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW297378.1 JP 2013523650-A/1397: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCGGATCAAACA
>HW297364.1 JP 2013523650-A/1383: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>HW297363.1 JP 2013523650-A/1382: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>HW297362.1 JP 2013523650-A/1381: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>HW297360.1 JP 2013523650-A/1379: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>HW297356.1 JP 2013523650-A/1375: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTAGCTTATCA
>HW297354.1 JP 2013523650-A/1373: RNA INTERFERENCE IN OCULAR INDICATIONS
TCACTAGCTTATA
>HW297352.1 JP 2013523650-A/1371: RNA INTERFERENCE IN OCULAR INDICATIONS
ATCTTTTGCTCTA
>HW297350.1 JP 2013523650-A/1369: RNA INTERFERENCE IN OCULAR INDICATIONS
TATCTTTTGCTCA
>HW297348.1 JP 2013523650-A/1367: RNA INTERFERENCE IN OCULAR INDICATIONS
AACCACTAGTTCA
>HW297346.1 JP 2013523650-A/1365: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAACCACTAGTA
>HW297344.1 JP 2013523650-A/1363: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAAAGACAGAA
>HW297342.1 JP 2013523650-A/1361: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGACTGCTGTGA
>HW297340.1 JP 2013523650-A/1359: RNA INTERFERENCE IN OCULAR INDICATIONS
GGATTCGCCATTA
>HW297338.1 JP 2013523650-A/1357: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCGGATCAAACA
>HW297336.1 JP 2013523650-A/1355: RNA INTERFERENCE IN OCULAR INDICATIONS
GATTATGCGGATA
>HW297334.1 JP 2013523650-A/1353: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCAGATTATGCA
>HW297332.1 JP 2013523650-A/1351: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAACAGTCCTA
>HW297330.1 JP 2013523650-A/1349: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCTACTGTTTAA
>HW297328.1 JP 2013523650-A/1347: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTGGTGCTACTA
>HW287591.1 JP 2013138674-A/5: METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS
CTAGANCTGGAGG
>HW287588.1 JP 2013138674-A/2: METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS
CTAGANCTGGAGG
>HW287587.1 JP 2013138674-A/1: METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS
CTAGANCTGGAGG
>HW297326.1 JP 2013523650-A/1345: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCTCTCCTTTTA
>HW297324.1 JP 2013523650-A/1343: RNA INTERFERENCE IN OCULAR INDICATIONS
TCTCTCTCCTTTA
>HW297322.1 JP 2013523650-A/1341: RNA INTERFERENCE IN OCULAR INDICATIONS
AATCTCTCTCCTA
>HW297320.1 JP 2013523650-A/1339: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATAAGGTTTCA
>HW297318.1 JP 2013523650-A/1337: RNA INTERFERENCE IN OCULAR INDICATIONS
ACACTCAGCTCTA
>HW297316.1 JP 2013523650-A/1335: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAAAGAGAAAGA
>HW297314.1 JP 2013523650-A/1333: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAAAAGAGAAAA
>HW297312.1 JP 2013523650-A/1331: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGAAAAGAGAAA
>HW297310.1 JP 2013523650-A/1329: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGAAACCACTAA
>HW297308.1 JP 2013523650-A/1327: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTTATTGGTGTA
>HW297306.1 JP 2013523650-A/1325: RNA INTERFERENCE IN OCULAR INDICATIONS
TTAATCCAGAAAA
>HW297304.1 JP 2013523650-A/1323: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCCTTAATCCAA
>HW297302.1 JP 2013523650-A/1321: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGTCCTTAATCA
>HW297300.1 JP 2013523650-A/1319: RNA INTERFERENCE IN OCULAR INDICATIONS
GAACAGTCCTTAA
>HW297298.1 JP 2013523650-A/1317: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAACAGTCCTTA
>HW297296.1 JP 2013523650-A/1315: RNA INTERFERENCE IN OCULAR INDICATIONS
GATGAGCTTCCTA
>HW297294.1 JP 2013523650-A/1313: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297292.1 JP 2013523650-A/1311: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297290.1 JP 2013523650-A/1309: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297288.1 JP 2013523650-A/1307: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297286.1 JP 2013523650-A/1305: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297285.1 JP 2013523650-A/1304: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297284.1 JP 2013523650-A/1303: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW297282.1 JP 2013523650-A/1301: RNA INTERFERENCE IN OCULAR INDICATIONS
AGATTCAAGTCAA
>HW297280.1 JP 2013523650-A/1299: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297278.1 JP 2013523650-A/1297: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297276.1 JP 2013523650-A/1295: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297274.1 JP 2013523650-A/1293: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297272.1 JP 2013523650-A/1291: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297270.1 JP 2013523650-A/1289: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297268.1 JP 2013523650-A/1287: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297266.1 JP 2013523650-A/1285: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297264.1 JP 2013523650-A/1283: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGATTCAAGTCA
>HW297262.1 JP 2013523650-A/1281: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGACAAAACCAA
>HW297260.1 JP 2013523650-A/1279: RNA INTERFERENCE IN OCULAR INDICATIONS
TGACAGCAAAGAA
>HW297258.1 JP 2013523650-A/1277: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTGGAGCAACA
>HW297256.1 JP 2013523650-A/1275: RNA INTERFERENCE IN OCULAR INDICATIONS
AGATTCAAGTCAA
>HW297254.1 JP 2013523650-A/1273: RNA INTERFERENCE IN OCULAR INDICATIONS
CAATCTATGACAA
>HW297252.1 JP 2013523650-A/1271: RNA INTERFERENCE IN OCULAR INDICATIONS
ACAGCAAAGATAA
>HW297250.1 JP 2013523650-A/1269: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTCTACCAGAAA
>HW297248.1 JP 2013523650-A/1267: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTCTACCAGAA
>HW297246.1 JP 2013523650-A/1265: RNA INTERFERENCE IN OCULAR INDICATIONS
GCAAAGATAATGA
>HW297244.1 JP 2013523650-A/1263: RNA INTERFERENCE IN OCULAR INDICATIONS
GAACTCTACCAGA
>HW297242.1 JP 2013523650-A/1261: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAATATAGCAAA
>HW297240.1 JP 2013523650-A/1259: RNA INTERFERENCE IN OCULAR INDICATIONS
CACACAGCATATA
>HW297238.1 JP 2013523650-A/1257: RNA INTERFERENCE IN OCULAR INDICATIONS
AATCTATGACAAA
>HW297236.1 JP 2013523650-A/1255: RNA INTERFERENCE IN OCULAR INDICATIONS
CAAGCAGAGTACA
>HW297234.1 JP 2013523650-A/1253: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGTTCAAGCAGA
>HW297232.1 JP 2013523650-A/1251: RNA INTERFERENCE IN OCULAR INDICATIONS
TATGACAAGTTCA
>HW297230.1 JP 2013523650-A/1249: RNA INTERFERENCE IN OCULAR INDICATIONS
CAACGAAATCTAA
>HW297228.1 JP 2013523650-A/1247: RNA INTERFERENCE IN OCULAR INDICATIONS
CTATGACAAGTTA
>HW297226.1 JP 2013523650-A/1245: RNA INTERFERENCE IN OCULAR INDICATIONS
TTAAAGATGGAGA
>HW297224.1 JP 2013523650-A/1243: RNA INTERFERENCE IN OCULAR INDICATIONS
GACAAGTTCAAGA
>HW297222.1 JP 2013523650-A/1241: RNA INTERFERENCE IN OCULAR INDICATIONS
ATATATGTTCTTA
>HW297220.1 JP 2013523650-A/1239: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAGAGTACACA
>HW297218.1 JP 2013523650-A/1237: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCAACACATCAA
>HW297216.1 JP 2013523650-A/1235: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCAGAGTACAA
>HW297214.1 JP 2013523650-A/1233: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAGTACACACAA
>HW297212.1 JP 2013523650-A/1231: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCATATATATGA
>HW297210.1 JP 2013523650-A/1229: RNA INTERFERENCE IN OCULAR INDICATIONS
TCAAGCAGAGTAA
>HW297208.1 JP 2013523650-A/1227: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCATATATATA
>HW297206.1 JP 2013523650-A/1225: RNA INTERFERENCE IN OCULAR INDICATIONS
ACACACAGCATAA
>HW297204.1 JP 2013523650-A/1223: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAGTACACACA
>HW297202.1 JP 2013523650-A/1221: RNA INTERFERENCE IN OCULAR INDICATIONS
CAAGTTCAAGCAA
>HW297198.1 JP 2013523650-A/1217: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTGCTTCAGCTA
>HW297196.1 JP 2013523650-A/1215: RNA INTERFERENCE IN OCULAR INDICATIONS
ACAGCATATATAA
>HW297192.1 JP 2013523650-A/1211: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCTTCAGCTCA
>HW297190.1 JP 2013523650-A/1209: RNA INTERFERENCE IN OCULAR INDICATIONS
CATATATATGTTA
>HW297188.1 JP 2013523650-A/1207: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCAACAATTCA
>HW297186.1 JP 2013523650-A/1205: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCATATATATGA
>HW297182.1 JP 2013523650-A/1201: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTACATTGACTA
>HW297180.1 JP 2013523650-A/1199: RNA INTERFERENCE IN OCULAR INDICATIONS
GCATATATATGTA
>HW297176.1 JP 2013523650-A/1195: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTATTGCTTCA
>HW297172.1 JP 2013523650-A/1191: RNA INTERFERENCE IN OCULAR INDICATIONS
GTACATTGACTTA
>HW297170.1 JP 2013523650-A/1189: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCATATATATA
>HW297168.1 JP 2013523650-A/1187: RNA INTERFERENCE IN OCULAR INDICATIONS
CACAGCATATATA
>HW297166.1 JP 2013523650-A/1185: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTCCACGGAGAA
>HW297164.1 JP 2013523650-A/1183: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTGCAAGACTA
>HW297162.1 JP 2013523650-A/1181: RNA INTERFERENCE IN OCULAR INDICATIONS
GACTATCGACATG
>HW297160.1 JP 2013523650-A/1179: RNA INTERFERENCE IN OCULAR INDICATIONS
GCATCGAGGCCAT
>HW297158.1 JP 2013523650-A/1177: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCGGAAGCGCAT
>HW297156.1 JP 2013523650-A/1175: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAACATGATCGT
>HW297154.1 JP 2013523650-A/1173: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCAAGGTCCTG
>HW297152.1 JP 2013523650-A/1171: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATGATCGTGCG
>HW297150.1 JP 2013523650-A/1169: RNA INTERFERENCE IN OCULAR INDICATIONS
AACATGATCGTGC
>HW297148.1 JP 2013523650-A/1167: RNA INTERFERENCE IN OCULAR INDICATIONS
TACAGCAAGGTCC
>HW297146.1 JP 2013523650-A/1165: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTGGATCCACGA
>HW297144.1 JP 2013523650-A/1163: RNA INTERFERENCE IN OCULAR INDICATIONS
CAATTCCTGGCGA
>HW297142.1 JP 2013523650-A/1161: RNA INTERFERENCE IN OCULAR INDICATIONS
TGATCGTGCGCTC
>HW297140.1 JP 2013523650-A/1159: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTAATGGTGGAA
>HW297138.1 JP 2013523650-A/1157: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297136.1 JP 2013523650-A/1155: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297134.1 JP 2013523650-A/1153: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297132.1 JP 2013523650-A/1151: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297130.1 JP 2013523650-A/1149: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297128.1 JP 2013523650-A/1147: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297126.1 JP 2013523650-A/1145: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297124.1 JP 2013523650-A/1143: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297122.1 JP 2013523650-A/1141: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297120.1 JP 2013523650-A/1139: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297118.1 JP 2013523650-A/1137: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297116.1 JP 2013523650-A/1135: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297114.1 JP 2013523650-A/1133: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297112.1 JP 2013523650-A/1131: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297102.1 JP 2013523650-A/1121: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTCTACATTTCA
>HW297100.1 JP 2013523650-A/1119: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTGCCTAAGGAA
>HW297098.1 JP 2013523650-A/1117: RNA INTERFERENCE IN OCULAR INDICATIONS
ACGACAACGATGA
>HW297096.1 JP 2013523650-A/1115: RNA INTERFERENCE IN OCULAR INDICATIONS
CGACAACAACAAA
>HW297094.1 JP 2013523650-A/1113: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTCAAACGAGA
>HW297092.1 JP 2013523650-A/1111: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATCAGTGTTAA
>HW297090.1 JP 2013523650-A/1109: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGTCAGTTTAGA
>HW297088.1 JP 2013523650-A/1107: RNA INTERFERENCE IN OCULAR INDICATIONS
GTAAACCAGTGAA
>HW297086.1 JP 2013523650-A/1105: RNA INTERFERENCE IN OCULAR INDICATIONS
CGACGACAACGAA
>HW297084.1 JP 2013523650-A/1103: RNA INTERFERENCE IN OCULAR INDICATIONS
ATATGACCGAGAA
>HW297082.1 JP 2013523650-A/1101: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTCAAACGAGCA
>HW297080.1 JP 2013523650-A/1099: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAGAAACTCATA
>HW297078.1 JP 2013523650-A/1097: RNA INTERFERENCE IN OCULAR INDICATIONS
GTATTGCTATGCA
>HW297076.1 JP 2013523650-A/1095: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAAACTCATGA
>HW297074.1 JP 2013523650-A/1093: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGCTTGTAACAA
>HW297072.1 JP 2013523650-A/1091: RNA INTERFERENCE IN OCULAR INDICATIONS
GACAACAACAACA
>HW297068.1 JP 2013523650-A/1087: RNA INTERFERENCE IN OCULAR INDICATIONS
ATAAAACAGGTGA
>HW297064.1 JP 2013523650-A/1083: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCACTACAAAA
>HW297060.1 JP 2013523650-A/1079: RNA INTERFERENCE IN OCULAR INDICATIONS
GAATTTATTAGTA
>HW297056.1 JP 2013523650-A/1075: RNA INTERFERENCE IN OCULAR INDICATIONS
CTTGCACTACAAA
>HW297052.1 JP 2013523650-A/1071: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATACTTTGCCA
>HW297048.1 JP 2013523650-A/1067: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGTGTTCTGTTA
>HW297044.1 JP 2013523650-A/1063: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGGCTTAAGGAA
>HW297040.1 JP 2013523650-A/1059: RNA INTERFERENCE IN OCULAR INDICATIONS
ATCAGTGTTAAAA
>HW297036.1 JP 2013523650-A/1055: RNA INTERFERENCE IN OCULAR INDICATIONS
TATTTATTGTGTA
>HW297034.1 JP 2013523650-A/1053: RNA INTERFERENCE IN OCULAR INDICATIONS
ACGCCAAGGAGGT
>HW297032.1 JP 2013523650-A/1051: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCCACTAGGAA
>HW297030.1 JP 2013523650-A/1049: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTGATCAGAAA
>HW297028.1 JP 2013523650-A/1047: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGTCCACTAGGA
>HW297026.1 JP 2013523650-A/1045: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTCCACATATA
>HW297024.1 JP 2013523650-A/1043: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCCTGCTAATGT
>HW297022.1 JP 2013523650-A/1041: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGGTGATCAGAA
>HW297020.1 JP 2013523650-A/1039: RNA INTERFERENCE IN OCULAR INDICATIONS
CGCCAAGGAGGTT
>HW297018.1 JP 2013523650-A/1037: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTCCATCTACAA
>HW297016.1 JP 2013523650-A/1035: RNA INTERFERENCE IN OCULAR INDICATIONS
TCCATCTACAACA
>HW297014.1 JP 2013523650-A/1033: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTCCATCTACA
>HW297012.1 JP 2013523650-A/1031: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAAGGAGGTTTA
>HW297010.1 JP 2013523650-A/1029: RNA INTERFERENCE IN OCULAR INDICATIONS
GACAGGAACCTGG
>HW297008.1 JP 2013523650-A/1027: RNA INTERFERENCE IN OCULAR INDICATIONS
GGCTCTCCTTCGA
>HW297006.1 JP 2013523650-A/1025: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW297004.1 JP 2013523650-A/1023: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW297002.1 JP 2013523650-A/1021: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW297000.1 JP 2013523650-A/1019: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296998.1 JP 2013523650-A/1017: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296996.1 JP 2013523650-A/1015: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296994.1 JP 2013523650-A/1013: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296992.1 JP 2013523650-A/1011: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296990.1 JP 2013523650-A/1009: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296988.1 JP 2013523650-A/1007: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296986.1 JP 2013523650-A/1005: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296984.1 JP 2013523650-A/1003: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296982.1 JP 2013523650-A/1001: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296980.1 JP 2013523650-A/999: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296978.1 JP 2013523650-A/997: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296976.1 JP 2013523650-A/995: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296974.1 JP 2013523650-A/993: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296972.1 JP 2013523650-A/991: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296970.1 JP 2013523650-A/989: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296968.1 JP 2013523650-A/987: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296942.1 JP 2013523650-A/961: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296940.1 JP 2013523650-A/959: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296938.1 JP 2013523650-A/957: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296936.1 JP 2013523650-A/955: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296934.1 JP 2013523650-A/953: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296932.1 JP 2013523650-A/951: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296930.1 JP 2013523650-A/949: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296928.1 JP 2013523650-A/947: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296926.1 JP 2013523650-A/945: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296924.1 JP 2013523650-A/943: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296922.1 JP 2013523650-A/941: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296920.1 JP 2013523650-A/939: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296918.1 JP 2013523650-A/937: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296916.1 JP 2013523650-A/935: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296914.1 JP 2013523650-A/933: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296912.1 JP 2013523650-A/931: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296910.1 JP 2013523650-A/929: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296908.1 JP 2013523650-A/927: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296906.1 JP 2013523650-A/925: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296904.1 JP 2013523650-A/923: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296902.1 JP 2013523650-A/921: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296900.1 JP 2013523650-A/919: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296868.1 JP 2013523650-A/887: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296866.1 JP 2013523650-A/885: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296864.1 JP 2013523650-A/883: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296862.1 JP 2013523650-A/881: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296860.1 JP 2013523650-A/879: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296858.1 JP 2013523650-A/877: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296856.1 JP 2013523650-A/875: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296854.1 JP 2013523650-A/873: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296852.1 JP 2013523650-A/871: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296850.1 JP 2013523650-A/869: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296848.1 JP 2013523650-A/867: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296846.1 JP 2013523650-A/865: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296844.1 JP 2013523650-A/863: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296842.1 JP 2013523650-A/861: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296840.1 JP 2013523650-A/859: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTTCTAGTTGA
>HW296838.1 JP 2013523650-A/857: RNA INTERFERENCE IN OCULAR INDICATIONS
GCACCTTTCTAGA
>HW296836.1 JP 2013523650-A/855: RNA INTERFERENCE IN OCULAR INDICATIONS
GACCAAAAGTTAA
>HW296834.1 JP 2013523650-A/853: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACCAAAAGTA
>HW296830.1 JP 2013523650-A/849: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTGACCAAAAGA
>HW296828.1 JP 2013523650-A/847: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGTGACCAAAAA
>HW296824.1 JP 2013523650-A/843: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTGTGACCAAAA
>HW296822.1 JP 2013523650-A/841: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAGAGTGTGACA
>HW296820.1 JP 2013523650-A/839: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGAGCTTTCTGA
>HW296816.1 JP 2013523650-A/835: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCACCTTTCTAA
>HW296812.1 JP 2013523650-A/831: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTTGAGAGTGTA
>HW296810.1 JP 2013523650-A/829: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGTTTATTTGTA
>HW296806.1 JP 2013523650-A/825: RNA INTERFERENCE IN OCULAR INDICATIONS
ACAAGCCAGATTA
>HW296802.1 JP 2013523650-A/821: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTGCCTGTAACA
>HW296800.1 JP 2013523650-A/819: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTCGATTAGAA
>HW296798.1 JP 2013523650-A/817: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTGATTCGAAA
>HW296796.1 JP 2013523650-A/815: RNA INTERFERENCE IN OCULAR INDICATIONS
CATTCTGATTCGA
>HW296794.1 JP 2013523650-A/813: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGAGAAGGAAAA
>HW296792.1 JP 2013523650-A/811: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTGAGAAGGAA
>HW296790.1 JP 2013523650-A/809: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAAGTGTAATTA
>HW296786.1 JP 2013523650-A/805: RNA INTERFERENCE IN OCULAR INDICATIONS
GATAGCATCTTAA
>HW296782.1 JP 2013523650-A/801: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAAGAATGTTAA
>HW296778.1 JP 2013523650-A/797: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATTAACTCATA
>HW296776.1 JP 2013523650-A/795: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAGCTGACCTGG
>HW296774.1 JP 2013523650-A/793: RNA INTERFERENCE IN OCULAR INDICATIONS
TATCAAGTTTGAG
>HW296772.1 JP 2013523650-A/791: RNA INTERFERENCE IN OCULAR INDICATIONS
CCGCAAGATCGGC
>HW296770.1 JP 2013523650-A/789: RNA INTERFERENCE IN OCULAR INDICATIONS
AGACACGTTTGGC
>HW296768.1 JP 2013523650-A/787: RNA INTERFERENCE IN OCULAR INDICATIONS
CTAAATTCTGTGG
>HW296766.1 JP 2013523650-A/785: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTAAATTCTGTG
>HW296764.1 JP 2013523650-A/783: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTGACTTCGGC
>HW296762.1 JP 2013523650-A/781: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTGCGAAGCTG
>HW296760.1 JP 2013523650-A/779: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCGAAGCTGACC
>HW296758.1 JP 2013523650-A/777: RNA INTERFERENCE IN OCULAR INDICATIONS
TACGGAGACATGG
>HW296756.1 JP 2013523650-A/775: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTGTTCCAAGAC
>HW296754.1 JP 2013523650-A/773: RNA INTERFERENCE IN OCULAR INDICATIONS
GTACCAGTGCACG
>HW296752.1 JP 2013523650-A/771: RNA INTERFERENCE IN OCULAR INDICATIONS
CAATGACAACGCC
>HW296750.1 JP 2013523650-A/769: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCGAAGCTGAC
>HW296748.1 JP 2013523650-A/767: RNA INTERFERENCE IN OCULAR INDICATIONS
CGAAGCTGACCTG
>HW296746.1 JP 2013523650-A/765: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTTCCAAGACCT
>HW296744.1 JP 2013523650-A/763: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTATCAAGTTTG
>HW296742.1 JP 2013523650-A/761: RNA INTERFERENCE IN OCULAR INDICATIONS
CCGACTGGAAGAC
>HW296740.1 JP 2013523650-A/759: RNA INTERFERENCE IN OCULAR INDICATIONS
CTTGCGAAGCTGA
>HW296738.1 JP 2013523650-A/757: RNA INTERFERENCE IN OCULAR INDICATIONS
GGCCTTGCGAAGC
>HW296736.1 JP 2013523650-A/755: RNA INTERFERENCE IN OCULAR INDICATIONS
CGAGGTCATGAAG
>HW296734.1 JP 2013523650-A/753: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGACACGTTTGG
>HW296732.1 JP 2013523650-A/751: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGCTAAATTCTG
>HW296730.1 JP 2013523650-A/749: RNA INTERFERENCE IN OCULAR INDICATIONS
GGTCAGGCCTTGC
>HW296728.1 JP 2013523650-A/747: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTAGAGAAGCAG
>HW296726.1 JP 2013523650-A/745: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGAGTATGTACC
>HW296724.1 JP 2013523650-A/743: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCAGAACTGCAG
>HW296722.1 JP 2013523650-A/741: RNA INTERFERENCE IN OCULAR INDICATIONS
TCAAGTTTGAGCT
>HW296720.1 JP 2013523650-A/739: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTCAGGCCTTG
>HW296718.1 JP 2013523650-A/737: RNA INTERFERENCE IN OCULAR INDICATIONS
TGACTTCGGCTCC
>HW296716.1 JP 2013523650-A/735: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGACTTCGGCTC
>HW296714.1 JP 2013523650-A/733: RNA INTERFERENCE IN OCULAR INDICATIONS
GGAAGATGTACGG
>HW296712.1 JP 2013523650-A/731: RNA INTERFERENCE IN OCULAR INDICATIONS
GCGAAGCTGACCT
>HW296710.1 JP 2013523650-A/729: RNA INTERFERENCE IN OCULAR INDICATIONS
TCAGGCCTTGCGA
>HW296708.1 JP 2013523650-A/727: RNA INTERFERENCE IN OCULAR INDICATIONS
ACGGAGACATGGC
>HW296706.1 JP 2013523650-A/725: RNA INTERFERENCE IN OCULAR INDICATIONS
GACACGTTTGGCC
>HW296704.1 JP 2013523650-A/723: RNA INTERFERENCE IN OCULAR INDICATIONS
GGCGAGGTCATGA
>HW296702.1 JP 2013523650-A/721: RNA INTERFERENCE IN OCULAR INDICATIONS
AATGACAACGCCT
>HW296700.1 JP 2013523650-A/719: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGATGTACGGAG
>HW296698.1 JP 2013523650-A/717: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGAAGACACGTT
>HW296696.1 JP 2013523650-A/715: RNA INTERFERENCE IN OCULAR INDICATIONS
TAAATTCTGTGGA
>HW296694.1 JP 2013523650-A/713: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGGTCATGAAGA
>HW296692.1 JP 2013523650-A/711: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGACAACGCCTC
>HW296690.1 JP 2013523650-A/709: RNA INTERFERENCE IN OCULAR INDICATIONS
CGGAGACATGGCA
>HW296688.1 JP 2013523650-A/707: RNA INTERFERENCE IN OCULAR INDICATIONS
TCTGTGGAGTATG
>HW296686.1 JP 2013523650-A/705: RNA INTERFERENCE IN OCULAR INDICATIONS
CGAGCTAAATTCT
>HW296684.1 JP 2013523650-A/703: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGGCCTTGCGAA
>HW296682.1 JP 2013523650-A/701: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCGCAAGATCGG
>HW296680.1 JP 2013523650-A/699: RNA INTERFERENCE IN OCULAR INDICATIONS
TACCGACTGGAAG
>HW296678.1 JP 2013523650-A/697: RNA INTERFERENCE IN OCULAR INDICATIONS
AGGCCTTGCGAAG
>HW296676.1 JP 2013523650-A/695: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAGACACGTTTG
>HW296674.1 JP 2013523650-A/693: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGGTCAGGCCTT
>HW296672.1 JP 2013523650-A/691: RNA INTERFERENCE IN OCULAR INDICATIONS
GGTCATGAAGAAG
>HW296670.1 JP 2013523650-A/689: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCTGACCTGGA
>HW296668.1 JP 2013523650-A/687: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTGAAGTGTAA
>HW296666.1 JP 2013523650-A/685: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTTGTTCCTTAA
>HW296664.1 JP 2013523650-A/683: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAGAAAGGTTA
>HW296662.1 JP 2013523650-A/681: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATACCGAGCTA
>HW296660.1 JP 2013523650-A/679: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGTTGAGAGTGT
>HW296658.1 JP 2013523650-A/677: RNA INTERFERENCE IN OCULAR INDICATIONS
ATACCGAGCTAAA
>HW296656.1 JP 2013523650-A/675: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGGCCTTTATTA
>HW296654.1 JP 2013523650-A/673: RNA INTERFERENCE IN OCULAR INDICATIONS
GACTGGACAGCTT
>HW296652.1 JP 2013523650-A/671: RNA INTERFERENCE IN OCULAR INDICATIONS
TATACGAGTAATA
>HW296650.1 JP 2013523650-A/669: RNA INTERFERENCE IN OCULAR INDICATIONS
TTATCTAAGTTAA
>HW296648.1 JP 2013523650-A/667: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTGCTCAGATA
>HW296646.1 JP 2013523650-A/665: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCTGATCAGTTT
>HW296644.1 JP 2013523650-A/663: RNA INTERFERENCE IN OCULAR INDICATIONS
AGGTAGAATGTAA
>HW296642.1 JP 2013523650-A/661: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCTAAATTCTGT
>HW296640.1 JP 2013523650-A/659: RNA INTERFERENCE IN OCULAR INDICATIONS
CTATCAAGTTTGA
>HW296638.1 JP 2013523650-A/657: RNA INTERFERENCE IN OCULAR INDICATIONS
GGAAGACACGTTT
>HW296636.1 JP 2013523650-A/655: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTACCAGTGCAC
>HW296634.1 JP 2013523650-A/653: RNA INTERFERENCE IN OCULAR INDICATIONS
CAATGACATCTTT
>HW296632.1 JP 2013523650-A/651: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTCAGTAGCACA
>HW296630.1 JP 2013523650-A/649: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATTCTGTGGAG
>HW296628.1 JP 2013523650-A/647: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGTGGAGTATGT
>HW296626.1 JP 2013523650-A/645: RNA INTERFERENCE IN OCULAR INDICATIONS
CAAGTTTGAGCTT
>HW296624.1 JP 2013523650-A/643: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCCTATCAAGTT
>HW296622.1 JP 2013523650-A/641: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTACGGAGACAT
>HW296620.1 JP 2013523650-A/639: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTCTGTGGAGT
>HW296618.1 JP 2013523650-A/637: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCTATCAAGTTT
>HW296616.1 JP 2013523650-A/635: RNA INTERFERENCE IN OCULAR INDICATIONS
GCTGCGAGGAGTG
>HW296614.1 JP 2013523650-A/633: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCTTGCGAAGCT
>HW296612.1 JP 2013523650-A/631: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGTACGGAGACA
>HW296610.1 JP 2013523650-A/629: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCGACTGGAAGA
>HW296608.1 JP 2013523650-A/627: RNA INTERFERENCE IN OCULAR INDICATIONS
AGAGTGGAGCGCC
>HW296606.1 JP 2013523650-A/625: RNA INTERFERENCE IN OCULAR INDICATIONS
CATTACAACTGTC
>HW296604.1 JP 2013523650-A/623: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTACAACTGTCC
>HW296602.1 JP 2013523650-A/621: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGCCATTACAAC
>HW296600.1 JP 2013523650-A/619: RNA INTERFERENCE IN OCULAR INDICATIONS
CCATTACAACTGT
>HW296598.1 JP 2013523650-A/617: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTGGTCCAGACC
>HW296596.1 JP 2013523650-A/615: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGAGTGGAGCGC
>HW296594.1 JP 2013523650-A/613: RNA INTERFERENCE IN OCULAR INDICATIONS
AGACCTGTGCCTG
>HW296592.1 JP 2013523650-A/611: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTGCCTGGTCC
>HW296590.1 JP 2013523650-A/609: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTGGAAGACACG
>HW296588.1 JP 2013523650-A/607: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCCATTACAACT
>HW296586.1 JP 2013523650-A/605: RNA INTERFERENCE IN OCULAR INDICATIONS
GTTTGAGCTTTCT
>HW296584.1 JP 2013523650-A/603: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGAGCGCCTGTT
>HW296582.1 JP 2013523650-A/601: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTGGAGCGCCTG
>HW296580.1 JP 2013523650-A/599: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGCTTTCTGGCT
>HW296578.1 JP 2013523650-A/597: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCATTACAACTG
>HW296576.1 JP 2013523650-A/595: RNA INTERFERENCE IN OCULAR INDICATIONS
GGAGCGCCTGTTC
>HW296574.1 JP 2013523650-A/593: RNA INTERFERENCE IN OCULAR INDICATIONS
CGACTGGAAGACA
>HW296572.1 JP 2013523650-A/591: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGTGGAGCGCCT
>HW296570.1 JP 2013523650-A/589: RNA INTERFERENCE IN OCULAR INDICATIONS
ACAGGAAGATGTA
>HW296568.1 JP 2013523650-A/587: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296566.1 JP 2013523650-A/585: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296564.1 JP 2013523650-A/583: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296562.1 JP 2013523650-A/581: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW286781.1 JP 2013143941-A/6: Methods and Compositions for Modification of the Human Glucocorticoid Receptor Locus
AATGAGTAAGTTG
>HW286776.1 JP 2013143941-A/1: Methods and Compositions for Modification of the Human Glucocorticoid Receptor Locus
GACCTGTTGATAG
>HW296530.1 JP 2013523650-A/549: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296528.1 JP 2013523650-A/547: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296526.1 JP 2013523650-A/545: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296524.1 JP 2013523650-A/543: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296522.1 JP 2013523650-A/541: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296518.1 JP 2013523650-A/537: RNA INTERFERENCE IN OCULAR INDICATIONS
CATCTGCAATAAA
>HW296514.1 JP 2013523650-A/533: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTGATTGACAA
>HW296510.1 JP 2013523650-A/529: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATTTGATTGAA
>HW296506.1 JP 2013523650-A/525: RNA INTERFERENCE IN OCULAR INDICATIONS
TCACATTTGATTA
>HW296504.1 JP 2013523650-A/523: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGAAGAAAGTTA
>HW296502.1 JP 2013523650-A/521: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAGTCTAATGAA
>HW296500.1 JP 2013523650-A/519: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCAGTATAAGTA
>HW296498.1 JP 2013523650-A/517: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGCAACACTTGA
>HW296496.1 JP 2013523650-A/515: RNA INTERFERENCE IN OCULAR INDICATIONS
TACTGATAGGAGA
>HW296494.1 JP 2013523650-A/513: RNA INTERFERENCE IN OCULAR INDICATIONS
TCCAGATCACATA
>HW296490.1 JP 2013523650-A/509: RNA INTERFERENCE IN OCULAR INDICATIONS
ATCACATTTGATA
>HW296488.1 JP 2013523650-A/507: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTTCATGTCTA
>HW296486.1 JP 2013523650-A/505: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCTTTTAATGAA
>HW296484.1 JP 2013523650-A/503: RNA INTERFERENCE IN OCULAR INDICATIONS
GACCAGTATAAGA
>HW296482.1 JP 2013523650-A/501: RNA INTERFERENCE IN OCULAR INDICATIONS
AATACCAGTCTTA
>HW296478.1 JP 2013523650-A/497: RNA INTERFERENCE IN OCULAR INDICATIONS
CCACCAACTTACA
>HW296476.1 JP 2013523650-A/495: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTCCAAACACA
>HW296474.1 JP 2013523650-A/493: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTCCAAACAAA
>HW296472.1 JP 2013523650-A/491: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTCCAAACACAA
>HW296470.1 JP 2013523650-A/489: RNA INTERFERENCE IN OCULAR INDICATIONS
CCTTCCTTCGAAA
>HW296468.1 JP 2013523650-A/487: RNA INTERFERENCE IN OCULAR INDICATIONS
GTTGACATCCAGA
>HW296466.1 JP 2013523650-A/485: RNA INTERFERENCE IN OCULAR INDICATIONS
AACCTCTCCTATA
>HW296462.1 JP 2013523650-A/481: RNA INTERFERENCE IN OCULAR INDICATIONS
GATCACATTTGAA
>HW296460.1 JP 2013523650-A/479: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCCTATTATACA
>HW296456.1 JP 2013523650-A/475: RNA INTERFERENCE IN OCULAR INDICATIONS
TCCACCAACTTAA
>HW296454.1 JP 2013523650-A/473: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTCTCCTATTA
>HW296452.1 JP 2013523650-A/471: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAAACTGCTCAA
>HW296450.1 JP 2013523650-A/469: RNA INTERFERENCE IN OCULAR INDICATIONS
CATTTGATTGACA
>HW296448.1 JP 2013523650-A/467: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATACCAGTCTT
>HW296446.1 JP 2013523650-A/465: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTGCCTCAATT
>HW296444.1 JP 2013523650-A/463: RNA INTERFERENCE IN OCULAR INDICATIONS
CACATTTGATTGA
>HW296434.1 JP 2013523650-A/453: RNA INTERFERENCE IN OCULAR INDICATIONS
GGCTGATTCTGGA
>HW296432.1 JP 2013523650-A/451: RNA INTERFERENCE IN OCULAR INDICATIONS
GAATTGCAGTGAA
>HW296430.1 JP 2013523650-A/449: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTGAAATTTCA
>HW296428.1 JP 2013523650-A/447: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAAAGAGAACAA
>HW296426.1 JP 2013523650-A/445: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCAGTGATTTGA
>HW296424.1 JP 2013523650-A/443: RNA INTERFERENCE IN OCULAR INDICATIONS
AATGAAAGAGAAA
>HW296422.1 JP 2013523650-A/441: RNA INTERFERENCE IN OCULAR INDICATIONS
CACTCCAGTTGTA
>HW296420.1 JP 2013523650-A/439: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTCACTTTGCA
>HW296418.1 JP 2013523650-A/437: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCACTTTGCATA
>HW296416.1 JP 2013523650-A/435: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTGCATTTAGTA
>HW296414.1 JP 2013523650-A/433: RNA INTERFERENCE IN OCULAR INDICATIONS
CTTTGCATTTAGA
>HW296412.1 JP 2013523650-A/431: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAAGAGAACATA
>HW296410.1 JP 2013523650-A/429: RNA INTERFERENCE IN OCULAR INDICATIONS
TCTTTCTCAGTTA
>HW296408.1 JP 2013523650-A/427: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTTTCTCAGTA
>HW296406.1 JP 2013523650-A/425: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTAGTCAAAAA
>HW296404.1 JP 2013523650-A/423: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTTTGCATTTAA
>HW296402.1 JP 2013523650-A/421: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCATTTAGTCA
>HW296400.1 JP 2013523650-A/419: RNA INTERFERENCE IN OCULAR INDICATIONS
TTTCTCAGTTTAA
>HW296396.1 JP 2013523650-A/415: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGCTTTTGCCTA
>HW296392.1 JP 2013523650-A/411: RNA INTERFERENCE IN OCULAR INDICATIONS
GATTTGCTTTTGA
>HW296388.1 JP 2013523650-A/407: RNA INTERFERENCE IN OCULAR INDICATIONS
CACAGCCATGAAA
>HW296384.1 JP 2013523650-A/403: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTTCGTATTTA
>HW296380.1 JP 2013523650-A/399: RNA INTERFERENCE IN OCULAR INDICATIONS
GTGATTTGCTTTA
>HW296376.1 JP 2013523650-A/395: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTGCTTTTGCA
>HW296372.1 JP 2013523650-A/391: RNA INTERFERENCE IN OCULAR INDICATIONS
GATGAATCTGATA
>HW296370.1 JP 2013523650-A/389: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCTGCCAGCAAC
>HW296368.1 JP 2013523650-A/387: RNA INTERFERENCE IN OCULAR INDICATIONS
GACTCGAACGACT
>HW296366.1 JP 2013523650-A/385: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAGCAATTAATA
>HW296364.1 JP 2013523650-A/383: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCCAGCAATTAA
>HW296362.1 JP 2013523650-A/381: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGAGTCTGGAAA
>HW296360.1 JP 2013523650-A/379: RNA INTERFERENCE IN OCULAR INDICATIONS
AATGTGTATCTAT
>HW296358.1 JP 2013523650-A/377: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCAGCCGTGAAT
>HW296356.1 JP 2013523650-A/375: RNA INTERFERENCE IN OCULAR INDICATIONS
GATGTGATTGATA
>HW296354.1 JP 2013523650-A/373: RNA INTERFERENCE IN OCULAR INDICATIONS
GACCAGAGTGCTG
>HW296352.1 JP 2013523650-A/371: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTTTATGGACT
>HW296350.1 JP 2013523650-A/369: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGGTCACTGATT
>HW296348.1 JP 2013523650-A/367: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAACGAAAGCCA
>HW296346.1 JP 2013523650-A/365: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCATGAGAATTG
>HW296344.1 JP 2013523650-A/363: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTCAATTGCTTA
>HW296342.1 JP 2013523650-A/361: RNA INTERFERENCE IN OCULAR INDICATIONS
AATTCCACAGCCA
>HW296340.1 JP 2013523650-A/359: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAGCATTCCGAT
>HW296338.1 JP 2013523650-A/357: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGTGCTGAAACC
>HW296336.1 JP 2013523650-A/355: RNA INTERFERENCE IN OCULAR INDICATIONS
AAACAGGCTGATT
>HW296334.1 JP 2013523650-A/353: RNA INTERFERENCE IN OCULAR INDICATIONS
ACTACCATGAGAA
>HW296332.1 JP 2013523650-A/351: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCAGCCGTGAA
>HW286571.1 JP 2013135672-A/221: Detection method and materials therefor
ACCGTACTGGTTA
>HW286560.1 JP 2013135672-A/210: Detection method and materials therefor
GTTACATAAGGCC
>HW286548.1 JP 2013135672-A/198: Detection method and materials therefor
CGTGCACAAGGTC
>HW286539.1 JP 2013135672-A/189: Detection method and materials therefor
TTACAACGAGCAC
>HW296330.1 JP 2013523650-A/349: RNA INTERFERENCE IN OCULAR INDICATIONS
ATAGTCAGGAACT
>HW296328.1 JP 2013523650-A/347: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCCAATGATGA
>HW296326.1 JP 2013523650-A/345: RNA INTERFERENCE IN OCULAR INDICATIONS
TAGTGTGGTTTAT
>HW296324.1 JP 2013523650-A/343: RNA INTERFERENCE IN OCULAR INDICATIONS
ACGACTCTGATGA
>HW296322.1 JP 2013523650-A/341: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAATTAATAAA
>HW296320.1 JP 2013523650-A/339: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCAATTGCTTAT
>HW296318.1 JP 2013523650-A/337: RNA INTERFERENCE IN OCULAR INDICATIONS
AACTATCACTGTA
>HW296316.1 JP 2013523650-A/335: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATTCTATAGAA
>HW296314.1 JP 2013523650-A/333: RNA INTERFERENCE IN OCULAR INDICATIONS
ATAACTAATGTGT
>HW296312.1 JP 2013523650-A/331: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCCGATGTGATT
>HW296310.1 JP 2013523650-A/329: RNA INTERFERENCE IN OCULAR INDICATIONS
TATAAGCGGAAAG
>HW296308.1 JP 2013523650-A/327: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCAGCTGGATG
>HW296306.1 JP 2013523650-A/325: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTTGAATGGTGC
>HW296304.1 JP 2013523650-A/323: RNA INTERFERENCE IN OCULAR INDICATIONS
CACCTCACACATG
>HW296302.1 JP 2013523650-A/321: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCAGCAACCGAA
>HW296300.1 JP 2013523650-A/319: RNA INTERFERENCE IN OCULAR INDICATIONS
TCATGAATAGAAA
>HW296298.1 JP 2013523650-A/317: RNA INTERFERENCE IN OCULAR INDICATIONS
GGAAATAACTAAT
>HW296296.1 JP 2013523650-A/315: RNA INTERFERENCE IN OCULAR INDICATIONS
GGTTGAATGTGTA
>HW296294.1 JP 2013523650-A/313: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTGGTTGAATGT
>HW296292.1 JP 2013523650-A/311: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCCATGAATTT
>HW296290.1 JP 2013523650-A/309: RNA INTERFERENCE IN OCULAR INDICATIONS
CCAGAGTGCTGAA
>HW296288.1 JP 2013523650-A/307: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGAAACGAGTCA
>HW296286.1 JP 2013523650-A/305: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTGCATACAAG
>HW296284.1 JP 2013523650-A/303: RNA INTERFERENCE IN OCULAR INDICATIONS
TTAGATAGTGCAT
>HW296282.1 JP 2013523650-A/301: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAATGAGCATT
>HW296280.1 JP 2013523650-A/299: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGTTTCGCAGAC
>HW296278.1 JP 2013523650-A/297: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCCAACGAAAG
>HW296276.1 JP 2013523650-A/295: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTTTGTGGCTTC
>HW296274.1 JP 2013523650-A/293: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCTGGAAATAA
>HW296272.1 JP 2013523650-A/291: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGCCGTGAATTC
>HW296270.1 JP 2013523650-A/289: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGACGAGGACAT
>HW296268.1 JP 2013523650-A/287: RNA INTERFERENCE IN OCULAR INDICATIONS
TAGACACATATGA
>HW296266.1 JP 2013523650-A/285: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCTGATGAGTCT
>HW296264.1 JP 2013523650-A/283: RNA INTERFERENCE IN OCULAR INDICATIONS
TGCATTTAGTCAA
>HW296262.1 JP 2013523650-A/281: RNA INTERFERENCE IN OCULAR INDICATIONS
TAGTCAGGAACTT
>HW296260.1 JP 2013523650-A/279: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCATTCCGATGT
>HW296258.1 JP 2013523650-A/277: RNA INTERFERENCE IN OCULAR INDICATIONS
GCATTTAGTCAAA
>HW296256.1 JP 2013523650-A/275: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCAGTCCAGATT
>HW296254.1 JP 2013523650-A/273: RNA INTERFERENCE IN OCULAR INDICATIONS
ATATGATGGCCGA
>HW296252.1 JP 2013523650-A/271: RNA INTERFERENCE IN OCULAR INDICATIONS
GAATGGTGCATAC
>HW296250.1 JP 2013523650-A/269: RNA INTERFERENCE IN OCULAR INDICATIONS
CCGACCAAGGAAA
>HW296248.1 JP 2013523650-A/267: RNA INTERFERENCE IN OCULAR INDICATIONS
TGTTCATTCTATA
>HW296246.1 JP 2013523650-A/265: RNA INTERFERENCE IN OCULAR INDICATIONS
TACCAGTTAAACA
>HW296244.1 JP 2013523650-A/263: RNA INTERFERENCE IN OCULAR INDICATIONS
ATATAAGCGGAAA
>HW296242.1 JP 2013523650-A/261: RNA INTERFERENCE IN OCULAR INDICATIONS
CAGTCCAGATTAT
>HW296240.1 JP 2013523650-A/259: RNA INTERFERENCE IN OCULAR INDICATIONS
TTATGAAACGAGT
>HW296238.1 JP 2013523650-A/257: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGTTGAATGTGT
>HW296236.1 JP 2013523650-A/255: RNA INTERFERENCE IN OCULAR INDICATIONS
GCAGTCCAGATTA
>HW296234.1 JP 2013523650-A/253: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATGGAAAGCGA
>HW296232.1 JP 2013523650-A/251: RNA INTERFERENCE IN OCULAR INDICATIONS
TTGTCCAGCAATT
>HW296230.1 JP 2013523650-A/249: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTATAGAAGAA
>HW296228.1 JP 2013523650-A/247: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGTGTATCTATT
>HW296226.1 JP 2013523650-A/245: RNA INTERFERENCE IN OCULAR INDICATIONS
AGATAGTGCATCT
>HW296224.1 JP 2013523650-A/243: RNA INTERFERENCE IN OCULAR INDICATIONS
TGATTGATAGTCA
>HW296222.1 JP 2013523650-A/241: RNA INTERFERENCE IN OCULAR INDICATIONS
GCGAGGAGTTGAA
>HW296220.1 JP 2013523650-A/239: RNA INTERFERENCE IN OCULAR INDICATIONS
ATGATGAGAGCAA
>HW296218.1 JP 2013523650-A/237: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGTCCAACGAAA
>HW296216.1 JP 2013523650-A/235: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCTCATGAATAG
>HW296214.1 JP 2013523650-A/233: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTCTCATGAAT
>HW296212.1 JP 2013523650-A/231: RNA INTERFERENCE IN OCULAR INDICATIONS
GCGCCTTCTGATT
>HW296210.1 JP 2013523650-A/229: RNA INTERFERENCE IN OCULAR INDICATIONS
GAAATTTCGTATT
>HW296208.1 JP 2013523650-A/227: RNA INTERFERENCE IN OCULAR INDICATIONS
ACATGGATGATAT
>HW296206.1 JP 2013523650-A/225: RNA INTERFERENCE IN OCULAR INDICATIONS
AAAGCCATGACCA
>HW296204.1 JP 2013523650-A/223: RNA INTERFERENCE IN OCULAR INDICATIONS
ATTTCGTATTTCT
>HW296202.1 JP 2013523650-A/221: RNA INTERFERENCE IN OCULAR INDICATIONS
AAATTTCGTATTT
>HW296200.1 JP 2013523650-A/219: RNA INTERFERENCE IN OCULAR INDICATIONS
GCGGAAAGCCAAT
>HW296198.1 JP 2013523650-A/217: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCCATGACCAC
>HW296196.1 JP 2013523650-A/215: RNA INTERFERENCE IN OCULAR INDICATIONS
GCCATGACCACAT
>HW296194.1 JP 2013523650-A/213: RNA INTERFERENCE IN OCULAR INDICATIONS
ACCACATGGATGA
>HW296192.1 JP 2013523650-A/211: RNA INTERFERENCE IN OCULAR INDICATIONS
AGCGGAAAGCCAA
>HW296190.1 JP 2013523650-A/209: RNA INTERFERENCE IN OCULAR INDICATIONS
AAGCGGAAAGCCA
>HW296188.1 JP 2013523650-A/207: RNA INTERFERENCE IN OCULAR INDICATIONS
AGTCTCACCATTC
>HW296186.1 JP 2013523650-A/205: RNA INTERFERENCE IN OCULAR INDICATIONS
TCACAGCCATGAA
>HW296184.1 JP 2013523650-A/203: RNA INTERFERENCE IN OCULAR INDICATIONS
GACTGAGGTCAAA
>HW296182.1 JP 2013523650-A/201: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGTCTCACCATT
>HW296180.1 JP 2013523650-A/199: RNA INTERFERENCE IN OCULAR INDICATIONS
TGGACTGAGGTCA
>HW296178.1 JP 2013523650-A/197: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTGATGAATCT
>HW296176.1 JP 2013523650-A/195: RNA INTERFERENCE IN OCULAR INDICATIONS
GTCAGCTGGATGA
>HW296174.1 JP 2013523650-A/193: RNA INTERFERENCE IN OCULAR INDICATIONS
TTCTGAGGTCAAT
>HW296172.1 JP 2013523650-A/191: RNA INTERFERENCE IN OCULAR INDICATIONS
TGAGGTCAATTAA
>HW296170.1 JP 2013523650-A/189: RNA INTERFERENCE IN OCULAR INDICATIONS
TCTGAGGTCAATT
>HW296168.1 JP 2013523650-A/187: RNA INTERFERENCE IN OCULAR INDICATIONS
GAGGTCAATTAAA
>HW296166.1 JP 2013523650-A/185: RNA INTERFERENCE IN OCULAR INDICATIONS
CTGAGGTCAATTA
>HW296164.1 JP 2013523650-A/183: RNA INTERFERENCE IN OCULAR INDICATIONS
CTCATGAATTAGA
>HW295202.1 JP 2013521777-A/5: POLYNUCLEOTIDE MOLECULES FOR GENE REGULATION IN PLANTS
AAGATTAGCACGG
>HW307484.1 JP 2013526273-A/3: Kit and method
AAGACAGTGCTTA
>HW293257.1 JP 2013521006-A/47: Polypeptide Having Diterpene Synthase Activity
GGTCTTCCAGCCG
>HW298216.1 JP 2013525309-A/17: Methods for Treating Metabolic Disorders Using FGF
AGGTGAAATTTAA
>HW298215.1 JP 2013525309-A/16: Methods for Treating Metabolic Disorders Using FGF
AGATAAAAGGACA
>HW298214.1 JP 2013525309-A/15: Methods for Treating Metabolic Disorders Using FGF
AGGTGAAAGGGCA
>HW298213.1 JP 2013525309-A/14: Methods for Treating Metabolic Disorders Using FGF
AGGCGAAAGGACC
>HW298212.1 JP 2013525309-A/13: Methods for Treating Metabolic Disorders Using FGF
AGGTGAAAGGCTA
>HW298211.1 JP 2013525309-A/12: Methods for Treating Metabolic Disorders Using FGF
AGGTGAAAGGACA
>HW298210.1 JP 2013525309-A/11: Methods for Treating Metabolic Disorders Using FGF
AGGTGAAAGGACA
>HW298209.1 JP 2013525309-A/10: Methods for Treating Metabolic Disorders Using FGF
AGGTCAAAGGTCA
>HW297914.1 JP 2013524783-A/49: GENE-BASED PREDICTION OF PSA RECURRENCE FOR CLINICALLY LOCALIZED PROSTATE CANCER PATIENTS
ATGGCCCAAGGAC
>HW297893.1 JP 2013524783-A/28: GENE-BASED PREDICTION OF PSA RECURRENCE FOR CLINICALLY LOCALIZED PROSTATE CANCER PATIENTS
TTGCGGCATCCAC
>DI212598.1 KR 1020100127828-A/29: STEROIDAL LIGANDS AND THEIR USE IN GENE SWITCH MODULATION
AGGTCANAGGTCA
>DI212304.1 KR 1020100120708-A/6: Methods for transforming yeast
CCACGCTGCTGAG
>DI212303.1 KR 1020100120708-A/5: Methods for transforming yeast
GAAGGTGTGCACG
>DI211636.1 KR 1020100102235-A/6: A method to reduce directional bias in transcription
GCCAATTGTTGCC
>DI211635.1 KR 1020100102235-A/5: A method to reduce directional bias in transcription
AACAATTGGCGGC
>DI246067.1 KR 1020120107521-A/128: IDENTIFICATION OF CLONAL CELLS BY REPEATS IN (EG.) T-CELL RECEPTOR V/D/J GENES
AACGACGGCCAGT
>DI246060.1 KR 1020120107521-A/121: IDENTIFICATION OF CLONAL CELLS BY REPEATS IN (EG.) T-CELL RECEPTOR V/D/J GENES
GGGTATAGCAGCA
>DI246058.1 KR 1020120107521-A/119: IDENTIFICATION OF CLONAL CELLS BY REPEATS IN (EG.) T-CELL RECEPTOR V/D/J GENES
GAGTATAGCAGCT
>DI246050.1 KR 1020120107521-A/111: IDENTIFICATION OF CLONAL CELLS BY REPEATS IN (EG.) T-CELL RECEPTOR V/D/J GENES
TGACTACGGTGGT
>DI246047.1 KR 1020120107521-A/108: IDENTIFICATION OF CLONAL CELLS BY REPEATS IN (EG.) T-CELL RECEPTOR V/D/J GENES
TGACTACAGTAAC
>DI246026.1 KR 1020120107521-A/87: IDENTIFICATION OF CLONAL CELLS BY REPEATS IN (EG.) T-CELL RECEPTOR V/D/J GENES
GGTATAGTGGGAG
>DI233144.1 KR 1020110121696-A/15: TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
CGGCAGCCCTCGC
>DI232748.1 KR 1020110123748-A/17: MYCOPLASMA GALLISEPTICUM FORMULATION
GTAAAACGACGGC
>DI232463.1 KR 1020110111474-A/189: RECURRENT GENE FUSIONS IN CANCER
CTGTAACTGAAAA
>DI232451.1 KR 1020110111474-A/177: RECURRENT GENE FUSIONS IN CANCER
CCAGAATCTCCAC
>DI232440.1 KR 1020110111474-A/166: RECURRENT GENE FUSIONS IN CANCER
GGAGCGCGGCAGG
>DI232432.1 KR 1020110111474-A/158: RECURRENT GENE FUSIONS IN CANCER
ACTCATCACAGCC
>DI232407.1 KR 1020110111474-A/133: RECURRENT GENE FUSIONS IN CANCER
ACTGCCCTCCAGC
>DI232406.1 KR 1020110111474-A/132: RECURRENT GENE FUSIONS IN CANCER
ACTGCACTCCAGC
>DI232385.1 KR 1020110111474-A/111: RECURRENT GENE FUSIONS IN CANCER
GAGAGAAGACTCA
>DI232363.1 KR 1020110111474-A/89: RECURRENT GENE FUSIONS IN CANCER
AAGCCCTTCAGCG
>DI208926.1 KR 1020100098600-A/10: Engineered dendritic cells and uses for the treatment of cancer
AGGTCANAGGTCA
>DI208690.1 KR 1020100087303-A/2: Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
AGGTCANAGGTCA
>DI207751.1 KR 1020100018029-A/18: IMMUNO STIMULATING COMPLEX AND OLIGONUCLEOTIDE FORMULATIONS FOR INDUCING ENHANCED INTERFERON-GAMMA RESPONSES
CGGCGCCGTGCCG
>DI207682.1 KR 1020120078193-A/36: MULTIPLEX REAL TIME PCR METHOD FOR DISCRIMINATION OF RICE CULTIVAR
TTTGCGATCTTTC
>DI206624.1 KR 1020120057433-A/2: Production of Seonghwan-commercial chicken No. 1 using Korean native chicken and exotic chicken and distinction method of the product
ATAGTGACTACTT
>DI230532.1 KR 1020110079860-A/11: Optimizing Glycan Processing in Plants
AATACTTCCACCC
>DI202404.1 KR 1020110004800-A/7: Methods and reagents for the early detection of melanoma
ATCCGGCGGCCAC
>DI243048.1 KR 1020120068992-A/12: PROBE FOR DETECTING MPL GENE POLYMORPHISM AND USE OF THE SAME
GGAAACTGCTTCC
>DI197573.1 KR 1020100032393-A/17: CHIRAL DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX
AGGTCANAGGTCA
>DI195937.1 KR 1020100019429-A/47: NUCLEIC ACID ENZYMES AND COMPLEXES AND METHODS FOR THEIR USE
TGGAGGTGGGCTC
>DI195962.1 KR 1020100019429-A/74: NUCLEIC ACID ENZYMES AND COMPLEXES AND METHODS FOR THEIR USE
ACGGCGGAGTGAT
>DI226310.1 KR 1020110063453-A/36: METHOD OF IDENTIFYING DISEASE RISK FACTORS
CAGAATCCTGCGT
>DI194694.1 KR 1020090117814-A/5: COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID
AAAAAAAAAAAAA
>DI194690.1 KR 1020090117814-A/1: COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID
CGCAATNTAACGC
>DI194691.1 KR 1020090117814-A/2: COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID
GCGTTAAATTGCG
>DI194692.1 KR 1020090117814-A/3: COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID
TTTTTTNNTTTTT
>DI194697.1 KR 1020090117814-A/8: COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID
CGCAATNNAACGC
>DI194693.1 KR 1020090117814-A/4: COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID
TTTTTTNTTTTTT
>DI193700.1 KR 1020090094870-A/12: METHODS FOR PURIFYING AND DETECTING DOUBLE STRANDED DNA TARGET SEQUENCES BY TRIPLE HELIX INTERACTION
CCTTTTCCTCCTT
>DI193696.1 KR 1020090094870-A/8: METHODS FOR PURIFYING AND DETECTING DOUBLE STRANDED DNA TARGET SEQUENCES BY TRIPLE HELIX INTERACTION
GAAGAGGAAGAAG
>DI193704.1 KR 1020090094870-A/16: METHODS FOR PURIFYING AND DETECTING DOUBLE STRANDED DNA TARGET SEQUENCES BY TRIPLE HELIX INTERACTION
TTTCCTCTCCCTC
>DI193701.1 KR 1020090094870-A/13: METHODS FOR PURIFYING AND DETECTING DOUBLE STRANDED DNA TARGET SEQUENCES BY TRIPLE HELIX INTERACTION
GGCAACGGAGGAA
>DI240914.1 KR 1020120099378-A/4: USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES
AGGACAAAGGTCA
>DI240779.1 KR 1020120050480-A/41: ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS OF USE
GGCCNNNNNGGCC
>DI240752.1 KR 1020120100890-A/76: AN ASSAY FOR DETERMINING A MOLECULAR RISK ASSESSMENT OF A COMPLEX POLYMICROBIAL SAMPLE SUSPECTED TO CONTAIN AN EHEC
TGCACCAATTCAG
>DI240733.1 KR 1020120100890-A/26: AN ASSAY FOR DETERMINING A MOLECULAR RISK ASSESSMENT OF A COMPLEX POLYMICROBIAL SAMPLE SUSPECTED TO CONTAIN AN EHEC
TTAGGCCATCCCA
>DI240731.1 KR 1020120100890-A/16: AN ASSAY FOR DETERMINING A MOLECULAR RISK ASSESSMENT OF A COMPLEX POLYMICROBIAL SAMPLE SUSPECTED TO CONTAIN AN EHEC
GCTGGAASTTTGT
>DI222392.1 KR 1020110017012-A/123: PRIMER SET FOR AMPLIFICATION OF NAT2 GENE, REAGENT FOR AMPLIFICATION OF NAT2 GENE COMPRISING THE SAME, AND USE OF THE SAME
CGTCAATGGTCAC
>DI222385.1 KR 1020110017012-A/116: PRIMER SET FOR AMPLIFICATION OF NAT2 GENE, REAGENT FOR AMPLIFICATION OF NAT2 GENE COMPRISING THE SAME, AND USE OF THE SAME
CGTCAGTGGTCAC
>DI240454.1 KR 1020120107456-A/76: Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
GGATTTCTTTGGC
>DI240432.1 KR 1020120107456-A/54: Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
CGGCAGTGCCCCG
>DI240429.1 KR 1020120107456-A/51: Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
CCCGACGAGCCGG
>DI221653.1 KR 1020120052894-A/8: A Composition for prevention of hair loss and promotion of hair growth comprising extracts of Eclipta prostrata, fractions thereof, terthienyl derivatives or pharmaceutically acceptable salts thereof
TCTGGGTGGCAGT
>DI221513.1 KR 1020120044915-A/11: PROBE FOR DETECTING POLYMORPHISM, METHOD OF DETECTING POLYMORPHISM, METHOD OF EVALUATING DRUG EFFICACY, AND KIT FOR DETECTING POLYMORPHISM
CACCTTCTAGTTC
>DI183285.1 KR 1020100115030-A/30: Primer for Avellino Corneal Dystrophy
TACACGGACCACA
>DI183284.1 KR 1020100115030-A/29: Primer for Avellino Corneal Dystrophy
TACACGGACCGCA
>DI239497.1 KR 1020120018822-A/16: Immunostimulatory Compositions Comprising Liposome- Encapsulated Oligonucleotides and Epitopes
AGCAGCGTTCTTG
>DI174707.1 KR 1020090123149-A/4: Stroke early diagnosing chip and screening analysis thereof
CGGGAGGCGATTT
>DI210322.1 KR 1020100108356-A/20: METHOD FOR PRODUCING VACCINAL VIRAL STRAIN OF A VIRUS OF THE REOVIRIDAE FAMILY
ACTTACTGAGACG
>DI178773.1 KR 1020080107384-A/127: PRIMER SET FOR AMPLIFICATION OF OBESITY GENE, REAGENT FOR AMPLIFICATION OF OBESITY GENE COMPRISING THE PRIMER SET, AND USE OF THE PRIMER SET
CTCGGAGTCCAGG
>DI178767.1 KR 1020080107384-A/121: PRIMER SET FOR AMPLIFICATION OF OBESITY GENE, REAGENT FOR AMPLIFICATION OF OBESITY GENE COMPRISING THE PRIMER SET, AND USE OF THE PRIMER SET
CTCGGAGTCCGGG
>DI178646.1 KR 1020080107377-A/123: PRIMER SET FOR AMPLIFICATION OF NAT2 GENE, REAGENT FOR AMPLIFICATION OF NAT2 GENE COMPRISING THE SAME, AND USE OF THE SAME
CGTCAATGGTCAC
>DI178639.1 KR 1020080107377-A/116: PRIMER SET FOR AMPLIFICATION OF NAT2 GENE, REAGENT FOR AMPLIFICATION OF NAT2 GENE COMPRISING THE SAME, AND USE OF THE SAME
CGTCAGTGGTCAC
>DI177363.1 KR 1020090058451-A/8: Method for selective labeling and detection of target nucleic acids using immobilized peptide nucleic acid probes
CCGCAAGTGCAGA
>DI177361.1 KR 1020090058451-A/6: Method for selective labeling and detection of target nucleic acids using immobilized peptide nucleic acid probes
GCCATGATAGTGG
>DI177357.1 KR 1020090058451-A/2: Method for selective labeling and detection of target nucleic acids using immobilized peptide nucleic acid probes
CCCCTGAATCCAG
>DI176920.1 KR 1020100028985-A/17: Method for predicting lung cancer risk by measuring TP53 gene polymorphism and kit for diagnosing lung cancer risk using the same
TCCCCGCGTGGCC
>DI237729.1 KR 1020120046711-A/30: Primer for Avellino Corneal Dystrophy
TACACGGACCACA
>DI237728.1 KR 1020120046711-A/29: Primer for Avellino Corneal Dystrophy
TACACGGACCGCA
>DI237687.1 KR 1020120046710-A/30: Primer for Avellino Corneal Dystrophy
TACACGGACCACA
>DI237686.1 KR 1020120046710-A/29: Primer for Avellino Corneal Dystrophy
TACACGGACCGCA
>DI237645.1 KR 1020120052917-A/30: Primer for Avellino Corneal Dystrophy
TACACGGACCACA
>DI237644.1 KR 1020120052917-A/29: Primer for Avellino Corneal Dystrophy
TACACGGACCGCA
>DI237603.1 KR 1020120052916-A/30: Primer for Avellino Corneal Dystrophy
TACACGGACCACA
>DI237602.1 KR 1020120052916-A/29: Primer for Avellino Corneal Dystrophy
TACACGGACCGCA
>DI237561.1 KR 1020120052915-A/30: Primer for Avellino Corneal Dystrophy
TACACGGACCACA
>DI237560.1 KR 1020120052915-A/29: Primer for Avellino Corneal Dystrophy
TACACGGACCGCA
>DI174752.1 KR 1020090123149-A/49: Stroke early diagnosing chip and screening analysis thereof
GATGACCCCCCAG
>DI174751.1 KR 1020090123149-A/48: Stroke early diagnosing chip and screening analysis thereof
GATGAACCCCCAG
>DI174750.1 KR 1020090123149-A/47: Stroke early diagnosing chip and screening analysis thereof
GATGATCCCCCAG
>DI174749.1 KR 1020090123149-A/46: Stroke early diagnosing chip and screening analysis thereof
GATGAGCCCCCAG
>DI174748.1 KR 1020090123149-A/45: Stroke early diagnosing chip and screening analysis thereof
TCTTGCTATGCTA
>DI174747.1 KR 1020090123149-A/44: Stroke early diagnosing chip and screening analysis thereof
TCTTGCAATGCTA
>DI174746.1 KR 1020090123149-A/43: Stroke early diagnosing chip and screening analysis thereof
TCTTGCCATGCTA
>DI174745.1 KR 1020090123149-A/42: Stroke early diagnosing chip and screening analysis thereof
TCTTGCGATGCTA
>DI174744.1 KR 1020090123149-A/41: Stroke early diagnosing chip and screening analysis thereof
ACACGTTGGGGAG
>DI174743.1 KR 1020090123149-A/40: Stroke early diagnosing chip and screening analysis thereof
ACACGTAGGGGAG
>DI174742.1 KR 1020090123149-A/39: Stroke early diagnosing chip and screening analysis thereof
ACACGTCGGGGAG
>DI174740.1 KR 1020090123149-A/37: Stroke early diagnosing chip and screening analysis thereof
ACACGTGGGGGAG
>DI174739.1 KR 1020090123149-A/36: Stroke early diagnosing chip and screening analysis thereof
CAAGCTCTTTTCG
>DI174738.1 KR 1020090123149-A/35: Stroke early diagnosing chip and screening analysis thereof
CAAGCCCTTTTCG
>DI174737.1 KR 1020090123149-A/34: Stroke early diagnosing chip and screening analysis thereof
CAAGCACTTTTCG
>DI174736.1 KR 1020090123149-A/33: Stroke early diagnosing chip and screening analysis thereof
CAAGCGCTTTTCG
>DI174735.1 KR 1020090123149-A/32: Stroke early diagnosing chip and screening analysis thereof
CACAGGGCCTCAT
>DI174734.1 KR 1020090123149-A/31: Stroke early diagnosing chip and screening analysis thereof
CACAGGACCTCAT
>DI174733.1 KR 1020090123149-A/30: Stroke early diagnosing chip and screening analysis thereof
CACAGGCCCTCAT
>DI174732.1 KR 1020090123149-A/29: Stroke early diagnosing chip and screening analysis thereof
CACAGGTCCTCAT
>DI174731.1 KR 1020090123149-A/28: Stroke early diagnosing chip and screening analysis thereof
TTTAATTGCCCCT
>DI174730.1 KR 1020090123149-A/27: Stroke early diagnosing chip and screening analysis thereof
TTTAATCGCCCCT
>DI174729.1 KR 1020090123149-A/26: Stroke early diagnosing chip and screening analysis thereof
TTTAATAGCCCCT
>DI174728.1 KR 1020090123149-A/25: Stroke early diagnosing chip and screening analysis thereof
TTTAATGGCCCCT
>DI174706.1 KR 1020090123149-A/3: Stroke early diagnosing chip and screening analysis thereof
CGGGAGACGATTT
>DI174705.1 KR 1020090123149-A/2: Stroke early diagnosing chip and screening analysis thereof
CGGGAGTCGATTT
>DI174704.1 KR 1020090123149-A/1: Stroke early diagnosing chip and screening analysis thereof
CGGGAGCCGATTT
>DI174261.1 KR 1020090116475-A/8: Method of analyzing the accuracy of probe nucleic acids immobilized on a microarray substrate
TCGCGCCCTGGAA
>DI173464.1 KR 1020090099713-A/9: A knock-out vector constructed by using YFP reporter knock-in vector and methods for preparing thereof and knocking out gene in animal cell
CCGTCTTGGTACC
>DI173240.1 KR 1020090093706-A/13: Gene Delivery Systems Exhibiting Enhanced Tumor-Specific Expression
CCCAGCCCCTCCC
>DI172182.1 KR 1020090048160-A/1: DUAL BIOSENSOR FOR DETECTING ESTROGEN, DIOXIN, AND DERIVATIVES THEREOF AND USES THEREOF
GGTCACAGTGACC
>DI171869.1 KR 1020090042036-A/13: HUMAN CANCER SUPPRESSOR GENE, PROTEIN ENCODED THEREIN, EXPRESSION VECTOR CONTAINING SAME, AND CELL TRANSFORMED BY SAID VECTOR
AAGCTTCCTGCAA
>DI171868.1 KR 1020090042036-A/12: HUMAN CANCER SUPPRESSOR GENE, PROTEIN ENCODED THEREIN, EXPRESSION VECTOR CONTAINING SAME, AND CELL TRANSFORMED BY SAID VECTOR
AAGCTTAGCAGCA
>DI171867.1 KR 1020090042036-A/11: HUMAN CANCER SUPPRESSOR GENE, PROTEIN ENCODED THEREIN, EXPRESSION VECTOR CONTAINING SAME, AND CELL TRANSFORMED BY SAID VECTOR
AAGCTTTTACCGC
>DI171865.1 KR 1020090042036-A/9: HUMAN CANCER SUPPRESSOR GENE, PROTEIN ENCODED THEREIN, EXPRESSION VECTOR CONTAINING SAME, AND CELL TRANSFORMED BY SAID VECTOR
AAGCTTCCAGTGC
>DI215693.1 KR 1020110004490-A/11: Optimizing Glycan Processing in Plants
AATACTTCCACCC
>DI215555.1 KR 1020110004918-A/127: PRIMER SET FOR AMPLIFICATION OF OBESITY GENE, REAGENT FOR AMPLIFICATION OF OBESITY GENE COMPRISING THE PRIMER SET, AND USE OF THE PRIMER SET
CTCGGAGTCCAGG
>DI215549.1 KR 1020110004918-A/121: PRIMER SET FOR AMPLIFICATION OF OBESITY GENE, REAGENT FOR AMPLIFICATION OF OBESITY GENE COMPRISING THE PRIMER SET, AND USE OF THE PRIMER SET
CTCGGAGTCCGGG
>DI214672.1 KR 1020110031912-A/13: Novel regulatory elements
GCCGCCACCATGG
>DI169267.1 KR 1020040086383-A/31: Anti-CD20 antibodies and fusion proteins thereof and methods of use
GATCGCGGCCGCA
>DI169266.1 KR 1020040086383-A/30: Anti-CD20 antibodies and fusion proteins thereof and methods of use
AGCTTGCGGCCGC
>DI235721.1 KR 1020120013992-A/248: METHODS FOR ASSESSING RESPONSIVENESS OF B-CELL LYMPHOMA TO TREATMENT WITH ANTI-CD40 ANTIBODIES
CGTGCGCCGCCAA
>DI235676.1 KR 1020120013992-A/203: METHODS FOR ASSESSING RESPONSIVENESS OF B-CELL LYMPHOMA TO TREATMENT WITH ANTI-CD40 ANTIBODIES
TGCTCACTTCCCC
>DI213672.1 KR 1020110007202-A/140: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
CCNGGACAAGTGC
>DI213647.1 KR 1020110007202-A/115: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
TTGACAAACTGAC
>DI213623.1 KR 1020110007202-A/91: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
TCCACCATGCAAG
>DI213619.1 KR 1020110007202-A/87: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
TACCAGTGCCATA
>DI213588.1 KR 1020110007202-A/56: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
TNCGGTTCTACAG
>DI213586.1 KR 1020110007202-A/54: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
NTGATAGCCCTGT
>DI213581.1 KR 1020110007202-A/49: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
CACAAGTTCGGNT
>DI213560.1 KR 1020110007202-A/28: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
CCCAGCAGACAAT
>DI213559.1 KR 1020110007202-A/27: Peptide nucleic acid probes, kits and methods for expression profiling of microRNAs
TGCATGGATTTGC
>DI168586.1 KR 1020000076597-A/3: Oligonucleotide primers for efficient reverse transcription of hepatitis C virus (HCV) RNA and methods of use thereof
AGTATCAGCACTC
>JB837337.1 Sequence 15 from Patent WO2013106639
GAGCCCGAAAGGG
>JB836695.1 Sequence 61 from Patent EP2563939
AGTGCTCCGCGCA
>JB833802.1 Sequence 24 from Patent EP1877579
TTGCTCACACATT
>JB833794.1 Sequence 16 from Patent EP1877579
GAAATCGACTCCC
>JB833793.1 Sequence 15 from Patent EP1877579
GAAATCGGCTCCC
>HJ493186.1 Sequence 6 from patent US 8558288
GTCGTACGGCTAA
>HJ492867.1 Sequence 157 from patent US 8557973
AAGGCACAGCTTG
>HJ492834.1 Sequence 124 from patent US 8557973
GGTGGACCGGTCG
>HJ492828.1 Sequence 118 from patent US 8557973
CCACCTCCTGCGT
>HJ492780.1 Sequence 70 from patent US 8557973
CACACACCTCCCA
>HJ492779.1 Sequence 69 from patent US 8557973
ACACAGAACCTCA
>HJ492777.1 Sequence 67 from patent US 8557973
CTCCAGGATGACG
>HJ492776.1 Sequence 66 from patent US 8557973
ACACCTCCCAACG
>HJ492759.1 Sequence 48 from patent US 8557973
GTTCCTGGCGCAG
>HJ492757.1 Sequence 46 from patent US 8557973
TTCCAGAACCACG
>HJ492753.1 Sequence 42 from patent US 8557973
TATCGCCATCCAG
>HJ492752.1 Sequence 41 from patent US 8557973
CTGTTTGCCGACA
>HJ492744.1 Sequence 33 from patent US 8557973
AAAAATAACCCCA
>HJ489905.1 Sequence 19 from patent US 8557290
CAGTTAGGGTTAG
>HJ489451.1 Sequence 12 from patent US 8552168
GCCGCCNCCATGG
>HJ487868.1 Sequence 109 from patent US 8551710
GGTCTAGCTACAG
>HJ487863.1 Sequence 104 from patent US 8551710
AATCTCGATGGAG
>HJ487787.1 Sequence 28 from patent US 8551710
GGTAGTTGGAGCT
>HJ487782.1 Sequence 23 from patent US 8551710
TTGGAGCTGGGTG
>HJ487776.1 Sequence 17 from patent US 8551710
GTAGTTGGAGCTG
>HJ487768.1 Sequence 9 from patent US 8551710
TGGCGTAGGCAAG
>HJ487762.1 Sequence 3 from patent US 8551710
GTGGCGTAGGCAA
>HJ487753.1 Sequence 109 from patent US 8551708
GGTCTAGCTACAG
>HJ487748.1 Sequence 104 from patent US 8551708
AATCTCGATGGAG
>HJ487672.1 Sequence 28 from patent US 8551708
GGTAGTTGGAGCT
>HJ487667.1 Sequence 22 from patent US 8551708
GTTGGAGCTGGTG
>HJ487662.1 Sequence 17 from patent US 8551708
GTAGTTGGAGCTG
>HJ487660.1 Sequence 15 from patent US 8551708
CGTAGGCAAGAGT
>HJ487654.1 Sequence 9 from patent US 8551708
TGGCGTAGGCAAG
>HJ487648.1 Sequence 3 from patent US 8551708
GTGGCGTAGGCAA
>HJ482958.1 Sequence 788 from patent US 8546350
TGCTGCATCTCTG
>HJ481915.1 Sequence 2 from patent US 8546319
TCGCGAGCTTCCT
>HJ480405.1 Sequence 1241 from patent US 8546082
TGCAGCTGATTGT
>HJ480366.1 Sequence 1202 from patent US 8546082
TGCAGCTGATTGT
>HJ479780.1 Sequence 616 from patent US 8546082
TGGTGCTAGCATT
>HJ479776.1 Sequence 612 from patent US 8546082
TGGTGCTAGCATT
>JB759877.1 Sequence 85 from Patent WO2013113326
GGGTTTTTTTGGG
>JB759866.1 Sequence 74 from Patent WO2013113326
GGTTTTTTTTTGG
>JB765430.1 Sequence 5 from Patent EP2612918
TACACCCNNNCAT
>JB767742.1 Sequence 13 from Patent EP2500437
ATTTATTTATTTA
>JB759969.1 Sequence 60 from Patent WO2013113325
GGTTTTTTTTTGG
>JB767423.1 Sequence 61 from Patent EP2612928
AGCGAGAGATGCC
>JB767749.1 Sequence 20 from Patent EP2500437
ATTTATTTATTTA
>JB767745.1 Sequence 16 from Patent EP2500437
ATTTATTTATTTA
>JB765032.1 Sequence 14 from Patent EP2603609
AAGTTTCCAAAGA
>JB761201.1 Sequence 71 from Patent WO2013113502
GGGTTTTTTTGGG
>JB761190.1 Sequence 60 from Patent WO2013113502
GGTTTTTTTTTGG
>JB776410.1 Sequence 13 from Patent EP2507263
ATTAATCCTGACA
>JB772454.1 Sequence 86 from Patent EP2604625
GGCCATTACGGCC
>JB767310.1 Sequence 61 from Patent EP2612927
AGCGAGAGATGCC
>JB760554.1 Sequence 85 from Patent WO2013113501
GGGTTTTTTTGGG
>JB760543.1 Sequence 74 from Patent WO2013113501
GGTTTTTTTTTGG
>JB760406.1 Sequence 85 from Patent WO2013113736
GGGTTTTTTTGGG
>JB760395.1 Sequence 74 from Patent WO2013113736
GGTTTTTTTTTGG
>JB759980.1 Sequence 71 from Patent WO2013113325
GGGTTTTTTTGGG
>JB759146.1 Sequence 38 from Patent WO2013101750
CCATGTCAATGCC
>JB831695.1 Sequence 21 from Patent EP2516649
TAGTTAAATAAAA
>JB831692.1 Sequence 18 from Patent EP2516649
TAGTTAATTAAAA
>HJ420957.1 Sequence 7 from patent US 8541237
ATCCAGGGAGCGT
>HJ419959.1 Sequence 22 from patent US 8540999
AATGATCGATGCT
>JB758507.1 Sequence 65 from Patent EP2612914
ACGTGGGCAGCAG
>JB758495.1 Sequence 53 from Patent EP2612914
AGTAGAGGCAGGC
>JB758492.1 Sequence 50 from Patent EP2612914
CCGGCCGCTGACC
>JB758488.1 Sequence 46 from Patent EP2612914
CCTATGAGGGTGC
>JB758454.1 Sequence 12 from Patent EP2612914
CTGCTGCCCACGT
>JB758450.1 Sequence 8 from Patent EP2612914
GCCTGCCTCTACT
>JB758448.1 Sequence 6 from Patent EP2612914
GGTCAGCGGCCGG
>JB758446.1 Sequence 4 from Patent EP2612914
GCACCCTCATAGG
>HW285615.1 JP 2012152219-A/31: OPTIMIZATION OF GENE EXPRESSION ANALYSIS USING IMMOBILIZED CAPTURE PROBES
AGTCGACACGTTC
>HW285193.1 JP 2012147797-A/44: Humanized Antibodies that Recognize Beta-Amyloid Peptide
ACTTATGTTTTTG
>HW285189.1 JP 2012147797-A/40: Humanized Antibodies that Recognize Beta-Amyloid Peptide
ACTTATATGTGTT
>HW285182.1 JP 2012147797-A/33: Humanized Antibodies that Recognize Beta-Amyloid Peptide
ACTTATTCCCATT
>HW279352.1 JP 2012161319-A/5: Beta2 ADRENERGIC POLYMORPHISM DETECTION
CCCAATGGAAGCC
>JB749352.1 Sequence 1 from Patent WO2013090040
GCCGGCGGTATCG
>JB747359.1 Sequence 38 from Patent WO2013066805
CGCTAGCCCCAAC
>JB737600.1 Sequence 1923 from Patent EP2558854
TTCCTTGGTGCCT
>JB737540.1 Sequence 1863 from Patent EP2558854
TTCCTTGGTGCCT
>JB737438.1 Sequence 1761 from Patent EP2558854
AGCCGAATCCATC
>JB737292.1 Sequence 1615 from Patent EP2558854
ACTCCTTTGAAAC
>JB737233.1 Sequence 1556 from Patent EP2558854
TTAAAATAAAATA
>JB737118.1 Sequence 1441 from Patent EP2558854
ATATATATTTTTT
>JB734305.1 Sequence 39 from Patent WO2013079924
ACGAGCGTCTTTA
>JB623853.1 Sequence 3 from Patent EP2610341
RNSGAGMGRMRRR
>JB623818.1 Sequence 3 from Patent EP2610340
RNSGAGMGRMRRR
>JB616045.1 Sequence 28 from Patent WO2013109754
GCTAGCCGCCAGC
>JB626225.1 Sequence 41 from Patent EP2585600
ACAACCAAAAATG
>JB626224.1 Sequence 40 from Patent EP2585600
GGATCCAACAATG
>JB420577.1 Sequence 67 from Patent EP2589668
CGGAGATGGCCCA
>JB416422.1 Sequence 85 from Patent EP2623121
GGGTTTTTTTGGG
>JB416411.1 Sequence 74 from Patent EP2623121
GGTTTTTTTTTGG
>JB407416.1 Sequence 359 from Patent WO2012116811
GGGTTTTTTTGGG
>JB407406.1 Sequence 348 from Patent WO2012116811
GGTTTTTTTTTGG
>JB406786.1 Sequence 5 from Patent WO2013017702
GCTAGCTCGATGA
>JB406785.1 Sequence 4 from Patent WO2013017702
GCTAGCTCGATGA
>JB415901.1 Sequence 31 from Patent WO2012042052
ACGGTGGACGCGT
>JB415885.1 Sequence 15 from Patent WO2012042052
AGGTCGCATCGCG
>JB415873.1 Sequence 3 from Patent WO2012042052
AGGTACGTTCGCT
>JB402450.1 Sequence 359 from Patent WO2012116715
GGGTTTTTTTGGG
>JB402440.1 Sequence 348 from Patent WO2012116715
GGTTTTTTTTTGG
>JB399541.1 Sequence 8 from Patent WO2012030714
CAGCGTCGAGACA
>JB399540.1 Sequence 7 from Patent WO2012030714
CAGTGTTGAGACA
>JB399539.1 Sequence 6 from Patent WO2012030714
CAGTGTCGAGACG
>JB399538.1 Sequence 5 from Patent WO2012030714
CAGTGTCGAGACA
>JB392950.1 Sequence 12 from Patent WO2012038744
TGATTAAGGCCCA
>JB392949.1 Sequence 11 from Patent WO2012038744
TGGGCCTTAATCA
>JB392806.1 Sequence 8 from Patent WO2012047589
TTTTTTTTTTTTT
>JB380744.1 Sequence 41 from Patent WO2013021088
ATGGAGGCTTGAC
>JB379244.1 Sequence 71 from Patent WO2012113513
GGGTTTTTTTGGG
>JB379234.1 Sequence 60 from Patent WO2012113513
GGTTTTTTTTTGG
>JB378001.1 Sequence 359 from Patent WO2012116714
GGGTTTTTTTGGG
>JB377991.1 Sequence 348 from Patent WO2012116714
GGTTTTTTTTTGG
>JB376649.1 Sequence 23 from Patent WO2012033848
ATCNGTNTGNCTA
>JB376517.1 Sequence 28 from Patent WO2012042053
ACGGTGGACGCGT
>JB376501.1 Sequence 12 from Patent WO2012042053
AGGTCGCATCGCG
>JB360539.1 Sequence 36 from Patent EP2449104
AATACATCATCAT
>JB360528.1 Sequence 25 from Patent EP2449104
AATACATCATCAT
>JB360520.1 Sequence 17 from Patent EP2449104
AATACATCATCAT
>JB356607.1 Sequence 57 from Patent EP2554670
GGGGTGCCGGTGG
>JB356605.1 Sequence 55 from Patent EP2554670
TGTTGCTGGGGTG
>JB344946.1 Sequence 21 from Patent EP2482824
CGCCGGTAGCTCT
>JB387652.1 Sequence 359 from Patent WO2012116810
GGGTTTTTTTGGG
>JB387642.1 Sequence 348 from Patent WO2012116810
GGTTTTTTTTTGG
>JB345870.1 Sequence 26 from Patent EP2550359
AGGTCANAGGTCA
>HW259203.1 JP 2013514813-A/8: NOVEL PNEUMOVIRUS COMPOSITIONS AND METHODS FOR USING THE SAME
TAGTTAAATAAAA
>HW259200.1 JP 2013514813-A/5: NOVEL PNEUMOVIRUS COMPOSITIONS AND METHODS FOR USING THE SAME
TAGTTAATTAAAA
>HW251104.1 WO 2013089157-A/17: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
CTGCATGGCACCT
>HW251101.1 WO 2013089157-A/14: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
GCAGCTTCTTATC
>HW251100.1 WO 2013089157-A/13: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
TTAAAGCAACCTT
>HW251099.1 WO 2013089157-A/12: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
GCTCCAGTAGCCT
>HW251098.1 WO 2013089157-A/11: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
TCTTGGAGGCTTG
>HW251097.1 WO 2013089157-A/10: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
TCCATGTAGCCCT
>HW251096.1 WO 2013089157-A/9: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
TCGGGCAGATGCC
>HW251095.1 WO 2013089157-A/8: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
CATGGCACCTACG
>HW251094.1 WO 2013089157-A/7: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
CTGCATGGCACCT
>HW251093.1 WO 2013089157-A/6: Oligonucleotide and therapeutic agent for hyperlipidemia containing the same as an active ingredient
ATCCAGCTTTATT
>JB324351.1 Sequence 289 from Patent EP2513312
TGGGGTCAGGGCA
>JB324350.1 Sequence 288 from Patent EP2513312
TGGGGCCAGGGCA
>JB324349.1 Sequence 287 from Patent EP2513312
TGGGGCCAAGGCA
>JB324348.1 Sequence 286 from Patent EP2513312
TGGGGCGCAGGGA
>JB324347.1 Sequence 285 from Patent EP2513312
TGGGGCCAGGGAA
>JB324346.1 Sequence 284 from Patent EP2513312
CTACTGTGCCAGA
>JB324345.1 Sequence 283 from Patent EP2513312
TTTCTGTGCAAGA
>JB324344.1 Sequence 282 from Patent EP2513312
TTACTGTGCAAGA
>JB324343.1 Sequence 281 from Patent EP2513312
TTACTGTGCGAGA
>JB318391.1 Sequence 20 from Patent EP2351859
ATTTATTTATTTA
>JB318387.1 Sequence 16 from Patent EP2351859
ATTTATTTATTTA
>JB318384.1 Sequence 13 from Patent EP2351859
ATTTATTTATTTA
>JB317398.1 Sequence 21 from Patent EP2482825
CGCCGGTAGCTCT
>JB313349.1 Sequence 108 from Patent EP2566972
AAAGCGTGCTCCG
>JB313348.1 Sequence 107 from Patent EP2566972
AAAGCGGGCTCCG
>JB313347.1 Sequence 106 from Patent EP2566972
AAAGCGCGCTCCG
>JB313346.1 Sequence 105 from Patent EP2566972
AAAGCGAGCTCCG
>JB313340.1 Sequence 99 from Patent EP2566972
ACTCTGTTGGAAG
>JB313339.1 Sequence 98 from Patent EP2566972
ACTCTGGTGGAAG
>JB313338.1 Sequence 97 from Patent EP2566972
ACTCTGCTGGAAG
>JB313337.1 Sequence 96 from Patent EP2566972
ACTCTGATGGAAG
>JB311405.1 Sequence 3 from Patent EP2432796
CGNTGACTNNNAC
>JB308563.1 Sequence 86 from Patent EP2429565
GAATTCCGATGAG
>JB308560.1 Sequence 83 from Patent EP2429565
GAATTCCGATGAG
>JB308553.1 Sequence 76 from Patent EP2429565
GAATTCCGCCGTC
>JB308552.1 Sequence 75 from Patent EP2429565
GATACCGGAATTC
